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ABSTRACT 
Age related macular degeneration (AMD) is the leading cause of blindness in 
people over the age of 50 in the western world. The wet form of AMD is 
associated with choroidal neovascularisation. The pathogenesis of choroidal 
neovascularisation is complex involving neovascular growth, vascular leakage, 
hypoxia and inflammation. Evidence suggests that immunological events play a 
key role in the pathogenesis of AMD. In AMD a chronic low grade inflammatory 
process may instigate the pathophysiological process culminating in eventual 
visual loss.  Minocycline is a tetracycline derivative with anti-inflammatory in 
addition to antibiotic effects. This study investigated the effects of minocycline 
on retinal pigment epithelial cells in culture. Cell viability and apoptosis was 
studied with flow cytometry. Cells were exposed to glycated albumin and 
hypoxia as these processes occur during ageing.  The effects of minocycline on 
IL-8 and MCP-1 production from ARPE-19 cells in culture were investigated 
with enzyme linked immunosorbent assay. 
The results showed a potential narrow therapeutic window for minocycline to act 
on retinal pigment epithelial cells. Cell viability decreased rapidly at minocycline 
doses above 5µM. Minocycline suppressed the production of inflammatory 
cytokines IL-8 and MCP-1 in cell culture.  
A clinical trial was conducted to investigate whether combination therapy aimed 
at targeting different pathways in the AMD disease process would be effective. 
This trial was powered to determine adverse events when a quadruple therapy 
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of reduced fluence photodynamic therapy (PDT), intravitreal ranibizumab, 
dexamethasone and oral minocycline were used as treatments. 
The clinical trial demonstrated that anti-VEGF treatment administered in 
combination with other agents was not as effective as monthly anti-VEGF 
monotherapy at sustaining visual improvement. However, the trial did 
demonstrate that combination therapy could be delivered safely.  
The results demonstrate that minocycline has a potential therapeutic role for the 
inflammatory changes in neovascular age related macular degeneration. 
.  
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Chapter 1 
1.1 Definition and symptoms of age related macular 
degeneration (AMD) 
Age related macular degeneration (AMD) is an eye condition with onset usually 
after the age of 50 which progressively destroys the macula, the central portion 
of the retina, impairing central vision. Early symptoms include blurring of central 
vision with visual distortion. As central vision is needed for reading, driving, 
recognising faces and doing detailed work patients generally report difficulties 
with these tasks. Peripheral vision is usually preserved. The decline to severe 
loss of vision can vary from months to years depending on the type and severity 
of AMD. 
                               
Figure 1: Diagram of the basic anatomy of the eye 
1.2 Epidemiology of AMD 
At least 1.75 million individuals in the USA suffer from AMD and this figure will 
rise with the overall ageing of the population. Some estimates have suggested 
that up to 2.95 million people in the USA may be affected by AMD by the year 
ANTERIOR 
POSTERIOR 
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2020.1 In the UK, at least 0.5 million are affected by AMD and 250,000 are 
registered blind or partially sighted as a result but this may not fully reflect the 
amount of sight loss as many people who could register chose not to do so.2 In 
one study, women had a slightly increased prevalence of AMD compared to 
men for those over the age of 75.3 However, this finding contrasts to the results 
of three pooled studies, the Beaver Dam, Blue Mountain, and Rotterdam Eye 
Study, where no significant differences in risk were found between men and 
women.4 This discrepancy is probably related to the longer life expectancy of 
women relative to men. Ethnic variations in the prevalence of AMD have also 
been reported and it has been suggested that this is due to variations in the 
complement factor H risk allele.5  
1.3 Macular Anatomy and ageing changes 
The retina is the light sensitive tissue at the back of the eye. The retina contains 
specialised light sensitive cells known as photoreceptors which are responsible 
for a process known as visual transduction.6   Visual transduction is a process 
by which light is converted into electrical signals.  Moving from the front towards 
the back of the eye from the retina several layers of tissues are present 
consisting of the retinal pigment epithelium, Bruch’s membrane, the 
choriocapillaris and the sclera (Figure 2). The choriocapillaris or choroid layer is 
a densely vascular structure supplying the outer third of the retina with a blood 
supply.6 The macula is an area approximately 5.5mm in diameter located at the 
centre of the retina. Visual acuity depends on the function of the macula. This is 
because the macula is the region of the retina with the highest concentration of 
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photoreceptors, primarily cone cells. At the centre of the macula the fovea is 
present, an area approximately 1.5mm in diameter. The foveola forms the 
central floor of the fovea and has a diameter of 0.35mm. It is the thinnest part of 
the retina and consists only of cones and their nuclei.6 (Figure 3). The foveal 
avascular zone is an area devoid of blood vessels at the centre of the fovea. 
The retinal pigment epithelium (RPE) is a single layer of hexagonal cells, the 
apices of which manifest villous processes that envelope the outer segments of 
the photoreceptors. The cells consist of an outer non-pigmented basal element 
containing the nucleus, and an inner pigmented apical section containing 
abdundant melanosomes. A melanosome is an organelle containing the light 
absorbing pigment melanin. At the fovea, RPE cells are taller and thinner, more 
regular in shape and contain larger melanosomes than in the periphery. The 
adhesion between the RPE and sensory retina is weaker than between the RPE 
and Bruch’s membrane, which underlies the RPE. The potential space between 
the RPE and retina is known as the subretinal space. The RPE maintains the 
integrity of the sub-retinal space by constituting the outer blood retinal barrier, 
formed by the intervening tight junctional complexes (zonula occludentes).  This 
prevents extracellular fluid, which normally leaks from the choriocapillaris from 
entering the sub-retinal space and also actively pumps ions and water out of the 
subretinal space.  The RPE cell layer facilitates photoreceptor turnover by the 
phagocytosis and lysosomal degradation of cone outer segments following 
shedding. The RPE layer also functions to store, metabolise and transport 
vitamin A in the visual cycle, the process by which light energy is converted to 
electrical impulses.6 Bruch’s membrane separates the RPE from the 
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choriocapillaris and consists of five elements, the basal lamina of the RPE, an 
inner collagenous layer, a thicker band of elastic fibres, an outer collagenous 
layer and the basal lamina of the outer layer of the choriocapillaris.  
 
Figure 2: Anatomy of retina and posterior eye 
(image from whyfiles.org/163amd_eye/images/retina_cross.gif) 
 
 
Figure 3: Cross section of the fovea (image from Kanski JJ and Bowling B (2011) 
Clinical Ophthalmology: A systemic approach. Chapter 14 pg 595) 
 
 
 
 
 
  
5 
 
 
 
 
 
 
 
 
 
 
Figure 4: Schematic representation of the normal structural anatomy of the 
posterior eye 
 
Numerous biological and histological changes take place in the ageing eye and 
not all of these lead to the development of age related macular degeneration. 
These changes may evolve concurrently or consecutively and the relationship 
between them is not entirely clear.   
With age, choroidal vascular atrophy occurs and the choriocapillaris loses the 
ability to transfer oxygen and nutrients to the surrounding cells7, plasma levels 
of vitamin C and E decrease 8, 9 and lipid peroxidation increases.10 
Fine yellow brown pigment granules composed of the lipid residues of 
lysosomal digestion are known as lipofuscin. It has been reported11 that 
lipofuscin accounts for 1% of the RPE cytoplasmic volume in the first decade of 
life and that this increases to 19% by the 8th decade.  Lipofuscin compromises 
the function of the RPE cells and leads to photoreceptor cell death. 
Reactive oxygen species are a product of cellular metabolism and as the 
photoreceptors and RPE cells account for 90% of the oxygen consumption from 
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the choriocapillaris the generation of metabolic by-products is high. Light 
irradiation also stimulates the production of free radicals and leads to oxidative 
stress and tissue injury. However, it is difficult to quantify the total amount of 
light exposure throughout life and there is as yet no proven causal relationship 
between exposure to ultra-violet light and AMD.12, 13 
The outer segments of the photoreceptors are highly susceptible to oxidative 
stress. Approximately 50% of the outer membrane is composed of 
polyunsaturated fatty acids, particularly docosahexaenoic acid (DHA). 14, 15 
The choriocapillaris density decreases with age and the choroidal thickness 
decreases from 200µm at birth to approximately 80µm at the age of 80.16 
Therefore, with age, the photoreceptors are deprived of the oxygen and 
nutrients delivered by the choriocapillaris that are required for normal metabolic 
function. There is a close association between the metabolic processes within 
the RPE and the photoreceptors.17 Ischaemia induced damage and dysfunction 
of the RPE causes secondary degeneration of rods and cones. 
Several changes occur in Bruch’s membrane with age. Ramrattan and co-
workers16 reported in normal adults the thickness of the membrane increases by 
135% (from 2µm to 4.7µm) between birth and the age of 90 years. In eyes that 
had advanced macular degeneration the density of the choriocapillaris was less 
than normal for each measurement, as was the choriocapillaris diameter. The 
thickness of the choroid itself was not different between normal and diseased 
eyes.  Therefore, it was concluded that age was the only factor affecting the 
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thickness of Bruch’s membrane and that it was not connected to the age related 
atrophy of the choriocapillaris.16 
 
1.4 Pathophysiology of AMD 
Risk factors for AMD include increased age, smoking, diet, light exposure and 
studies have linked genetics, oxidative stress, RPE senescence, hypoxia and 
other factors.17-23 Age is the major risk factor and family history is important. 
The risk of developing AMD is greatly increased by having an affected first 
degree relative.23 Variants in many genes have been implicated in AMD risk and 
protection such as chromosome 1q32 for complement factor H (CFH), which 
protects cells from complement mediated damage, the hemicentin gene on 
1q24-25, and the ABCR gene on chromosome 1p. The ABCR gene is also 
implicated in other retinal conditions such as Stargardt disease and fundus 
flavimaculatus.6   Smoking is considered to approximately double the risk of 
AMD and hypertension and other cardiovascular risk factors are likely to be 
associated.6 There is substantial evidence from the AREDS24 study that taking 
high dose antioxidant vitamins and minerals on a regular basis can decrease 
the risk of AMD progression. The regimen used in AREDS included 500mg 
vitamin C, 400IU of vitamin E, 15mg of beta-carotene and 80mg of zinc, with 
2mg of copper (cupric oxide) to prevent zinc induced copper deficiency. The 
reduction in risk of progression to further visual loss at 5 years is in the order of 
25% for those taking supplements with the more advanced of these signs at 
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baseline. Supplements did not discernibly reduce progression in those with 
early or no AMD.24 More recently, the AREDS 2 clinical trial examined  whether 
lutein and xeaxanthin and omega 3 long chain polyunsaturated fatty acids (DHA 
and EPA) were associated with a reduced risk of advanced AMD in addition to 
the original AREDS formulation. 25 The secondary goal of the AREDS 2 study 
was to test the effects of eliminating beta carotene and zinc from the original 
AREDS formulation. The results of the AREDS 2 study25, a prospective 
randomised trial conducted over a 5 year period showed no statistically 
significant effect of additional supplements in addition to the original AREDS 
formulation. 
However, although antioxidants appear to reduce the risk of progression of 
AMD, the exact aetiology and pathogenesis of AMD remains largely unclear. An 
increasing collection of evidence suggests that immunologic events play a key 
role in the pathogenesis of AMD. 
Ocular inflammation associated with uveitis manifests with inflammatory cell 
infiltrate, oedema and tissue damage. In AMD, the inflammatory process is less 
overt and may link the risk factors together finally leading to visual loss. The 
inflammatory process results from interactions between various immune 
components. 
1.5 Inflammation in AMD 
AMD is predicted to become more prevalent worldwide as life expectancy 
continues to increase. The pathogenesis of this condition is incompletely 
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understood and chronic oxidative stress has been recognised recently as an 
important contributory factor in the pathophysiology.19 The evidence for the role 
of inflammation in the aetiology of neovascular AMD will be discussed before 
considering a therapeutic role for minocycline. 
 
1.5.1 General aspects of inflammation 
Inflammation is the response of a tissue to a noxious stimulus.26 Inflammation is 
usually described as several phases. In the acute phase, the classic cardinal 
signs of redness (rubor), heat (calor), mass (tumor), pain (dolor) and loss of 
function are usually described. These are caused by an increased rate and 
volume of blood flow, exudation of fluid (oedema) and cells and irritating 
chemicals. Chemical mediators increase vascular permeability by causing the 
usually “tight” junctions between adjacent vessel endothelial cells to open, 
allowing fluid to leak into the surrounding tissue spaces. The subacute phase of 
inflammation varies greatly and is concerned with the healing response.26 The 
outcome of this phase may be restoration of normal haemostasis, scarring, or 
chronicity of the inflammatory response. The chronic phase of inflammation 
involves specific cellular responses. The inflammatory response is complex 
involving a multitude of chemical mediators and a variety of cells and pathways. 
The foregoing is not intended as an exhaustive review of the inflammatory 
response. The evidence for inflammation and the immune response in the 
context of the aetiology of AMD will be discussed.    
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1.5.2 Infection and inflammation in AMD 
Evidence for the role of inflammation in the aetiology of AMD arises from links 
with past infections and the condition. Chlamydia pneumonia is an obligate 
intracellular pathogen that can give rise to persistent asymptomatic infection, 
resulting in chronic inflammation.27 Chlamydia pneumonia infection results in an 
activation of pro-inflammatory pathways some of which are also implicated in 
AMD. The alternative pathway of complement that is strongly implicated in AMD 
pathogenesis can be activated by Chlamydia. Infection with this pathogen may 
lead to complement overactivity in patients with the Y402H variant of 
complement factor H (CFH) that leads to impaired complement inhibitor function 
by CFH.  AMD has been associated with macrophage accumulation, and 
studies have shown that Chlamydia infection promotes differentiation of 
monocytes to macrophages.28 Chlamydia infected monocytes exhibit enhanced 
migration through the blood brain barrier 29 and this poses the question whether 
a similar process may occur through the blood retinal barrier.  
Two studies 30, 31 showed serum antibodies for Chlamydial pneumonia proteins 
are associated with increased risk of AMD development and progression. In 
vitro, macrophages produce vascular endothelial growth factor (VEGF) after 
infection with Chlamydia pneumonia.32 However, further studies 33, 34 failed to 
demonstrate an association between Chlamydia pneumonia and AMD. Further 
studies are needed to elucidate the potential patho-physiological connection 
between Chlamydia infection and AMD. 
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1.5.3 Inflammation, the complement system and AMD 
In patients with posterior segment intraocular inflammation (PSII) the incidence 
of choroidal neovascularisation (CNV) varies with different types of 
inflammation. CNV is a recognised feature of PSII conditions such as multifocal 
choroiditis with panuveitis, punctuate inner choroidopathy, serpiginous 
choroiditis, posterior sympathetic ophthalmia, angioid streaks, ocular 
toxoplasmosis and pathological myopia.35 Chronic inflammation and 
angiogenesis are linked together not just in retinal disorders but also in other 
conditions such as rheumatoid arthritis, diabetes, and cancer. In rheumatoid 
arthritis, new blood vessels are formed during early stages of inflammation, 
increasing leukocyte movement into the synovium 36 where leukocyte–
endothelial interaction may play an important role in initiation and progression of 
synovial angiogenesis.37 During cancerogenesis, the ischemic 
microenvironment and tumour-associated macrophages are central for tumour 
angiogenesis.38 In the retina, however, detailed mechanisms on how 
angiogenesis is formed (either from the choroid or de novo from the retina) in 
the presence of chronic inflammation remain poorly defined.35 
Immunity is defined as the ability of a host to protect itself against a foreign 
antigen. Host defence mechanisms in humans against pathogens take the form 
of an innate system which is non specific and rapidly mobilised. This comprises 
a first line of defence involving a physical barrier to entry such as eyelids and 
tears, molecules such as complement, phagocytic/ cytotoxic cells such as 
natural killer cells and macrophages and cytokines such as the interleukins and 
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tumour necrosis factor α (TNF). The adaptive immune response includes cells 
(lymphocytes) with receptors that specifically recognise foreign organisms and 
molecules (antigens) and specific molecules (antibodies) which specifically 
counteract foreign antigen. 
The complement system comprises several soluble and membrane bound 
proteins, and can be divided into three main pathways: classical, lecithin and 
alternative.39 The classical pathway is activated largely by immune complexes 
(antibody bound to antigen); the lecithin pathway is activated primarily by 
mannose and N-acetyl glucosamine residues that are particularly abundant on 
bacterial cell surfaces, and the alternative pathway is initiated by a variety of 
activating substances including microbial surfaces and polysaccharides. 
Activation of these pathways results in a pro-inflammatory response including 
generation of membrane attack complexes (MAC) which mediate cell lysis, 
release of chemokines to attract inflammatory cells to the site of damage, and 
enhance capillary permeability 39,40. Intraocular complement regulatory proteins 
tightly control the process of complement regulation to ensure elimination of 
potential pathogens without damage to healthy tissue. Complement 
dysregulation has been well characterized in autoimmune anterior uveitis 41 and 
may be implicated in AMD pathogenesis.  
The complement component C5 and components C5b-9 forming the membrane 
attack complex have been identified in drusen from human eyes, including eyes 
with AMD.42 Also C3a and C5a have been localized to drusen, RPE cells and 
Bruch’s membrane in human AMD.43 Recently, genetic analyses for single 
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nucleotide polymorphisms (SNP) spanning the complement genes C3 and C5 
has linked the arginine to guanine at amino acid 80 (R80G) SNP in the C3 gene 
to AMD.44 
Complement factor H (CFH) is a regulator of the complement system. It impairs 
activation of the alternative pathway by inhibiting several steps and by 
promoting degradation of activated complement components.  CFH binds 
heparin on cell surfaces to prevent complement mediated damage to heparin. It 
also binds C- reactive protein (CRP) to inhibit CRP mediated activation of the 
alternate pathway in response to damaged tissue.45 CFH is expressed in a 
variety of human ocular tissues, including sclera, pigment epithelium, retina and 
choroid. Studies in mice46 demonstrated that ocular expression of CFH 
increases with age. Hence CFH might accumulate with age to inhibit alternate 
pathway activation and impairment in CFH function might create a pro-
complement, that is, pro-inflammatory environment leading to AMD. Several 
studies have reported that the tyrosine to histidine SNP at position 402 (Y402H) 
in the CFH gene in the 1q32 region increases the risk of AMD and a meta-
analysis by Thakkinstian47 suggested that up to 50% of all AMD is associated 
with this polymorphism.  
The link between CFH and AMD has been further strengthened by a variety of 
in vitro studies. Oxidative stress has been associated with AMD and long term 
treatment of RPE cells with oxidized photoreceptors, but not non-oxidized 
photoreceptors impairs CFH secretion. The presence of pro-inflammatory 
cytokines such as IL-6 also decreases CFH secretion by RPE cells.48 Hence it 
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is also possible that not only genetic variation in CFH but also processes such 
as oxidative stress which impair CFH synthesis and/ or secretion may lead to 
overaction of the alternative pathway and AMD pathology. Deficiency or 
impaired function of CFH is also associated with membranoproliferative 
glomerulonephritis type 2, a renal condition which is associated with deposits 
that may result from a similar inflammatory process as that which produces 
drusen seen in AMD.49 
Macrophages and chemokines that mediate macrophage recruitment to the 
retina have also been associated with AMD.  One chemokine that has 
generated particular interest is CCL2 and its receptor CCR2.  CCR2 is a 
chemokine receptor found on macrophages which binds CCL2 chemokine.  
Deficiencies in CCR2 lead to decreased leukocyte adhesion to 
microvasculature as well as decreased extravasation of monocytes from the 
circulatory system into surrounding tissue. As yet, there have been no direct 
studies of CCL2 or CCR2 in human AMD. However, altered expression of 
CCR2 has been implicated in studies of apolipoprotein E (ApoE) polymorphism 
in human AMD.  Bojanowski 50 demonstrated that the Apo E 112R variant is 
associated with decreased risk of AMD by decreasing expression of CCL2 in 
RPE cells and therefore reducing macrophage recruitment to the retina. This 
suggests macrophages are involved pathologically, rather than in a restorative 
role in AMD. 
However, a study of CCL2 and CCR2 deficiency in a knockout mouse animal 
model suggested macrophages may serve a beneficial role in the retina.51 
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These deficient mice developed AMD like lesions starting at 9 months of age, 
histologically these lesions consisted of lipofuscin granules, and thickening of 
Bruch’s membrane.  By the age of 16 to 18 months these mice developed 
macula atrophy and choroidal neovascularisation.  The study 51 also 
demonstrated that drusen components such as C5, IgG and glycosylation 
products upregulate CCR2 expression by RPE cells and choroidal endothelial 
cells. The study 51 showed in vitro, that macrophages adhere to IgG and C5 and 
facilitate their clearance.  At present it is still unclear whether macrophages 
contribute to the pathology of AMD as suggested by limited human studies or 
whether they accumulate as an adaptive response.  
Grossniklaus 52 and co- workers derived a possible mechanism whereby 
macrophages may promote choroidal neovascularisation (CNV). They 52 
showed that macrophages express the pro-angiogenic vascular endothelial 
growth factor (VEGF) so may directly promote the formation of CNV. 
Kamei et al 53 suggested another plausible function of macrophages at sites of 
CNV lesions. They 53 demonstrated that CNV membranes contain oxidized 
lipoprotein and that these membranes stain positive for macrophages bearing 
scavenger receptors for oxidized proteins including lecithin like oxidized low 
density lipoprotein receptor-1 (LOX-1). The study 53 suggests that macrophages 
seen in AMD may ingest oxidized low density lipoprotein that accumulates with 
age. This emphasized similarities with the mechanism in atherosclerosis and 
suggested macrophages play a pathologic role in CNV. Overall, although these 
studies52, 53 suggest a role for macrophages in CNV, they do not prove a 
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causative role. This is largely due to the limitations of human studies where it is 
impossible to manipulate macrophage numbers to determine whether they 
increase or decrease the likelihood of CNV formation. Research is therefore 
confined to animal models for CNV formation.  
There are myeloid derived cells in the retina, called microglial cells. These cells 
have been implicated in ocular inflammatory disease such as uveitis and they 
may have a role in the pathogenesis of AMD.  In vitro studies involving 
treatment of healthy photoreceptors with activated microglia suggest that this 
may induce injury to healthy photoreceptor cells.54 The microglia chemokine 
receptor CX3CR1 has been studied in human and animal models of AMD. This 
receptor is G-protein coupled and has been found on inflammatory cells, 
including microglia, macrophages, astrocytes, and T cells. The ligand CX3CL1 
is a chemokine that binds to CX3CR1 receptors on leukocytes to promote 
activation of the leukocytes and mobilization of these leukocytes to sites of 
inflammation.55 CX3CR1 is expressed in the retina where it may mediate influx 
of microglia and macrophages to clear accumulated deposits.56  
Combadiere and co-workers 57 demonstrated that CX3CR1 positive cells in the 
outer retina and subretinal space of human AMD eyes, in drusen and near 
choroidal neovasculization are microglial cells. They showed CX3CR1 deficient 
mice exhibited signs of retinal degeneration.57 The microglia formed drusen like 
deposits between the photoreceptor outer segment and RPE and similar 
deposits were identified in human AMD eyes.57 
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1.5.4 Role of growth factors in age related macular degeneration 
Growth factors, neurotrophic factors, chemokines and cytokines are cell 
secreted mediators of autocrine and paracrine functions, involved in cell 
maintenance, survival, growth and death. They are also involved in 
angiogenesis, vascular permeability, and inflammation.58 Vascular endothelial 
growth factor (VEGF), identified as being important in angiogenesis, is now 
thought to have a role as mediator of leukocyte adhesion in vascular cells and 
as a neurotrophic factor in the central nervous system.58 Inhibition of VEGF is 
now in widespread use for treating exudative AMD. However, inhibition of 
angiogenesis alone is not sufficient to restore macula function in AMD if in 
addition to CNV the clinical and pathological spectrum of AMD shows a variety 
of changes, ranging from drusen deposition and pigment epithelium 
detachments to scar formation. 
1.5.5 Growth factors in AMD pathogenesis 
Many growth factors have been implicated in the pathogenesis of AMD, based 
on experimental data obtained from studies in cultured retinal pigment 
epithelium (RPE) and from histopathological studies in surgically removed 
human CNV or in laser induced CNV in transgenic rodent models.60,61 These 
studies identified the RPE as an important source of growth factors involved in 
tissue maintenance, homeostasis, inflammation and CNV formation and also as 
the central cell type involved in regulating these processes (Table 1). This is of 
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particular relevance for research exploring transplantation of the RPE as a 
therapeutic approach in AMD. 
Table 1 Growth factors and cytokines:  functions in choroidal 
neovascularization62 
 
 
 
Process Growth factors involved 
Neutrophil infiltration TGF-β, MCP-1 
Macrophage infiltration TGF-β, MCP-1 
Angiogenesis VEGF-A, PLGF, FGF2, angiopoietins, 
HGF, MCP-1 
Fibroplasia PDGF, TGF-β, CTGF, IGFs 
Matrix deposition FGF2, IGF-1, TGF-β, MCP-1, CTGF 
Scarring IGF-1, TGF-β, CTGF 
Re- epitheiliaization FGF2, IGFs, MCP-1, TGF-β 
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1.6 Clinical features of AMD 
The clinical features of AMD were first described by Needelship in 1884 as a 
central choroidal atrophy.63 It was Haab in 1885 who used the term senile 
macular degeneration to describe the condition.64 The earliest clinical 
manifestation and pathological feature of AMD is the development of drusen, 
extracellular deposits of glycoproteins, lipids and cellular debris located inside 
Bruch’s membrane and beneath the RPE. A few small drusen can be found in 
healthy individuals over the age of 50, however, the presence of large or 
numerous drusen confers significant risk for AMD. 18, 19 Hard drusen are well 
defined and less than half a retinal vein width (<63µm) in diameter. Their 
presence as the only finding probably carries little increased risk of visual loss. 
Soft drusen are less distinct and generally substantially larger than hard drusen. 
It has been suggested that the presence of more than five soft drusen might be 
taken as the defining feature of age related maculopathy (ARM) 6 As soft drusen 
enlarge and become more numerous, they may coalesce giving a localised 
elevation of the RPE, a “drusenoid RPE detachment”. Dystrophic calcification 
may develop in both types of drusen (figure 5). 
  
20 
 
 
Figure 5: Atrophic age related macular degeneration (a) Drusen and mild RPE 
change (b) Drusen and moderate retinal atrophy (c) Drusen and geographic 
atrophy (d) geographic atrophy and disappearance of drusen 
(black arrows point to the drusen) 
(image from Kanski JJ and Bowling B (2011) Clinical Ophthalmology: A systemic approach, 
chapter 14, pg.617 pub Elsevier Saunders) 
 
 
 
 
Figure 6: Schematic representation of the structural anatomy of the posterior eye 
in a patient with drusen and dry age related macular degeneration 
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Clinically and histologically, AMD is generally classified into two major sub-
types: dry and wet. Choroidal neovascularisation (CNV) is a characteristic of the 
wet form, accounting for approximately 10% of cases.19 Dry AMD progresses 
more slowly and manifests with drusen, geographic atrophy of RPE and 
photoreceptor dysfunction and degeneration. Wet AMD is more debilitating and 
often presents after dry AMD. Choroidal neovascularisation (CNV) is the growth 
of new vessels from the choroid into the region underlying the RPE or extending 
past the RPE into the subretinal space and retina (figure 7).This choroidal 
neovascularisation can lead to leakage of blood into the subretinal space, which 
combined with RPE atrophy and photoreceptor degeneration, leads to visual 
loss. Fluorescein angiography (FA) is used primarily to confirm a suspected 
diagnosis of CNV prior to committing the patient to anti-VEGF treatment. 
Fluorescein angiography is a technique for examining the circulation of the 
retina using the dye tracing method. It involves an injection of sodium 
fluorescein into the systemic circulation, and then an angiogram is obtained by 
photographing the fluorescence emitted after illumination of the retina with blue 
light. A barrier yellow filter in the camera allows only light from the fluorescence 
to reach the camera.  The terminology used to describe the FA appearances of 
CNV is derived from the Macular photocoagulation study (MPS). 65 
Classic CNV is a well defined membrane which fills with dye in a ‘lacy’ pattern 
during the early phases of dye transit, then leaks into the sub-retinal space and 
around the CNV over 1-2 minutes (Figure 8). Classic CNV is classified 
topographically according to its relation to the centre of the foveal avascular 
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zone (FAZ): Extra-foveal; 200-1500µm from the centre, Juxta-foveal; 1-200µm 
and sub-foveal. Most membranes are sub-foveal at presentation.6 
Occult CNV is used to describe CNV when its limits cannot be fully defined on 
FA, typically when growth is between the RPE and Bruch’s membrane. Variants 
distinguished in the MPS classification 65 are fibrovascular pigment epithelial 
detachment (PED) and ‘late leakage of an undetermined source’ (LLUS), areas 
of leakage in the late phase of the angiogram without classic CNV or 
fibrovascular PED. CNV may be said to be ‘predominantly’ or ‘minimally’ classic 
when the classic component is greater or less than 50% of the total lesion size. 
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Figure 7: Schematic illustration of progression of pathological 
neovascularisation associated with wet AMD 
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Figure 8: FA of choroidal neovascularization. (a and b) Classic subfoveal; (c and 
d) very large subfoveal; (e and f) occult (image from Kanski J(2007) Clinical 
Ophthalmology: A systemic approach  Pub Elsevier Saunders) 
 
1.7 Treatments for AMD 
The goal of AMD treatment is to delay or reduce the risk of visual acuity loss. 
There is still a high incidence of persistence and recurrence of CNV shown in 
histopathological studies of excised, previously treated CNV membranes.62 
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1.7.1 Laser 
Lasers are devices that emit light (electromagnetic radiation) based on 
stimulated emission of photons. The term “laser” originated as an acronym for 
light amplification by stimulated emission of radiation.66  Photocoagulation is the 
process by which clotting of tissue occurs on exposure to laser energy that is 
selectively absorbed by haemoglobin, the pigment in red blood cells, in order to 
seal leaking blood vessels.  
During the 1980s and 1990s the Macular Photocoagulation Group (MPS) 65 
established the efficacy of thermal laser photocoagulation to treat selected 
patients with neovascular age related macular degeneration. In controlled 
studies the MPS group showed that laser photocoagulation slowed the loss of 
visual acuity in selected patients with CNV secondary to AMD.65 The likelihood 
of success with laser photocoagulation was affected by initial visual acuity, CNV 
type, size of the lesion, and the location of the lesion relative to the fovea. As a 
result of these findings, laser photocoagulation is recommended only for 
patients with well defined extra-foveal or juxta-foveal CNV.67, 68 Additionally, 
patients with small sub-foveal lesions can be treated if the lesion is well 
demarcated and has evidence of classic CNV.69 Application of these eligibility 
criteria in clinical practice has shown that laser photocoagulation is a suitable 
treatment for about 13 to 26% of patients with neovascular AMD.67 Laser 
photocoagulation has its limitations. Treatment of sub-foveal lesions by laser 
therapy destroys the retinal tissue overlying the lesion and may result in an 
immediate loss of visual acuity and irreversible loss of visual function. A high 
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rate of recurrence of CNV after thermal laser photocoagulation has been 
reported. Over 50% of laser treated eyes have persistent CNV or recurrent CNV 
within 3 to 5 years of treatment and this is usually associated with further 
deterioration of vision. 68-70 
1.7.2 Photodynamic Therapy 
Verteporfin therapy is a two step process in which the drug is first administered 
by intravenous infusion and then activated in the target area by red light at a 
specific wavelength (689nm) by a non thermal diode laser. Activation of 
verteporfin leads to the formation of singlet oxygen that disrupts endothelial 
cells in the CNV target tissue, and induces platelet aggregation, 
photothrombosis, vascular occlusion, stasis of blood flow, and eventual 
eradication of CNV.71-74 
Verteporfin (visudyne) photodynamic therapy has been shown to inhibit leakage 
of blood and fluid from CNV 71 and has been used as an effective alternative to 
thermal laser therapy. The approval of verteporfin for subfoveal, predominantly 
classic CNV due to AMD in 2000 by the Food and Drug administration (FDA) in 
the USA represented a significant breakthrough. The safety and efficacy of 
verteporfin monotherapy has been demonstrated in approximately 1000 
patients enrolled in the Treatment of age related macular degeneration with 
photodynamic therapy (TAP) investigation, Verteporfin in photodynamic therapy 
(VIP) trial and Verteporfin in minimally classic CNV (VIM) trial. 72-77 Visual acuity 
benefits of verteporfin over placebo were sustained throughout 1 to 2 year 
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follow up.75, 76 The durable effects of verteporfin on vision and contrast 
sensitivity outcomes were demonstrated in the 5 year TAP extension75 and no 
new safety concerns or evidence of cumulative toxicities from repeated 
verteporfin therapy were raised.75, 76 Between 0.7% and 4.9% of patients treated 
with verteporfin in the TAP and VIP AMD trials developed acute severe visual 
acuity loss. 76 This was defined as a decrease in visual acuity of ≥ 20 letters 
within 7 days of therapy. However, it has been suggested that this does not 
outweigh the benefits of therapy.77 One of the advantages of verteporfin therapy 
is that it offers a finite course of therapy. Yearly treatment rates declined from 
3.5 treatments in the first year to 1 in the fifth year.  
1.7.3 Verteporfin in combination with anti-inflammatory agents 
In addition to robust anti-inflammatory effects, corticosteroids have 
antiangiogenic, antifibrotic and antipermeability properties.78, 79 Corticosteroids 
are potent inhibitors of neovascularisation, and have been shown to act on the 
neovascular cascade by directly suppressing levels of VEGF.80, 81 Combination 
therapy of verteporfin with intravitreal triamcinolone appears to be associated 
with stabilization of visual acuity rather than sustained improvements. 82, 83 
Intravitreal triamcinolone is associated with increased intraocular pressure 84 
and cataract progression,85 it is still considered a therapeutic option if patients 
are monitored regularly and prescribed glaucoma medication if necessary. 
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1.7.4 Anti-VEGF treatment 
Angiogenesis, which is the growth of new blood vessels from existing 
vasculature is associated with loss of visual acuity in various ocular conditions86 
In neovascular AMD growth of abnormal blood vessels in the macula region 
leads to loss of vision. Early events in choroidal neovascularisation (CNV) 
development such as oxidative stress and ischaemia promote the production of 
vascular endothelial growth factor (VEGF) which is a key component of the 
pathogenic process leading to development of CNV.87-89 The main aims of anti-
VEGF therapies are to inhibit cell proliferation, reduce the formation and growth 
of new blood vessels and minimize vascular leakage. 
In 1948 Michaelson 90 postulated that a diffusible substance produced by the 
retina was responsible for retinal and iris neovascularisation. In 1992 Shweiki91 
et al demonstrated hypoxia induced VEGF mRNA expression in cell culture. 
Aiello et al 92 confirmed VEGF levels in ocular fluid correlated with 
neovascularisation secondary to diabetic retinopathy and ischaemic retinal vein 
occlusion. In 1996 Kvanta et al 93 confirmed a role for VEGF in choroidal 
neovascularisation. Since initial discovery of the VEGF gene (now known as 
VEGF-A) several closely related genes have been identified including VEGF-B, 
VEGF-C, VEGF-D and PIGF (placental growth factor). VEGF-A signalling 
represents the rate limiting step in normal and pathogenic angiogenesis.94 The 
VEGF-A gene consists of several different isoforms.95 VEGF-165 is the 
predominant isoform and the primary mediator of neovascularisation in the 
eye.96  
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The primary trigger of VEGF-A gene expression in the eye is hypoxia. 97,98 
Hypoxia inducible factor (HIF-1) a transcription factor, is a key player in hypoxic 
responses in the cell 98 and is the primary mediator of hypoxia induced gene 
expression of VEGF-A. 
VEGF exerts multiple effects on endothelial cells relating to its function as a pro-
angiogenic factor. These include stimulation of cell proliferation, invasion, 
migration and enhancement of cell survival. The mitogenic effects of VEGF are 
mediated through protein C and MAPK (mitogen activated protein kinase) 
pathways. Endothelial cell survival is mediated by the phosphatidylinositol-3-
kinase (PI3 kinase/Akt pathway), and also by upregulation of anti-apoptotic 
proteins Bcl-2, and XIAP. Cell invasion and migration are mediated through 
upregulation of integrin expression, alteration of the cytoskeleton and induction 
of metalloproteinases.96, 99 VEGF has a potent effect on vascular permeability 
and this is of particular importance in the pathogenesis of choroidal 
neovascularisation. Vascular leakage is considered to facilitate angiogenesis 
because the leakage of plasma proteins and fibrin creates a gel like 
environment conducive to endothelial cell growth and migration. Increased 
permeability is a result of both vasodilatation and an uncoupling of endothelial 
tight junctions. VEGF induced increased vascular permeability seems to be 
mediated in part via the nitrous oxide synthase (NOS) pathway100 and this may 
explain why hypertension has been observed in some patients treated with 
VEGF inhibitors. 
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Pegaptanib (Macugen; OSI/Eyetech Pharmaceuticals, New York, USA) was the 
first anti-VEGF agent to be approved for neovascular AMD, conferring greater 
efficacy compared with sham injections.101 Despite this, a mean decline in 
visual acuity of up to 10 letters was observed at 54 weeks in patients receiving 
0.3 to 3.0mg pegaptanib.101 Pegaptanib has proved less efficacious than current 
treatments, possibly due to selective binding of VEGF-165 and is no longer 
used in most countries.102 
Subsequently, ranibizumab was developed and is the first therapy for 
neovascular AMD to result in significant improvement in visual acuity.103 
Ranibizumab (Lucentis; Genentech, San Francisco, CA, USA) was approved by 
the Food and Drug Adminstration (FDA), USA in June 2006 for use in the 
treatment of CNV secondary to age related macular degeneration. The 
fragment antigen binding (Fab fragment) is a region on an antibody that binds to 
antigens. The fragment crystallizable (Fc region) is the region of an antibody 
that interacts with cell surface receptors called Fc receptors and proteins of the 
complement system. Ranibizumab is a humanized, affinity maturated Fab 
fragment of a murine monoclonal antibody directed against human VEGF-A. As 
ranibizumab lacks the Fc region of a full length antibody it is less likely to incite 
an immune response as it is unable to bind to the complement C1q or Fc 
receptors.94 Its small size allows efficient penetration through the retina after 
intravitreal injection to reach pathologic blood vessels that are being formed in 
the retinal pigment epithelium-choroid complex.104 A randomized controlled 
trial105 in 716 patients with CNV due to AMD showed that after 12 months, 95% 
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of patients treated with monthly intravitreal ranibizumab (0.5mg) lost < 15 letters 
compared to 64% of those receiving placebo (p < 0.001). More patients 
receiving ranibizumab had improvements in visual acuity of ≥ 15 letters 
compared to placebo recipients (34% versus 5%; P <0.001) and benefits in 
visual acuity were maintained at 24 months.105 Ranibizumab was also shown to 
be superior to verteporfin in the treatment of 423 patients with predominantly 
classic neovascular AMD. The results106 showed approximately 95% of those 
treated with ranibizumab lost < 15 letters at 1 year, compared to 64% in the 
verteporfin group (P < 0.001).106  
Bevacizumab (Avastin; Genentech) is a full length humanised murine 
monoclonal antibody directed against human VEGF-A. It was approved by the 
FDA in 2004 for the intravenous treatment of metastatic colorectal cancer. Its 
potential for the treatment of CNV was first tested by Michels et al107 via 
intravenous infusion in a 12 week uncontrolled study. Positive effects were 
observed on both visual acuity and optical coherence tomography (OCT) and 
angiographic characteristics of neovascular lesions. Patients experienced a 
mean increase of blood pressure of 12mmHg in systolic blood pressure which 
was felt to be a deterrent to use of this systemic therapy for neovascular age 
related macular degeneration. However, the promising visual and anatomic 
results led investigators to consider intravitreal injection of bevacizumab.108 
Several short term, uncontrolled, non-randomized studies have demonstrated 
that bevacizumab has activity in patients with sub-foveal CNV secondary to 
AMD. Anatomic improvements in retinal thickness were accompanied by 
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increases in visual acuity.108-112 Intravitreal administration of bevacizumab has 
not resulted in systemic side effects of hypertension in any of these studies. The 
systemic concentration of bevacizumab after intravenous administration is 
several times larger than the systemic concentration seen after intravitreal 
injections and this may account for this observation. No specific toxicity 
associated with bevacizumab use has been demonstrated at the present time. 
However, the lack of large scale trials to establish safety have limited its use 
and it remains an unlicensed treatment for neovascular age related macular 
degeneration in the UK. 
Afilbercept is a novel anti VEGF drug developed by Regeneron 
Pharmaceuticals Inc. (Tarrytown, NY, USA). Structurally, Afilbercept is a fusion 
protein of key binding domains of VEGF receptors 1 and 2 combined with a 
human IgG Fc fragment.113 Afilbercept   is designed to inhibit placental growth 
factors 1 and 2, in addition to all isoforms of VEGF-A.113 In November 2011 the 
drug was approved by the FDA for use in neovascular AMD in the USA. The 
drug was approved by the national institute for health and clinical excellence 
(NICE) in July 2013 for wet AMD meaning that it is available for NHS patients. 
1.7.5 Factors limiting anti VEGF monotherapy in AMD 
The use of antiVEGF therapy has revolutionised the treatment of neovascular 
age macular degeneration, a condition which previously was largely untreatable 
and a significant cause of sight loss in the elderly. Despite the positive benefits 
  
33 
 
of therapy in maintaining and improving vision in patients, several factors may 
limit the use of anti-VEGF monotherapy that will now be discussed. 
Anti VEGF monotherapy does not improve vision in all patients and it appears 
frequent retreatment is necessary to maintain efficacy.105,106 In the two pivotal 
clinical trials establishing efficacy of treatment approximately two thirds of 
patients did not gain ≥ 15 letters at 12 months after treatment with 
ranibizumab.105,106 The cost of treatment and attendance for monthly treatment 
and follow up for many elderly patients led to studies to determine whether a 
less frequent dosing regimen was as effective as monthly intravitreal therapy.   
In one such study114 patients received ranibizumab monthly for 3 months 
followed by therapy quarterly thereafter. This provided improved visual acuity 
benefits compared with placebo at the 12 month follow up although the 
treatment effect declined in the ranibizumab groups during the quarterly dosing 
phase.114 The decreased treatment effect was accompanied by an increase in 
vascular leakage and mean retinal thickness during the quarterly dosing 
regimen suggesting some patients needed ranibizumab injections more 
frequently to control neovascular leakage.114 
VEGF inhibition alone although successful in reducing the level of sub-retinal 
fluid associated with CNV and helping prevent early CNV development is 
unlikely to have an impact on CNV pathogenesis once the vasculature becomes 
more established.115,116 In experimental models, anti-VEGF therapy becomes 
less effective at inhibiting vessel growth and regressing vessels as 
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neovascularisation develops over time. 116, 117 Hence, it is unlikely that complete 
and sustained resolution of CNV will be achieved with anti-VEGF therapy alone. 
Intravitreal injections merely control active leakage from the CNV and do not 
treat the underlying pathological process. Therefore, a rationale exists for a 
combination therapeutic approach targeting different processes involved in 
CNV. 
Currently, patients are subjected to a rigorous treatment regimen incorporating 
imaging and monthly intravitreal injections with no defined end point. Long term 
patient compliance is also likely to be affected by a high frequency of injections 
and some patients may be considered unsuitable for this type of treatment, 
including those with a chronic ocular or periocular infection. Induction 
maintenance anti VEGF regimens, comprising an induction phase of three 
injections at monthly intervals followed by injections as needed depending on 
assessment of disease activity based on OCT thickness is now in widespread 
use, following the protocol established in the prospective OCT imaging of 
patients with neovascular AMD treated with intraocular ranibizumab study 
(PrONTO) study.118 The aims of this study were to investigate after an induction 
phase of three consecutive monthly intravitreal ranibizumab injections whether 
an OCT guided treatment regimen could be used to maintain improvements in 
visual acuity over 2 years. However, the burden in terms of frequency of 
monthly clinic attendances still remains significant despite a reduction in the 
number of intravitreal injections administered. Sustaining improvements in 
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visual acuity associated with controlling disease activity with fewer treatments is 
a goal of combination therapy.  
Although ranibizumab is generally well tolerated, it has been associated with 
relatively infrequent serious ocular adverse events such as endophthalmitis. 
The incidence of endophthalmitis with ranibizumab was reported at 0.03% 
following 6,347 injections performed as an office based procedure.119 
The concern that anti VEGF blockage may lead to increased occurrences of 
stroke and cardiovascular events in patients has implications for long term use 
of intravitreal anti-VEGF therapies.120 Serious non ocular adverse events 
including myocardial infarction and cerebral vascular events were reported in 
<5% of patients in the MARINA and ANCHOR trials.105, 106 Recently, the 
comparison of age related macular degeneration treatments trial (CATT) has 
been published that aimed to assess the relative safety and efficacy of 
ranibizumab and bevacizumab and to determine whether an as needed regimen 
would compromise long term visual acuity as compared with a monthly 
regimen.121 The results of this trial demonstrated that the two drugs were 
comparable in efficacy when administered in identical regimens. However, 
mean decrease in central retinal thickness was greater in the ranibizumab 
administered monthly group than in other groups. Rates of death, myocardial 
infarction and stroke were similar for patients receiving either bevacizuamab or 
ranibizumab. The proportion of patients with serious systemic adverse events 
(primary hospitalizations) was higher with bevacizumab than with ranibizumab 
(24% vs. 19%, risk ratio 1.25; 95% confidence interval, 1.01 to 1.66). It is 
  
36 
 
important to note the limitations of the CATT121 study in answering the 
questions many have regarding the safety of bevacizumab.  
VEGF is an important molecule within the eye, which is not exclusively 
expressed by pathogenic neovascular tissues. Reduction of the number of anti-
VEGF injections would lower the risk of potential disruption of normal 
physiologic processes mediated by VEGF, as well as possible ocular and 
systemic side effects.122-124 
With regard to the current and future economic situation, savings in NHS 
expenditure are now an important government priority. The cost of drug 
treatment is an increasingly important consideration once equivalent efficacy 
and safety has been demonstrated. Ranibizumab costs significantly more than 
bevacizumab. 121 When this cost is extrapolated to the projected increased 
incidence of AMD with an ageing population this has important economic 
implications. 
1.8 Tetracyclines 
1.8.1 Anti-inflammatory actions of tetracyclines  
Tetracyclines were first identified in 1948 as the natural fermentation product of 
the soil bacterium Streptomyces aureofaciens and six years later were 
chemically purified for the first time.125 Since then, semisynthetic (SST) and 
chemically modified non-antibiotic tetracyclines (CMT) have been synthesized. 
The molecular modifications have served to enhance antibacterial activity, 
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improve tissue absorption and prolong their half life. Prolonged use of these 
compounds may lead to antibiotic resistance, however, chemical modification 
has been shown126 to generate compounds devoid of antibiotic action therefore 
rendering potential for long term use in the treatment of complications related to 
oxidative stress. 
Tetracyclines, are considered to possess clinically useful anti-inflammatory 
properties. Minocycline is a tetracycline derivative. In animals, tetracyclines 
have been shown to suppress delayed type hypersensitivity reactions, the 
rejection of transplants, 127 and the levels of immunoglobulins in the serum.126 
There is increasing awareness of the role of oxidative stress in causing tissue 
damage and disease progression in a variety of conditions. A therapeutic role 
for the non- antimicrobial actions of the tetracyclines will be discussed in this 
context before considering their potential for treatment of AMD. 
1.8.2 Therapeutic role for anti-oxidant actions of tetracyclines  
Oxidative stress is a unifying mechanism for production of reactive oxygen 
species and plays a significant role in the manifestation of insulin resistance, 
atherogenic dyslipidaemia129 and periodontal disease. 130 The term metabolic 
syndrome is used to describe a collection of risk factors for cardiovascular 
disease and type 2 diabetes. These include hyperglycaemia, hypertension, 
dyslipidaemia and a pro-inflammatory state often associated with obesity.131 
Fluctuating glucose levels associated with higher levels of cytokines during 
hyperglycaemic spikes contribute to oxidative stress induced damage more so 
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than chronically elevated levels.132 A nutritional overload resulting in excessive 
amounts of glucose and fatty acids leads to reactive oxygen species (ROS) 
production. Interactions between glucose and plasma proteins result in the 
formation of advanced glycation end products (AGE) which in turn initiate the 
production of TNF-α, IL-6, IL-18 and ROS contributing to chemical modification 
of lipoproteins and atherogenesis.133 Patients with the metabolic syndrome 
show significant correlation with the prevalence of severe periodontal disease 
initiated by pathogenic bacterial plaque. Periodontal disease is characterised by 
destruction of tooth supporting soft and hard tissues. This is associated with 
high levels of inflammatory cytokines, other markers of inflammation and 
oxidative stress such as C-reactive protein and low density lipoproteins.134 The 
link between cardiovascular and periodontal diseases is well documented while 
a causal relationship is more difficult to establish. Three months after intensive 
periodontal treatment in patients with a proven history of cardiovascular disease 
there was a significant reduction in levels of CRP and oxidised low density 
lipoprotein. 135  
Periodontal disease has a microbial aetiology and an inflammatory 
pathogenesis. Treatment strategy is based on controlling pathogenic bacteria to 
sub threshold levels for disease progression. This is achieved by performing 
periodontal root surface debridement.  The use of adjunctive antimicrobials in 
the management of periodontal diseases is well established.136 A systemic 
review comprising a meta analysis of 19 studies has shown that combining root 
surface debridement with sustained release antimicrobials was significantly 
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more effective in resolving periodontal disease than root surface debridement 
alone.137 Minocycline and doxycyline gel were used as sustained delivery for 
placement in the periodontal pocket.  
The tetracyclines are particularly versatile in their ability to combat oxidative 
stress, mop up free radicals and inhibit an excessive inflammatory response 
secondary to an antigenic stimulus.137 Doxycycline hyclate has been shown to 
accelerate periodontal wound healing in diabetic mice138 and humans.139 Similar 
studies with Arestin (minocycline microspheres) have shown reduction in 
glycosylated haemoglobin measured by HbA1c levels and improved periodontal 
disease control compared to root debridement alone.140 Adjunctive locally 
delivered doxycycline in periodontal pockets of smokers has been shown to be 
more effective than debridement alone141 in reducing inflammatory periodontal 
disease. These studies suggest use of adjunctive tetracyclines have a beneficial 
effect on healing responses in the management of periodontal diseases in 
diabetic patients who smoke.  
The tetracyclines have been shown to have cardioprotective effects related to 
suppression of inflammatory processes. Myocardial ischaemia is associated 
with the activation of matrix metalloproteinases and the serine proteinase 
plasmin. In a rat model, pretreatment with doxycycline has been shown to 
reduce myocardial infarct size by 37%.142 Doxycycline inhibited plasmin while 
treatment with a broad spectrum matrix metalloproteinase inhibitor had no 
effect. This suggests that doxycycline may reduce myocyte death and 
contribute to cardioprotection.  The antioxidant potency of minocycline has been 
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shown to be comparable with α-tocopherol, a synthetic form of vitamin E.143 The 
radical scavenging actions of minocycline are consistent with its multi-
substituted phenol ring similar to that of vitamin E belonging to the class of 
phenolic antioxidants. Minocycline was found to be more potent than α-
tocopherol in its radical scavenging potency and inhibition of lipid peroxidation 
by 316 and 200 fold respectively. Minocycline hydrochloride has been shown to 
be very effective at quenching H2O2 levels. These actions of minocycline could 
explain its potency in reducing periodontal disease progression and 
cardioprotection in reducing the size of myocardial infarcts.142 
A further study 144 investigated the effectiveness of Minocycline in attenuating 
oxidative stress induced neurotoxicity. The condition studied was vitiligo, an 
acquired and progressive disorder manifested by the selective destruction of 
melanocytes in the skin. A high level of hydrogen peroxide in plasma as well as 
within the skin lesions has been reported in vitiligo patients, which is thought to 
result in disappearance of melanocytes in this condition.  
In the study, 144 to investigate whether minocycline rescues melanocytes from 
hydrogen peroxide induced apoptosis, cultured mouse melanocytes were 
treated with hydrogen peroxide in the presence or absence of minocycline.  The 
results showed hydrogen peroxide decreased cell viability in a concentration 
dependent manner that was attenuated by Minocycline. The protective effect of 
Minocycline was associated with inhibition of c –Jun N terminal kinase (JNK) 
and p38 mitogen activated protein kinase (MAPK). The conclusions were that 
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minocycline may be used to prevent melanocyte loss in the early stages of 
vitiligo. 
1.8.3 Minocycline as a neuroprotectant 
It is well established 148 that inflammatory processes associated with 
neurodegenerative conditions and CNS trauma may exacerbate loss of 
neurones  and enhance functional deficits. Before describing the proposed anti-
inflammatory effects of minocycline a brief overview of the inflammatory 
response associated with spinal cord injury will be described. 
A spinal cord injury triggers a series of secondary mechanisms which cause 
progressive damage to an increasing amount of tissue adjacent to the primary 
injury over a period of hours to weeks. Secondary mechanisms include vascular 
changes, haemorrhage, ischaemia, metabolic failure, free radical formation, 
lipid peroxidation, cytokine release and inflammation.145, 146 These 
pathophysiological changes lead to necrotic together with apoptotic, neuronal 
and oligodendrocyte death, demyelination, cellular phagocytosis and axonal 
damage. 145, 146 The cellular reactions occur over hours to weeks, during which 
time therapeutic intervention may be achieved.  
Early after spinal cord injury, microglia, the immunocompetent cells of the CNS, 
are activated and are the primary source of pro-inflammatory cytokines, namely 
tumour necrosis factor (TNF-α), interleukin-1beta (IL-1β), and IL-6.147 This is 
followed by neutrophil invasion. Neutrophils produce and release many potential 
cytotoxic factors, including proteases, reactive oxygen species, and nitric oxide 
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and contribute to lipid peroxidation and protein nitration.148 Strategies to prevent 
the detrimental effects of neutrophil invasion and toxicity are beneficial after 
spinal cord injury.148 
Macrophages are the next immune cells to infiltrate the area. The activation of 
immune cells may be of benefit at some stages of spinal cord injury, other 
studies have shown that activated macrophages and associated cytotoxic 
products such as IL-6 contribute to secondary damage after spinal cord injury148  
 
1.8.4 Mechanism of Minocycline’s anti-inflammatory action in spinal 
cord injury 
Minocycline has been suggested to exert its anti-inflammatory effects by 
modulating microglia, immune cell action and subsequent release of cytokines, 
lipid mediators of inflammation, matrix metalloproteinases (MMPs), and nitric 
oxide release. Caspases are a family of cysteine protease enzymes that play 
essential roles in apoptosis (programmed cell death), necrosis and 
inflammation. A common finding in many of the minocycline studies is the 
consistent reduction of caspase 1 mediated liberation of IL-1β.149, 150 Similarly, 
minocycline suppressed TNF-α messenger RNA (mRNA) levels after spinal 
cord injury and prevented lipopolysaccharide (LPS) induced production of TNF-
α in primary glial cultures.151 In addition, the anti-inflammatory cytokine IL-10 
was up regulated following minocycline application immediately after spinal cord 
injury.152 
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Therefore, modulation of pro-inflammatory cytokines may contribute to 
minocycline’s neuroprotective effects. Minocycline may be neuroprotective by 
decreasing immune cell migration to sites of inflammation by altering levels of 
chemokines or chemokine receptor expression.  
Minocycline can also modify lipid mediators of inflammation. Minocycline 
treatment inhibited both secreted and non secreted forms of phospholipase A2 
in vitro.153 In a rat model of focal ischaemia, pre-treatment with minocycline 
almost completely reduced protein (COX-2) levels and reduced prostaglandin 
(PGE2) levels by 55%.149 Minocycline treatment has also been shown to abolish 
5-lipoxygenase translocation to the nuclear membrane in PC12 cells subjected 
to oxygen-glucose deprivation.154 PC12 is a cell line derived from rat adrenal 
medulla and is useful as a model for neuronal differentiation.155 Hence lipid 
mediated inflammatory signalling may be attenuated at several steps following 
minocycline treatment. 
An important role for MMPs in inflammation is well established. Both in vitro and 
in vivo studies have shown that minocycline treatment may reduce inflammation 
by inhibiting MMPs by diminishing cell infiltration and migration. Several MMPs 
especially MMP-12 increase after spinal cord injury and following brain 
haemorrhage and minocycline application downregulated MMP-12. 156  
Many studies148 have shown that minocycline may be neuroprotective by 
regulating nitric oxide production. Microglia/macrophage release of nitric oxide 
is thought to mediate neurotoxicity in several neurodegenerative diseases. In 
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cultured microglial cells, minocycline reduced hypoxia and excitotoxin induced 
nitric oxide production.157 In a gerbil model of global ischaemia, minocycline 
treatment reduced mRNA levels of cytokine derived nitric oxide synthase 
(iNOS) by 30% compared to saline treated controls, suggesting minocycline is 
effective at reducing iNOS expression in vivo.158 In addition to an indirect effect 
on cell death through dampening inflammatory reactions, minocycline has been 
shown to have a direct effect on preventing apoptotic cell death. 
1.8.5 Minocycline: An Anti-apoptotic agent 
Apoptosis is an active and highly regulated form of cell death characterized 
morphologically by cytoplasmic shrinkage, chromatin condensation and 
fragmentation, membrane blebbing, and the disintegration of the cell into 
membrane bound intracellular inclusion bodies.148 The apoptotic cell is 
subsequently removed by phagocytosis, a process, in contrast to necrosis, 
which does not induce an inflammatory response. Many of the features of 
apoptosis can be attributed to the specific cleavage of cellular proteins 
mediated by a family of cysteine proteases known as caspases. Mammalian 
caspases are synthesized as inactive pro-caspases, which require cleavage for 
activation and are often grouped according to function. Initiator caspases 
(caspase 2, 8, 9, and 10) function to activate effector caspases (caspase 3,6 
and 7), which cleave several apoptotic substrates involved in the orderly 
breakdown of the cell.159 
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Two main apoptotic pathways, the death receptor (extrinsic) pathway and the 
mitochondrial (intrinsic) pathway, have been described (Figure 9). The death 
receptor pathway involves binding of a death receptor (eg, Fas/CD95, TNF-α 
receptor) with its ligand and recruitment and activation of the initiator caspase-8, 
which in turn activate effector caspases (eg. caspase-3). The mitochondrial 
pathway involves activation of upstream pro-apoptotic factors that cause 
mitochondrial release of proteins cytochrome-c and second mitochondria 
derived activator of caspases (Smac), formation of an apoptosome, and 
sequestering of the inhibitor of apoptosis proteins (IAPs). These processes lead 
to the activation of initiator caspase-9, which in turn activates caspase-3. In 
addition, caspase independent cell death pathways involve the release of 
apoptosis inducing factor (AIF) from the mitochondria into the cytosol, where it 
translocates to the nucleus and contributes to DNA condensation and 
fragmentation. Once caspase-3 is activated, it cleaves many substrates 
including ICAD (inhibitor of caspase-activated deoxyribonuclease [CAD]) 
allowing for the liberation of CAD, an endonuclease that mediates the apoptotic 
internucleosomal cleavage of DNA.148 
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Figure 9: Apoptotic cell-death pathways and intervention following minocycline 
application. Minocycline may inhibit apoptosis by preventing the release of 
proapoptotic molecules (cytochrome c and apoptosis inducing factor [AIF]) (red 
signs = inhibition) and up-regulating antiapoptotic proteins including Bcl-2 and 
XIAP (green signs =stimulation). Dotted circle represents location of 
apoptosome. 
(modified from Stirling DP, Koochesfahani KM, Steeves JD and Tetzlaff W. 
Minocycline as a neuroprotective agent. Neuroscientist 2005; 11:314) 
 
The death receptor pathway involves activation of procaspase-8 and 
subsequent activation of effector caspases such as procaspase-3. The 
mitochondrial pathway involves cytochrome c release and formation of an 
apoptosome leading to activation of procaspase-9 and subsequent activation of 
procaspase- 3. 
 
1.8.6 Mechanism of minocycline’s survival promoting actions 
Minocycline treatment reduced caspase-3 activation160 following spinal cord 
injury (SCI). However, a direct effect of minocycline on caspase-1 and -3 activity 
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was ruled out using cell-free extracts, suggesting minocycline may act upstream 
of caspase activation.161 In support of these findings, reconstitution 
experiments, by adding cytochrome c to isolated cytosol extracts of kidney cells, 
confirmed that minocycline acts at the level of the mitochondria, and not 
downstream of cytochrome c release.162  
Minocycline mediated protection targets both caspase dependent (cytochrome 
c, Smac) and caspase independent (AIF) forms of cell death.159 Minocycline 
may also prevent apoptosis by increasing levels of anti-apoptotic factors 
potentially upstream of cytochrome c release. In vitro studies have shown that 
minocycline treatment protected kidney epithelial cells against apoptosis 
induced by hypoxia, azide, cisplatin, and staurosporine by selectively increasing 
the anti-apoptotic protein Bcl-2 (both mRNA and protein).162 Minocycline may 
also be neuroprotective by increasing levels of IAPs such as XIAP and thus 
preventing caspase activation and subsequent cell death. In support of this, it 
was demonstrated that in vivo pre-treatment with minocycline before 
ischemia/reperfusion injury of isolated rat hearts reduced both protein and 
mRNA expression of several initiator and effector caspases, diminished infarct 
volume, and lessened apoptotic cell death.163 Concomitantly, minocycline 
treatment reduced caspase activity as well as cytosol levels of cytochrome c 
and Smac, and increased XIAP expression. In addition, treatment with 
minocycline alone without ischemia/ reperfusion also reduced caspase-1, 3, 7, 
8, 9, and 12 expression below basal levels.163 
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Collectively, the results suggest that minocycline has a direct effect in inhibiting 
cell death by priming a “survival mode” rendering a cell less vulnerable to 
apoptotic stimuli. This may be due to up-regulation of anti-apoptotic proteins 
such as members of the Bcl-2 and/or IAP family that have been shown to 
antagonize the pro-apoptotic members of the Bcl-2 family and reduce caspase 
activation (Figure 9). In addition, minocycline may target the mitochondria 
directly and prevent the liberation of pro-apoptotic molecules such as 
cytochrome c, Smac, and AIF. 
Minocycline’s anti-apoptotic combined with its anti-inflammatory properties 
protects cells from several death-inducing stimuli and likely explains 
minocycline’s neuroprotective effects in CNS trauma and disease.148 Common 
signalling pathways may account for minocycline’s dual effects on cell death 
and inflammation, such as the p38 MAPK (mitogen activated protein kinase) 
pathway.148 
1.8.7 Effects of minocycline in the eye  
Several clinically diverse eye conditions involve inflammation as an important 
factor in their aetiology. The meibomian glands are modified sebaceous glands 
present in the eyelids that produce the lipid component of the tear film6 and 
chronic inflammation of the glands produces a condition known as blepharitis.6 
Minocycline has been used to treat meibomian gland dysfunction.164 In a 
prospective study of sixteen patients, to evaluate clinical impact, tear related 
parameters and meibomian gland dysfunction, three months of oral minocycline 
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resulted in clinical improvement in all cases of meibomianitis.  Minocycline has 
also been shown to have neuroprotective properties in retinal ganglion cells.165 
To investigate the effect of minocycline on the survival of retinal ganglion cells, 
a rat model of myelin oligodendrocyte glycoprotein induced experimental 
encephalomyelitis, an animal model of brain inflammation, was used. 
Inflammation of the optic nerve, known as optic neuritis in this model was 
diagnosed by recording visual evoked potentials. Visually evoked potentials 
record the electrical activity of the brain with a visual stimulus. The study165 
demonstrated minocycline induced neuroprotection is related to direct 
antagonism of multiple mechanisms leading to neuronal cell death such as 
induction of anti-apoptotic intracellular signalling pathways and a decrease in 
glutamate excitotoxicity. The conclusion was that minocycline exerts 
neuroprotective effects independent of its anti-inflammatory properties. 
Recently further research166 has been undertaken to elucidate the role of 
nuclear factor kappa B and mitogen activated protein kinases in light induced 
apoptosis of photoreceptors in culture and to explore the potential inhibitory 
effect of minocycline and sulforaphane on apoptosis. Mitogen-activated protein 
kinases (MAPKs) are serine or threonine kinases that play an important role in 
signal transduction from the cell surface to the nucleus. The mammalian MAPKs 
include p38, an extracellular signal-regulated kinase (p44/42), and Jun N-
terminal kinase (JNK). It has been shown that a balance between the survival-
promoting p44/42 pathway and the death-promoting the p38 and JNK pathways 
determine the fate of cells. Nuclear factor- B (NF- B) is a ubiquitous 
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transcriptional factor that regulates a broad range of genes and plays a role in 
cell death or survival. The MAPK and NF- B pathways may have both positive 
and negative effects on apoptosis, depending on the types of cells and stimuli. 
Researchers 166 investigated the expression of immunologic signalling 
molecules in light-induced apoptotic mouse 661W cells in culture. Cellular 
pathways regulating the light-induced photoreceptor apoptosis process, and the 
potential therapeutic effect of minocycline and sulforaphane on light-induced 
photoreceptor apoptosis was also studied.166 Sulforaphane is a naturally 
occurring isothiocyanate found in broccoli. The 661W photoreceptor cell line 
was originally isolated from transgenic mice. However, when compared with the 
in vivo photoreceptor cells, the 661W cells have limitations, they proliferate in 
culture, unlike photoreceptor cells in the differentiated retinas, they do not 
exhibit cone photoreceptor morphology, such as formation of outer-segment–
like membranes,  they do not express outer segment structural proteins, such as 
peripherin/rds and ROM1, and they do not express RPE65, an important 
determinant in rhodopsin regeneration as part of the visual cycle and light-
damage susceptibility in mice.166 
During the study, 166 661W cells in culture were exposed to light for four hours 
and were used as a model to investigate photoreceptor apoptosis. The results 
showed pretreatment of 661W cells with minocycline inhibited light-induced 
photoreceptor apoptosis and the down-modulation of the NF- B p65 subunit. 
However, minocycline had no direct effect on the expression of the MAPKs. 
Minocycline inhibited proteolytic cleavage of NF- B proteins. These 
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observations suggest that minocycline inhibits light-induced photoreceptor 
apoptosis partly through an NF- B-dependent mechanism. 
Results166 showed pre-treatment of 661W cells with sulforaphane inhibited light-
induced photoreceptor apoptosis and inhibited down-modulation of the p65 
subunit of NF- B, but it had no effect on the expression of the MAPKs. Like 
minocycline, sulforaphane also inhibited the proteolytic cleavage of NF- B 
proteins. The study166 suggests that sulforaphane inhibits light-induced 
photoreceptor apoptosis partly through an NF- B-dependent mechanism. 
 
1.9 Experimental Models for AMD research 
With the use of specific measures, RPE cells in vitro can be made to 
differentiate into a phenotype resembling RPE in vivo, displaying polarity, a 
columnar morphology, the presence of gap or even tight junctions and the 
presence of microvilli at their apical surface.167, 168 
RPE cells may be cultured on filter systems, to allow evaluation of polarized 
growth factor secretion or in co-culture systems with choriocapillaris endothelial 
cells or neuroretinal explants.167 Exposing the cells to substances such as rod 
outer segments, or advanced glycation end products (AGE), provides ways to 
investigate mechanisms involved in AMD, such as lipofuscin formation and 
oxidative stress.168 Increased protein cross linking and the accumulation of 
AGEs develop in ageing human Bruch’s membrane.169 In addition to effects on 
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the structural integrity of Bruch’s membrane, AGEs also exert pathogenic 
effects by interaction with cell receptors, the best characterised is RAGE 
(receptor for AGEs). RAGE has been implicated in long term diabetic 
complications, neurodegenerative diseases, acute and chronic inflammatory 
disorders and cancer.170 RAGE is a multi-ligand receptor and in addition to 
binding AGEs, RAGE also acts as a signal transduction receptor for amyloid β 
(Aβ) and S100/calgranulins. The S100/ calgranulins are a group of proteins 
involved in inflammatory responses. Amyloids are proteinaceous deposits 
contributing to the pathology of several pathological conditions. Amyloid is a 
component of drusen, with deposition thought to be AMD specific and several 
studies have addressed the molecular contribution of amyloid to the 
development of AMD.171, 172  
Ma et al (2007) 173 investigated the hypothesis that activation of RAGE by its 
ligands including AGEs, amyloid-β peptide (Aβ), and S100B/calgranulins 
modulates secretion of VEGF by retinal pigment epithelial (RPE) cells. The 
ARPE-19 cell line was used and VEGF secretion and gene expression were 
assessed by ELISA and quantative real time PCR. The results173 demonstrated 
ARPE-19 cells basally secreted VEGF under normal cell culture conditions. 
Immobilized ligands of RAGE increased VEGF secretion in a dependent 
manner. RAGE mediated upregulation of VEGF secretion by ARPE-19 cells 
was largely dependent on NF-ĸB. Inhibition of NF-ĸB effectively abrogated the 
response of RPE cells to RAGE ligands under conditions that would normally 
upregulate VEGF secretion. The authors173 used parthenolide, an active 
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substance in the medical herb Feverfew (Tanacetum parthenium) traditionally 
used in the treatment of inflammation. The authors173 concluded that the NF-ĸB 
dependent nature of RAGE stimulated VEGF secretion in RPE cells renders this 
pathway together with the RAGE axis itself a potential therapeutic target for the 
reduction of neovascular stimulus in eyes at high risk for progression of macular 
degeneration and further study would be necessary to define the role of RAGE 
and its ligands in the progression of AMD. 173  
Howes et al (2004)174 evaluated RAGE mediated cellular activation in the 
aetiology of human retinal aging and disease. Maculas of human donor retinas 
from normal eyes and eyes with early age related macular degeneration and 
advanced macular degeneration were assayed for AGE and RAGE by 
immunocytochemistry. Cultured ARPE-19 cells were challenged with known 
ligands for RAGE, AGE and S100B to test for activation capacity. 
Immunocytochemistry, real time polymerase chain reaction (PCR), immunoblot 
analysis and the terminal deoxynucleotidyl transferase dUTP nick end labelling 
(TUNEL) assay were used to determine the consequences of RPE cellular 
activation.174 The results174 demonstrated little immunolabelling for AGE or 
RAGE in photoreceptor and RPE cell layers in normal retinas. When small 
drusen were present AGE and RAGE were identified in the RPE or both RPE 
and photoreceptors.174 In early and advanced AMD the RPE and remnant 
photoreceptor cells showed intense AGE and RAGE immunolabelling. Both 
AGE and S100B activated cultured RPE cells, as revealed by upregulated 
expression of RAGE, NF-ĸB nuclear translocation and apoptotic cell death.174   
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Similarly, an in vitro RPE system that was challenged with matrix 
metalloproteinases (MMPs), their tissue inhibitors (TIMPS) and TNF-α was 
developed to study the pathogenesis of sub-RPE deposit formation.175 ARPE-
19 cells treated with TNF-α or MMP-2 showed a reduction in all types of sub-
RPE deposit and TNF-α stimulated MMP-9 production. 
1.9.1 Response of RPE cells to Oxidative stress 
Continual phagocytosis of photoreceptor segments and the high blood flow 
through the choriocapillaris results in oxidative stress via the production of 
hydrogen peroxide.17 
The RPE cells are responsible for the maintenance of the blood retinal barrier 
that is dependent on the function of tight junctions between the cells. 
Breakdown of this barrier may allow immune cells to gain access to the retina 
with subsequent release of pro-inflammatory cytokines. Tight junction proteins 
ZO-1 and occludin are present in ARPE-19 cell lines.61 Adherens junctions 
maintain the morphology of the RPE cells and various factors may disrupt the 
function of both tight and adherens junction proteins. Treatment of RPE cells 
with hepatocyte growth factor results in redistribution and loss of protein 
components.176 
The effect of oxidative stress on the ARPE-19 cell line, junctional integrity and 
the induction of stress proteins has been studied.177 Results showed ARPE-19 
cells response to oxidative stress induced with hydrogen peroxide differed with 
time in culture. 177 The cells cultured for five weeks were less sensitive to 
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oxidative stress than those cultured for one week.  The more differentiated cells 
expressed increased levels of heat shock proteins, Hsp27 and Hsp70 and it 
was suggested this may play a protective role by increasing intracellular 
glutathione, and also conferring resistance to apoptosis.177   
1.9.2 Response of RPE cells to effects of T lymphocyte products 
T lymphocytes are integral to the initiation, maintenance and resolution of the 
immune response. Human retinal epithelial cells (HRPE) express cell adhesion 
molecules and chemokines for leukocytes. 178,179 The T cell receptor –CD3 
complex and associated cell surface receptors are key mediators of lymphocyte 
activation when antigen is presented to lymphocytes by antigen presenting cells 
bearing HLA-DR antigens.180  Interleukin-8 (IL-8) and monocyte chemotactic 
protein-1 (MCP-1) are two chemokines responsible for the majority of pro-
inflammatory cytokine induced human RPE derived leukocyte chemotactic 
activity.178 IL-8 is chemotactic for neutrophils, lymphocytes and eosinophils 
whereas MCP-1 is chemotactic for monocytes and lymphocytes. Interferon-γ 
(IF- γ), a lymphokine produced by T-lymphocytes has been shown to have 
important immunomodulatory effects on human RPE cells including the 
induction of human leukocyte antigen (HLA)-DR and intercellular adhesion 
molecule.178-180 Research was conducted to examine the effects of T-
lymphocyte products on human retinal pigment epithelial (HRPE) cell 
interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) secretion and 
gene expression.178 Results of this study showed T lymphocyte secretions 
induce HRPE IL-8 and MCP-1 gene expression and secretion. TNF and IF-γ 
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appear to be necessary components of T-lymphocyte conditioned media for the 
induction of HRPE IL-8 and MCP-1. IL-2 did not appear to modulate cytokine 
induced HRPE IL-8 or MCP-1. The study178 suggested lymphokine secretions 
containing TNF-α and IF-γ may affect leukocyte recruitment at the blood retina 
barrier by inducing local chemotactic cytokines IL-8 and MCP-1 from the 
vascular endothelium and HRPE. Expression of HLA-DR and intercellular 
adhesion molecule-1 on HRPE cells and vascular endothelium was also 
induced, resulting in leukocyte accumulation, activation, and trafficking at the 
retinal-choroidal interface. 
1.9.3 Glycated albumin 
Various stimuli, such as IL-1β, tumour necrosis factor (TNF-α), and glycated 
human serum albumin (GHSA) have been shown to stimulate human RPE IL-8 
and MCP-1 secretion.181-183 GHSA is a glycation adduct. Protein glycation 
occurs in both normal and hyperglycaemic serum when glucose 
nonenzymatically attaches to lysine residues of the proteins and forms labile 
Schiff base intermediates that undergo Amadori rearrangement and lead to the 
relatively stable early adducts ketoamine or fructosamine.184 The ambient 
glucose concentration and protein turnover rate determines whether the early 
glycated proteins may eventually form irreversible advanced glycation end 
products (AGEs). Glycated proteins increase under hyperglycaemic conditions. 
Plasma levels of GHSA may vary from normal (400µg/ml) to 1000µg/ml in 
diabetics. 185 
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Enhanced protein glycation can be observed in experimental diabetes mellitus. 
A close correlation has been demonstrated between plasma glucose 
concentration and the degree of albumin glycation.186 Therefore, the amount of 
glycated albumin has been used as an index of short to intermediate term 
glycaemic control. 186 Increasing evidence has suggested that early glycated 
albumin is not just an index of glycaemia or the precursor of AGEs. Glycated 
albumin itself, may have important direct effects on cellular function and hence 
play a pathophysiological role in microvascular complications of diabetic 
nephropathy and retinopathy. 181,187-190 Further evidence for the 
pathophysiological role of early glycated albumin is suggested by the existence 
of specific receptors for early glycated albumin.191-195 These receptors 
differentially bind Amadori modified glycated albumin, but not AGEs, suggesting 
that the functional role of early glycated albumin may differ from AGEs. An 
example of this is that early and advanced glycation products differently affect 
retinal microvascular cell growth.189 
1.9.4 Hypoxia 
In conditions of hypoxia, although oxygen is present demand exceeds supply. 
Aerobic organisms are dependent on the efficient oxygen dependent release of 
energy, stored in the chemical bonds of glucose through oxidative 
phosphorylation. Hypoxic conditions are not wholly pathological as uptake of 
oxygen is restricted in many species such as whales and burrowing animals.196 
Many indigenous human populations live at high altitudes so experiencing 
lowered oxygen tension and relative hypoxia. Acute hypoxia may be caused by 
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decreased blood flow, vessel contraction or occlusion and inflammatory 
conditions. Chronic hypoxia may be caused by high altitude. Specialised tissue 
such as the carotid body is sensitive to lowered oxygen tension. Hypoxia 
mediates effects on the nervous, respiratory and cardiac systems.196 Reduced 
oxygen tension in the liver and kidney results in the production and release of 
erythropoietin (EPO) with subsequent increase in the production of red blood 
cells.196 
The retina is the most metabolically active tissue in the human body, and hence 
the retina is highly sensitive to reduction in oxygen tension.196Therefore, any 
disturbances in oxygen delivery into the retina as a result of lung or cardiac 
disease, or local occlusive vascular diseases with inflammation in the eye will 
ultimately lead to hypoxia conditions in the retina that may elicit development of 
AMD. 197, 198 
1.94.1 Regulation of vascular endothelial growth factor  
In adults VEGF has been widely considered to be a pathological factor in the 
development of choroidal neovascularisation (CNV), However, VEGF has 
important functions in the adult healthy retina. VEGF protects the retinal 
pigment epithelium (RPE), Muller cells, photoreceptors and retinal neurons. 199, 
200  
 VEGF expression and secretion are regulated on many levels by various 
factors, such as different transcription factors, 201 protein kinases 202 and 
receptor signalling. 203 
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For ocular tissue, differential involvement of mitogen activated protein kinases 
(MAPK) has been shown,204  as p38 is involved in constitutive VEGF expression 
and secretion, while extracellular signal regulated kinase 1/2 accounts only for 
oxidative stress induced VEGF increase, which is a likely transient 
phenomenon.205 
Klettner et al (2013)206 investigated the regulation of constitutive vascular 
endothelial growth factor in porcine RPE/choroid organ cultures. 206 VEGF 
content was evaluated with ELISA. The influence of several molecular factors 
was assessed with commercially available inhibitors. For toxicity measurements 
of inhibitors, primary RPE cells of porcine origin were used and toxicity was 
evaluated with methyl thiazolyl tetrazolium assay. The results showed VEGF 
secretion as measured in RPE/choroid organ culture was diminished after long 
term (48 hour) inhibition of VEGF receptor 2 by VEGF receptor 2 antagonist 
SU1498. VEGF secretion was also diminished by after phosphatidylinositol 3 
kinase was inhibited by Ly294002 for 48 hours. Coapplication of substances did 
not show an additive effect, suggesting that they use the same pathway in an 
autocrine positive VEGF regulation loop. 
Biochemical inhibitors were used, as small interfering RNA or specific 
antibodies were not feasible or affordable. Biochemical inhibitors have been 
well described in the literature. 207-209 The specificity of some biochemical 
inhibitors is under debate 210 which is a limitation of this study.  
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In endothelial cells VEGF induces the expression of HIF-1α, an important 
regulator of VEGF in hypoxia.211 HIF-1α induced upregulation of VEGF in 
hypoxia has been shown for RPE, 201 however, in the study of Klettner et al 206 
HIF-1α did not have an effect on constitutive VEGF secretion.  
Klettner et al 206 reported that inhibition of the transcription factor NF-ĸB by 
biochemical inhibitors exhibited a strong effect on VEGF secretion at all time 
points tested, 6 hours, 24 hours and 48 hours. This suggested constant 
influence of NF-ĸB on constitutive VEGF secretion. NF-ĸB is an important 
regulator of the innate immune response, 212 inhibitor of autophagic 
processes213 and involved in ageing. 214 All these factors are associated with 
development of AMD. 215 Control of VEGF expression regulated by NF-ĸB may 
be an interesting target for prevention of AMD development. 
Klettner et al 206 also showed that p38 inhibition for 24 and 48 hours regulated 
constitutive VEGF expression and secretion. The pattern of VEGF reduction in 
p38 inhibition resembled the pattern displayed by NF-ĸB inhibition. The effects 
of p38 and NF-ĸB inhibition appeared to be additive, suggesting the 
involvement of different pathways. VEGF secretion was completely abolished 
by coapplication of p38 and NF-ĸB inhibitors. 206 Similar inhibition of VEGF 
secretion is usually only seen when extracellular VEGF inhibitors such as 
bevacizumab or ranibizumab are used.216   This suggests that these pathways 
may offer alternatives for VEGF inhibition and possible therapeutic opportunities 
to delicately alter the amount of available VEGF in the retina. However, the 
results of Klettner et al 206 should be interpreted in view of the limitations of their 
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study. There are limitations in using biochemical inhibitors, and an in vitro 
porcine model may not reflect functioning in the aged human eye. 
 
 
1.94.2 Measurement of retinal hypoxia 
Due to the small calibre of retinal vessels, it is not possible clinically to directly 
measure blood flow, perfusion pressure or oxygen tension of the retina and 
optic nerve. Therefore, other indirect non invasive methods to measure these 
parameters are used. Photography, spectral or pulsatile changes of vessels, 
confocal scanning laser Doppler flowmeter, colour Doppler imaging, laser 
Doppler flowmeter, and Heidelberg retina flowmeter are examples of techniques 
that have been used to assess the blood flow of retina and optic nerve head.217 
1.94.3 Hypoxia in AMD 
It has been suggested that foveolar choroidal blood flow decreases in patients 
with AMD.218 As such, the reduction in choroidal blood flow could lead to 
ischaemia and hypoxia resulting in a plausible role for hypoxia in the 
development of CNV. This hypothesis is supported by deposition of materials 
and thickening of the RPE-Bruch’s membrane complex that occurs in AMD. 
This process may impede the diffusion of substances 219 and would increase 
the distance that oxygen must travel from the choriocapillaris to the 
photoreceptors, further reducing the availability of oxygen to the outer retina. 220 
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Studies in patients with asymmetric AMD disease suggest that ocular circulatory 
abnormalities may have role in the development of CNV. 221, 222 
Grunwald et al197 used laser Doppler flowmetry to assess relative foveolar 
choroidal blood velocity, volume, and flow. The study included a control group 
and the AMD study eyes were subdivided into three groups according to 
increasing risk for AMD. The results demonstrated that choroidal circulatory 
parameters decreased with an increase in severity of AMD features associated 
with risk for the development of CNV. This suggests a role for ischaemia in the 
development of AMD.  
Metelitsina TI et al 198 reported the results of a prospective study in a cohort of 
patients with AMD at risk of development of CNV. The purpose of the study was 
to investigate in a longitudinal fashion whether fovelolar choroidal blood flow 
decreases before the development of CNV and whether changes in blood flow 
precede the formation of CNV. The study was conducted over a time period of 5 
years. 
All study eyes198 had typical ophthalmoscopic features of AMD at baseline but 
no signs of CNV. CNV developed in 21% of eyes during the study.  In eyes with 
CNV, foveolar choroidal circulatory measurements decreased by approximately 
10% before the formation of CNV. This contrasted with findings in eyes that did 
not go on to develop CNV where choroidal circulatory parameters increased. 
Eyes with lower baseline foveolar choroidal flow were more likely to show visual 
loss than eyes with higher baseline parameters. These results198 suggest that 
  
63 
 
decreases in foveolar choroidal circulation precede the development of CNV in 
AMD and may play some role in its development.  
Alteration of transepithelial transport may function in the pathogenesis of age 
related macular degeneration. In 20-25% of patients with AMD, drusen become 
large and confluent 223 and establish large diffusion barriers between blood 
vessels and the RPE. This may lead to development of areas with reduced 
supply of oxygen and glucose, mimicking hypoxia. 17, 224 These regions of 
hypoxic stress may cause degeneration of adjacent photoreceptors and 
subsequent loss of vision in areas of drusen. A further consequence of 
metabolic stress might be the induction of choroidal neovascularisation (CNV), 
the most severe complication in the aetiology of age related macular 
degeneration.223 Hypoxia reduces the secretion of pigment epithelium derived 
growth factor (PEDF) by the RPE. 225 PEDF is a potent antiangiogenic factor. 
The hypoxic theory is supported by the observation that choroidal neovascular 
membranes contain high amounts of advanced glycation endproducts that are 
generated by reactive oxygen species during reduced metabolism. 226 
Recently, automatic retinal oximetry, which measures the haemoglobin oxygen 
saturation in retinal vessels has become a promising indirect method to quantify 
hypoxia in the retina. 227 Newer techniques confirmed previous hypotheses that 
because of decreased choroidal circulation, hypoxia is an important factor 
affecting the progression of AMD. 17,197,198,228 
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1.94.4 HIF gene 
Transcriptional regulation by an oxygen dependent transcription factor, hypoxia 
inducible factor (HIF) was discovered in the 1990s. HIF was originally found and 
characterised from human hepatoma cell culture where it was found to influence 
transcription of the erythropoietin gene. 229 
Specifically, HIF is a heterodimeric transcription factor composed of a labile 
oxygen sensitive alpha subunit (120kDa) and a stable constitutively expressed 
beta unit (92kDa). They bind to DNA at specific locations termed hypoxia 
responsive elements (HREs).230 
Human choroidal neovascular membranes associated with AMD contain HIF.231 
Since the production of VEGF in human retinal pigment epithelium cell culture is 
regulated by HIF232 any disturbance in HIF and associated inhibitory protein 
function instigated by oxidative stress and inflammation is likely to affect the 
formation of choroidal neovascularisation in the eye. 
Cells exposed to hypoxic stress either manifest an adaptive response or 
undergo cell death. The ability of cells to maintain a balance between 
adaptation and cell death is regulated through several mechanisms through 
which cells strive to prevent stress induced cellular damage. 232 
Oxidative stress has been implicated in the senescence of RPE cells and the 
pathogenesis of AMD. It occurs when the level of reactive oxygen species 
(ROS) exceeds the detoxifying capacity of antioxidants or molecular 
chaperones. 233 ROS which are formed damage lysosomal membranes of RPE 
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cells. This weakens their ability to remove the constant stream of metabolites 
released from rods and cones. In senescent RPE cells, this usually results in 
the accumulation of lipofuscin in lysosomes. 234 ROS and HIF are involved in 
stimulating angiogenesis in the retina.235 Intermittent hypoxia, followed by 
reoxygenation have been shown to determine the production of ROS, so 
leading to HIF activation and accelerated ageing and to the appearance of age 
related diseases. 236 Molecular responses ultimately lead to increased 
expression of VEGF which is the major growth factor triggering 
neovascularisation in the exudative form of AMD.  
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Chapter 2 
2.0 Rationale  
The following section provides an explanation for the rationale of the pre-clinical 
and clinical study presented in this thesis.  
2.1 Introduction 
Neovascular AMD is the leading cause of blindness in people ≥50 years of age 
in the Western world. The condition is characterized by choroidal 
vascularisation that has a complex pathogenesis involving neovascular growth, 
vascular leakage, matrix deposition, remodelling and inflammation. At present, 
the most effective treatment consists of VEGF blockade necessitating repeated 
intravitreal injections and a prolonged period of intensive follow up for patients. 
 
2.2 Retinal pigment cell physiology 
The retinal pigment epithelium (RPE) is a monolayer of pigmented cells forming 
the outer blood retinal barrier.237 As a layer of pigmented cells the RPE absorbs 
the light energy focused by the lens on the retina. The RPE transports ions, 
water and metabolic end products from the subretinal space to the blood. The 
RPE takes up nutrients such as glucose, retinol, and fatty acids from the blood 
and delivers these nutrients to photoreceptors. A well recognised process 
known as phototransduction occurs when absorption of light is converted to an 
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electrochemical signal. This process involves a substance, retinal, that is 
constantly exchanged between the photoreceptors and the RPE. This is known 
as the visual cycle.237 The photoreceptors contain high amounts of 
photosensitive molecules and are exposed to intense levels of light. This leads 
to accumulation of photo-damaged proteins and lipids. In addition, the retina 
itself generates photo-oxidative radicals. During each day, the concentration of 
light induced toxic substances increases inside the photoreceptors.238 Light 
transduction by photoreceptors is dependent on the proper function and 
structure of proteins and membranes. Therefore, to maintain the excitability of 
the photoreceptors, the photoreceptor outer segments (POS) undergo a 
constant renewal process. The tips of the POS that contain the highest 
concentration of radicals, photo-damaged proteins, and lipids are shed from the 
photoreceptors. Through co-ordinated POS tip shedding and formation of new 
POS, a constant length of POS is maintained.  Shed POS are phagocytosed by 
the RPE. The process of POS shedding and phagocytosis is under circadian 
control. 240 An increase in oxidative stress due to a reduction in protective 
mechanisms or an increase in number and concentration of active photo-
oxidative reactive species are believed to contribute to the pathogenesis of 
AMD.240  
2.3 Inflammatory pathophysiology of AMD 
It has been postulated that a starting point for the pathological process of AMD 
is the accumulation of lipofuscin in the RPE. 241 The onset of this chain of events 
is based on age dependent changes of the RPE. This includes a reduction in 
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the cell density of the RPE cells which may itself result from apoptosis, which is 
caused by accumulation of toxic substances. The increase in the amount of 
reactive oxygen species destabilizes intracellular membrane compartments 
such as lysosomes and mitochondria. The resulting decrease in metabolic 
efficiency produces more lipofuscin and reactive oxygen species. This 
generates a pro-inflammatory state promoting the development of AMD.  
Cytokine production including vascular endothelial growth factor release results 
in pathological neovascularisation leading to neovascular AMD.241 The 
inflammatory process and cytokine release involves complex pathways 
culminating in the pathological end point of neovascularisation. There is 
therefore a scientific rationale for targeting the inflammatory processes prior to 
the development of neovascularisation. The advantage of such an approach 
would be to implement therapy at an earlier stage of the pathological process so 
avoiding repeated anti VEGF injections with no defined end point to treatment. 
Repeated anti VEGF therapy imposes an increasing burden both for individual 
patients as well as the healthcare system. 
2.4 Rationale for anti-inflammatory therapy in neovascular AMD 
Anti-inflammatory agents such as intravitreal steroids are well established 
therapeutic modalities for ocular inflammatory conditions such as uveitis. 
However, their prolonged use is widely recognised to be associated with raised 
intraocular pressure and cataract formation. Minocycline has been recognised 
to have anti-inflammatory, antiapoptotic and neuroprotectant functions. It has 
also been shown to protect photoreceptors from light and oxidative stress. 
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However, the use of minocycline as a therapeutic agent in age related macular 
degeneration is yet to be established.  
The preclinical part of this study investigates the effects of minocycline on RPE 
cells in culture and the effects of minocycline on MCP-1 and IL-8 cytokine 
release. 
2.5 Rationale for clinical study 
Photodynamic therapy (PDT) was the first treatment shown to be of clinical 
benefit for most patients with subfoveal neovascular AMD. Standard 
photodynamic therapy is a two step process involving an initial intravenous 
infusion of verteporfin followed by irradiance with a 689nm laser for 83 seconds 
beginning 5 minutes after the infusion delivering a total energy of 50J/cm2. 
Verteporfin binds to low density lipoprotein receptors in the plasma during the 
infusion, which are then prefentially bound by choroidal neovascular tissue 
which then expresses low density lipoprotein receptors. Irradiation of the 
neovascular lesion by the laser creates toxic oxygen species that induce 
thrombosis and closure of the choroidal neovascularisation. 
Although the thrombosis predominantly affects choroidal neovascularisation, 
there is evidence of damage both to the choriocapillaris and retinal pigment 
epithelium. 242 The Verteporfin in Minimally Classic CNV Study examined the 
effects of both reduced fluence and standard fluence in minimally classic 
lesions. In such lesions, the study suggested that reduced fluence may be 
beneficial.243 Reduced- fluence PDT with 25 J/cm2 reduces choroidal perfusion, 
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inflammation, vascular leakage and VEGF upregulation that is associated with 
standard fluence PDT. 244 Reduced fluence PDT was used only once during the 
clinical study presented in this thesis. 
Anti-inflamatory agents such as intravitreal triamcinolone have been used as an 
adjunct for PDT to limit further VEGF upregulation initiated by the therapy.245 
Combination therapy has been shown to be beneficial when compared with 
PDT monotherapy in terms of functional results. 244,245 Triamcinolone has been 
associated with an increased risk of cataract formation 246 and raised intra-
ocular pressure.247 It was not until recently that replacement of triamcinolone 
with dexamethasone was considered.248 Triamcinolone that is injected as a 
suspension has prolonged effects, particularly with regard to raised intra-ocular 
pressure. Dexamethasone which is injected as a solution is more rapidly 
cleared from the vitreous; as there is no sustained release due to suspension, 
there is reduced risk of steroid induced side effects. 248 
Dexamethasone has anti-inflammatory, antifibrotic and anti-VEGF effects. 249-251 
Further, its antifibrotic effects are reduced in the presence of VEGF 252 so that 
the combination of dexamethasone with anti-VEGF therapy may assist with 
dexamethasone’s antifibrotic effects. Dexamethasone may reduce endothelial 
dysfunction and inhibit VEGF induced vascular dysfunction.249 
At the molecular level, dexamethasone exerts its anti-inflammatory effect by 
interfering with the activation of pro-inflammatory genes without affecting factors 
that inhibit inflammation.253 
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Minocycline is a semisynthetic derivative of tetracycline with a longer half life 
and improved penetration through the blood-brain barrier. Minocycline has been 
shown to protect melanocytes from apoptosis induced oxidative stress in vitiligo, 
a progressive disorder manifested by the selective destruction of melanocytes 
in the skin. 254 Leung et al 255 investigated whether minocycline and its 
structurally related analogues would protect photoreceptor cells in primary 
bovine culture from light and oxidative stress. Minocycline was shown to protect 
photoreceptors in culture but within a narrow therapeutic range of 
concentrations. 255 
It was postulated that minocycline may act as an adjunct for neovascular AMD 
in the combined treatment regimen used in the clinical study presented in this 
thesis. A reduced dose of ranibizumab (0.3mg in 0.05ml) was used in this study 
given the combined angio-occlusive effect of PDT and the effects of 
dexamethasone and minocycline. 
Combination therapy in exudative AMD is aimed at targeting the different 
pathways in the disease process while reducing or counteracting the adverse 
effects of individual therapeutic agents. The adverse ocular effects of PDT 
include choroidal hypoperfusion, inflammation, upregulation of VEGF production 
and scarring induced by irradiance. The adverse ocular effects of ranibizumab 
include the potential detrimental effects of chronic VEGF blockage on the 
function of the photoreceptors. Adverse ocular effects of dexamethasone 
include raised intra-ocular pressure and cataract. Minocycline as an individual 
agent has no specific adverse ocular effects except the rarely reported 
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association with idiopathic intracranial hypertension. 248 In terms of safety, 
potential negative synergistic effects of minocycline and PDT exist. In addition, 
a negative synergistic effect of inducing ischaemia in the choroidal and retinal 
circulation followed by atrophy exists with combined PDT, intravitreal 
ranibizumab and dexamethasone.  
In the clinical part of this study the safety and effectiveness of the combined 
therapy of intravitreal ranibizumab and dexamathasone, oral minocycline and 
verteporfin photodynamic therapy for subfoveal choroidal neovascularisation 
(CNV) secondary to age related macular degeneration (AMD) was assessed. 
The cause of AMD is not known, but it is known that many factors contribute to 
the final pathological end point of abnormal blood vessels. These factors involve 
cytokines and complex molecular reactions with a delicate balance between 
stimulatory and inhibitory factors.  Combined therapy, using agents that act at 
different points in the pathological pathway and therefore synergistically have 
the potential to be more efficiaous than monotherapy. This concept is gaining 
ground and many clinical trials have incorporated a number of combination 
modalities. 
2.6 Hypothesis and Aims 
Ischaemia and the resulting hypoxia at a cellular level are considered important 
aetiological factors in the pathogenesis of AMD the evidence for which has 
been discussed in Chapter 1 above.The biochemical changes of ageing lead to 
an accumulation of toxic substances within the RPE cell and in combination with 
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hypoxia are hypothesised to promote the process of inflammation. Inflammation 
and the release of cytokines are hypothesised to instigate pathological 
neovascularisation leading to neovascular AMD. 
Oxidative stress and inflammation are considered to be significant factors in the 
progression of metabolic conditions and minocyline has been shown to have 
therapeutic potential in inflammatory conditions and as a neuroprotectant as 
has been discussed in section 1.8.3 above. In this study, it is hypothesized that 
minocycline has a therapeutic role for the inflammatory component of 
neovascular AMD.  
The aim of this study is to investigate the mechanisms of action of minocycline 
on retinal pigment epithelium (RPE) cells in culture and to discuss the findings 
in the context of clinical trial data from patients with age related macular 
degeneration (AMD) receiving minocycline treatment. Minocycline is proposed 
to act as an anti-inflammatory agent and mediate its effects through reduction of 
oxidative stress and inhibition of apoptosis. The aims of this study will be 
achieved by culture of ARPE-19 cells using glycated human serum albumin and 
hypoxia as a source of oxidative stress. 
The effects of hypoxia and glycated human serum albumin on RPE cell viability 
and apoptosis and expression of pro-inflammatory cytokines, MCP-1 and IL-8 
will be investigated. The effects of minocycline on apoptosis rates and MCP-1 
and IL-8 production will be studied. 
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Chapter 3 
3.0 Pre-clinical study  
3.1 Introduction 
Primary cultures have been commonly utilized for RPE research as it is 
common for differentiated cells to lose their specialised properties after multiple 
passages. Primary cultures of RPE cells from various species have been shown 
to retain many normal physiological functions, including the ability to transport 
retinoids 238 and phagocytose rod outer segments. 239, 240 
Human eyes for use in primary culture are often difficult to obtain and as such 
cultures usually require purification before a uniform population of cells is 
established. Primary cultures may also exhibit physiological differences caused 
by donor to donor variability.  
3.2 ARPE-19 cell line 
ARPE-19 is a spontaneously arising human RPE cell line that has become a 
good alternative, though not superior to primary culture.256 
Dunn et al 257 extensively characterised this cell line in 1996 and demonstrated 
several phenotypic characteristics similar to those of primary RPE. Available 
passage numbers for this cell line are limited to those above p20.  
The transcriptional profile of RPE cultures including ARPE-19 cells and its 
proximity to native RPE has been described.258 Culture conditions were varied 
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and genes expressed were examined with array analysis. Hierarchical cluster 
analysis showed that confluent and differentiated serum withdrawn cultures 
clustered closest to native RPE, and that serum segregated cultured cells from 
native RPE. This suggests that serum influences multiple cellular functions 
including protein processing, signal transduction, cell cycle, metabolism, and 
transcription. As the outer blood retinal barrier is composed of the RPE and 
Bruch’s membrane, the RPE is probably partially shielded from serum by 
Bruch’s membrane. Hence RPE cells in vivo are not significantly exposed to 
serum.   
3.3 Materials and Methods 
3.3.1 Cell Culture 
The ARPE-19 cell line (American type culture collection, ATTC) were utilised in 
this study. Cells were cultured in Dulbecco’s modified eagle medium (DMEM) 
containing glutamax supplemented with 10% foetal bovine serum (GIBCO, 
Invitrogen, UK) and 1% penicillin-streptomycin (1000 units of penicillin/ 1mg 
streptomycin, GIBCO, Invitrogen, UK). Cells were incubated in 5% CO2 at 37°C. 
3.3.2 Cell passage and maintenance 
Cells were cultured in T75 flasks (Nunc, Thermo-fisher scientific, UK). A volume 
of 13ml of media was used per flask. All cell culture operations were performed 
in a class 2 laminar hood. Once established, cultures were visually checked 
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daily for media clarity. Turbidity suggested either infection or detached/dead 
cells. Media was replaced by fresh media every 2 days. 
When cells were approximately 80-90% confluent they were re-seeded in a 1:4 
ratio. Media, sterile phosphate buffered saline (PBS) and 0.25% trypsin-EDTA 
were warmed in a water bath to 37°C. 11ml of warm fresh media were placed in 
each of four T75 flasks and placed in the incubator with 5% CO2 at 37°C. Media 
was then removed from the flask to be passaged and the cells washed with 8ml 
of warmed sterile PBS. 2ml of warmed sterile 0.25% trypsin-EDTA (GIBCO, 
Invitrogen, UK) was added and the flask was placed at 37°C in 5% CO2 for 3 
minutes. The flask was tapped to detach and disperse the cells and viewed 
under the microscope. 8ml of fresh warm media was added to the flask and the 
contents of the flask ie. 10ml of cell suspension was centrifuged at 1200rpm for 
5 minutes at 4°C. The supernatant was discarded and the cell pellet 
resuspended in 8ml fresh warm media. The four flasks with 11ml of fresh warm 
media were retrieved from the incubator and 2ml of cell suspension from the 
flask to be passaged was added to each of the four flasks. The flasks were then 
replaced in the incubator with 5% CO2 at 37°C.  
All experimental work was performed using ARPE-19 cells seeded onto 6 well 
plates (NUNC, Thermoscientific, UK). Cells were cultured in DMEM 
supplemented with penicillin, streptomycin and 10% foetal bovine serum until 
80-90% confluent. Media was then changed to DMEM supplemented with 
penicillin streptomycin and 1% foetal bovine serum. Cells were maintained in 
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cuture with 1% foetal bovine serum for 2 weeks to allow differentiation before 
experiments were performed. 
 
3.3.3 Cell storage 
To ensure adequate cells were available for future use cells were frozen and 
stored. This was carried out when cells reached 80-90% confluence. Cells were 
detached with 0.25% trypsin-EDTA as decribed in section 3.3.2 and after 
adding media with 10% FBS, the suspension was centrifuged at 1200rpm for 5 
minutes at 4°C. The supernatant was discarded and the cell pellet resuspended 
in 1ml of freezing medium (10% dimethyl sulfoxide (DMSO), Fisher, UK) in FBS 
(GIBCO, Invitrogen, UK). 1ml samples of the suspension were then aliquoted 
into cryovials (NUNC, Thermo-fisher scientific, UK). The cryovials were stored 
at -150°C. 
3.3.4 Cell thawing 
When frozen cells were required for use 12ml of warmed media was added to a 
T75 flask and stored in the 5% CO2 incubator at 37°C. A cryovial containing 
frozen cells was warmed to 37°C in a water bath until no crystals remained. The 
contents of the cryovial were then added to the T75 flask and placed in the 5% 
CO2 incubator at 37°C. Cells were checked the next day under the microscope 
and media was replaced after 24 hours to ensure DMSO was completely 
removed from the culture media.  
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3.3.5 Cell counting 
Performing cell counts is a recognised method for studying cell behaviour in 
vitro. An immediate or short term reponse, such as an alteration in membrane 
permeability or perturbation of a particular metabolic pathway correlates with 
cell proliferation or survival.  
A Scepter hand held automated cell counter with 60µm disposable sensors 
(Merck Millipore, UK) was used to perform cell counts. The manufacture’s 
software allowed identification of the live cell population based on particle size. 
Smaller particles representing dead cells and debris were distinguished and 
excluded from the final cell counts. 
To perform cell counts, a sample of cell suspension was centrifuged at 1200rpm 
for 5 minutes at 4°C and the supernatant discarded. The cellular pellet was 
resuspended in 1ml of PBS, a 60µm sensor was attached to the Scepter cell 
counter and the sensor placed in the cell suspension. A reading was obtained 
and the live cell population identified by varying the software parameters. 
3.3.6 Cell viability and apoptosis 
Although the Scepter cell counter was able to broadly distinguish the live cell 
population from debris and dead cells, the limitations of the software did not 
allow identification of cells undergoing apoptosis. Hence flow cytometry was 
utilised with propididium iodide (PI), BD Pharmingen, UK) and FITC Annexin V 
(BD Pharmingen, UK). A BD Accuri™ C6 flow cytometer was used. 
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One part of 10X Annexin V binding buffer (BD Pharmingen, UK) containing 
0.1M Hepes/NaOH (pH 7.4), 1.4 M NaCl and 25mM CaCl2 was diluted with 9 
parts of distilled water for a 1X working solution. 
Cells were washed twice with cold PBS and then resuspended in 1X binding 
buffer at a concentration of 1 x 106 cells/ml. Then 100µl of the solution (1 X 105 
cells) was transferred to an eppendorf tube. Following this, 5µl of FITC Annexin 
V and 5µl of PI was added and the cells were gently vortexed and incubated for 
15 minutes at room temperature (25°C) in the dark. 400µl of 1X binding buffer 
was added to each tube. Analysis by flow cytometry was performed within 1 
hour. Samples were analysed in triplicate. Three control groups were used for 
compensation: unstained cells, cells stained with FITC Annexin V only, and 
cells stained with PI only. 
3.3.7 Glycated albumin 
The effects of glycated albumin were simulated by preparing a glycated albumin 
solution. A 25mg vial of lyophilised glycated albumin (Sigma Aldrich, UK) was 
reconstituted with 2.5ml PBS to make a solution of 10mg/ml. This solution was 
then diluted into 2mg/ml aliquots and stored at -25°C. 
For a negative control, non glycated human albumin (Sigma Aldrich, UK) was 
used. 50ml PBS was added to 5g of non glycated albumin to prepare a 
100mg/ml solution. This solution was then diluted into 2mg/ml aliquots and 
stored at -25°C.  
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ARPE-19 cells were cultured in T75 flasks (Nunc, Thermoscientific) in DMEM 
supplemented with 10% FBS until 80-90% confluent. Cells were then seeded at 
5 x 104 cells per well onto 6 well plates (Nunc, Thermoscientific) and maintained 
in culture until 80-90% confluent in a humidified incubator at 37°C with 5% CO2. 
Media was then replaced with serum free media (SFM) for 16 hours prior to 
experiments. 
Once defrosted, 500µg samples of diluted glycated albumin were added to each 
well of a six well plate. 500µg samples of diluted albumin were used as negative 
controls and cell counts and analysis with flow cytometry was performed after 
24 hours as described in sections 3.3.5 and 3.3.6. 
3.3.8 Positive controls: Interleukin 1-β and tumour necrosis factor-α 
Interleukin 1-β (IL-1β, Merck Millipore, UK) and tumour necrosis factor α (TNF-
α, Merk Millipore, UK) were used as positive controls to stimulate the production 
of MCP-1 and IL-8 in ARPE cells. 
A vial containing 10µg of recombinant human interleukin-1β (Merck Millipore, 
UK) was reconstituted with 100µl of distilled water to yield a dilution of 100ng/µl. 
This was then aliquoted into 2µl (200ng) samples and stored at -20°C until 
required. When required, a sample was defrosted and diluted by addition of 
18µl of PBS to yield a concentration of 10ng/µl. 
A vial containing 50µg of recombinant human TNF-α (TNF-α, Merk Millipore, 
UK) was reconstituted with 100µl of distilled water yielding a concentration of 
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500ng/µl. Aliquots of 4µl (2000ng) were stored at -20°C. For use, aliquots were 
defrosted and diluted with 396µl of PBS equivalent to a concentration of 20ng 
per sample. 
3.3.9 Inhibitor preparations 
Ly294002 (Sigma Aldrich, UK), a specific inhibitor of the phosphatidylinositol-3-
kinase (P13K) pathway was used. 1mg was added to 29ml of dimethyl sulfoxide 
(DMSO) (Sigma Aldrich, UK) resulting in a solution of 100µM/ml.  
500µl of this solution equivalent to 50µM was used to treat ARPE-19 cells.  
SB202190 (Sigma Aldrich, UK) a p38 inhibitor was prepared by adding 5mg to 
50ml DMSO (Sigma Aldrich, UK) resulting in a solution of 300µM/ml.  
100µl of this solution equivalent to 30µM was used to treat ARPE-19 cells 
JSH-23 (Sigma Aldrich, UK) a NF-ĸB p65 subunit inhibitor was used. 
5mg was added to 41.5ml of DMSO (Sigma Aldrich, UK) to prepare a solution of 
500µM/ml 
100µl of this solution equivalent to 50µM was used to treat ARPE-19 cells. 
3.4 Hypoxia 
For hypoxic experiments a second incubator (Sanyo, Panasonic, USA) was 
used. Cells were mainatained at 37°C in a humidified environment with 5% 
CO2. Nitrogen was used to diplace oxygen to generate various hypoxic states. 
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Cells were maintained in hypoxia (2% oxygen) for 24 or 48 hours prior to 
experiments. 
3.4.1 Experimental design 
Minocycline (Sigma Aldrich, UK) was used for experimental work. 0.1g was 
dissolved in 5ml of PBS. 0.5ml of this solution was diluted 1:2 to prepare a 
10mM concentrated solution. This was diluted 1:10 for a working solution of 
100µM/ml equivalent to 1µM in 10µl.  
The first experiments were conducted to determine the effects of minocycline on 
the viability and growth of human RPE (ARPE-19) cells in culture. 
ARPE-19 cells were thawed from frozen as described in section 2.14 and 
maintained in T75 flasks with DMEM supplemented with 10% FBS and penicillin 
streptomycin as described in section 2.12. When cells reached 80-90% 
confluence they were detached with trypsinisation as described in section 3.3.2 
Cells were reseeded at 5 x 104 per well in 6 well plates and the next day media 
was replaced with serum free media for 16 hours prior to addition of varying 
concentrations of minocycline. Cells were exposed to minocycline for 24 hours, 
then the media was discarded and the cells were detached with trypsin and 
resuspended in 1 ml of PBS for cell counts measured with the Scepter handheld 
automated cell counter.  
For construction of cell growth curves, eight 6 well plates were used. In each of 
the eight plates 3 wells were seeded with 5 x 104 cells per well. Cell counts 
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were performed in triplicate on eight successive days using the Scepter cell 
counter. 
To investigate the effects of hypoxia, IL-1β, TNF-α and minocycline on ARPE-
19 cell apoptosis rates, cells were analysed with annexin V and propidium 
iodide staining and flow cytometry. 
The effects of varying concentrations of minocycline on ARPE-19 cell viability 
were investigated. A concentration of minocycline that did not affect cell viability 
was identified. 
To investigate the effects of minocycline on MCP-1 and IL-8 production from 
ARPE-19 cells human glycated albumin (Sigma Aldrich, UK) 500µg was added 
to serum free culture medium for 16 hours to induce production of the cytokines. 
TNF-α (Millipore, UK) 20ng and IL-1β 20 ng (Millipore, UK) were also used to 
induce cytokine release from ARPE-19 cells as positive controls. TNF-α and IL-
1β are well established inflammatory mediators. Human albumin (non glycated) 
(Sigma Aldrich, UK) was used as a negative control when added to 6 well plates 
in the experiments. Experiments were performed in normoxic conditions where 
cells were placed in a 5% CO2 incubator at 37°C and also in hypoxic conditions 
where cells were placed in a hypoxic incubator with 2% O2, 5% CO2. 
Experiments with minocycline added as pretreatment to serum free media prior 
to stimulants was performed. Minocycline was also added to serum free media 
after 16 hours of exposure to stimulants to investigate treatment effect. 
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The supernatant was then collected and stored at -80°C. The cells were lysed 
with a cell lysis buffer and also stored at -80°C. 
Samples were then defrosted and analysed by enzyme linked immunosorbent 
assay. A brief description of the technique is described below, a detailed 
protocol is provided in Appendix A. 
For IL-8, a solid phase sandwich enzyme linked immunosorbent assay (ELISA) 
was used (Invitrogen, UK). A monoclonal antibody specific for human IL-8 had 
been coated onto the wells of a microtiter strip provided. Samples, including 
standards of known human IL-8 content, control specimens, and unknowns, 
were pipetted into these wells followed by the addition of a second biotinylated 
monoclonal antibody.  
During the primary incubation, the human IL-8 antigen binds to the immobilized 
(capture) antibody on one site and to the solution phase biotinylated antibody 
on a second site. 
After removal of excess second antibody, streptavidin- peroxidase (enzyme) 
was added. This bound to the biotinylated antibody to complete the four 
member sandwich. After a second incubation and washing to remove the 
unbound enzyme, a substrate solution was added, which was acted upon by the 
bound enzyme to produce colour.  The intensity of the coloured product is 
directly proportional to the concentration of human IL-8 present in the original 
specimen. The intensity of colour was measured at 450nm utilising a Varoskan 
Flash platereader (Thermoscientific, UK). 
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A similar process was used for MCP-1 ELISA (Abcam, UK). During this assay 
an antibody specific for human MCP-1 coated on a 96 well plate was used. 
Standards and samples were pipetted into the wells and MCP-1 present in a 
sample was bound to the wells by the immobilised antibody. The wells were 
washed and biotinylated antihuman MCP-1 antibody added. After washing away 
unbound biotinylated antibody, HRP –conjugated streptavidin was pipetted into 
the wells. The wells were again washed, a 3, 3’,5,5’-tetramethylbenzidine (TMB) 
substrate solution was added to the wells and colour developed in proportion to 
the amount of human MCP-1 present in the original specimen. Stop solution 
was then added to the wells and the colour changes from blue to yellow. The 
intensity of the colour was measured at 450nm with a Varoskan Falsh 
platereader (Thermoscientific, UK) 
3.4.2 Statistical analysis 
Data were analysed with graphpad prism, version 6.2 (Graphpad, CA, USA). 
Data for cell viability and apoptosis were analysed utilising a non-parametric 
approach using a Kruskal-Wallis test. This approach was used as it was 
assumed that the results would be skewed and not normally distributed. It was 
assumed that the results in each experimental group would have the same 
distribution which is a limitation of the test. Kruskal Wallis 259 tests whether the 
probability that a random observation from each group is equally likely to be 
above or below a random observation from another group.The data quantity 
used in the comparison is the median of all pairwise differences.  
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Results from IL-8 and MCP-1 ELISA were analysed with a one way ANOVA as 
a comparison between more than two experimental groups was utilised. The 
model assumes data is normally distributed, and the one way ANOVA is 
considered a robust test against the normality assumption. Tukey’s test260 was 
used in conjunction with an ANOVA to compare the mean of every experimental 
treatment to the mean of every other treatment. It was therefore applied 
simulataneously to the set of all pairwise comparisons. The assumptions of the 
Tukey260 test are that the groups with each mean in the test are normally 
distributed, there is equal within group variance across the groups associated 
with each mean in the test, and that the observations being tested are 
independent within and among the groups. 
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3.5 Results  
3.5.1 Effects of glycated albumin and hypoxia on ARPE-19 cell growth 
 
Figure 10: ARPE-19 cell growth curves in normoxia, normoxia with glycated 
albumin and hypoxia (2% oxygen). Each growth curve represents the results of 
three independent experiments performed in triplicate. Each data point 
represents the mean ± standard deviation. 
 
The first series of experiments were conducted to establish a therapeutic range 
for minocycline on ARPE-19 cells in culture. Minocycline concentrations above 
5µM adversely affected cell viability (Figure 11).  
 
 
 
 
 
 
 
 
 
 
Glycated 
Albumin 
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3.5.2 Concentration dependent effects of Minocycline on ARPE-19 cell           
         viability 
 
Figure 11: Concentration dependent effects of minocycline on ARPE-19 cell 
viability. The graph shows the percentage of non viable cells identified with 
propidium iodide staining utilising flow cytometry. Data shown in Appendix C, 
table 33, page 216 
  
89 
 
 
3.5.3 Effects of minocycline and hypoxia on ARPE-19 cell viability 
 
Figure 12: Proportion of cells that are non viable and prodium iodide (PI) positive 
after exposure to hypoxia and minocycline 5µm. Cells were exposed to each 
experimental condition for 24 hours. Three independent experiments were 
performed in triplicate for each condition investigated. Results show the 
mean±SD. A Krushkal wallis test did not demonstrate a difference between the 
four experimental conditions. C= Control 
Data shown in Appendix C (page 199) 
  
Figure 12 shows that hypoxia (2% oxygen) for 24 hours and minocycline 5µm 
did not adversely effect cell viability. 
The next set of experiments were conducted to determine the proportion of 
ARPE-19 cells undergoing apoptosis under different experimental conditions. 
The results are shown in  figure 13 below. 
 
 
Percentage of non viable cells 
C 
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3.5.4 Effects of minocycline and hypoxia on apoptosis  
 
Figure 13: Proportion of cells undergoing apoptosis and annexin V positive after 
exposure to hypoxia and minocycline 5µm. Cells were exposed to each 
experimental condition for 24 hours. Three independent experiments were 
performed in triplicate for each condition investigated. Results show the 
mean±SD. A Krushkal wallis test did not demonstrate a difference between the 
four experimental conditions. C = Control 
Data shown in Appendix C (page 200) 
  
 
Figure 13 shows that hypoxia (2% oxygen) for 24 hours and minocycline 5µm  
 
did not increase ARPE-19 apoptosis rates.  
 
 
 
 
 
 
 
 
 
 
 
 
C 
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3.5.5 Effects of glycated albumin on ARPE-19 cell viability after exposure 
to minocycline and hypoxia.  
  
 
Figure 14: Proportion of cells that are non viable and prodium iodide (PI) positive 
after exposure to glycated albumin, hypoxia and minocycline 5µm. Cells were 
exposed to each experimental condition for 24 hours. Three independent 
experiments were performed in triplicate for each condition investigated. Results 
show the mean±SD. A Krushkal wallis test did not demonstrate a difference 
between the four experimental conditions.  
C= Control. Data shown in Appendix C (page 201) 
 
Figure 14 shows cell viability did not differ when ARPE-19 cells were exposed 
to different conditions of glycated albumin, in combination with minocycline 5µm 
or hypoxia (2% oxygen). 
To investigate the effects of glycated albumin on apoptosis after exposure to 
minocycline and hypoxic conditions further experiments were conducted, the 
results of which are shown in figure 15. 
 
Percentage of non viable cells 
C 
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3.5.6 Effects of glycated albumin on apoptosis after exposure to 
minocycline and hypoxia. 
 
Figure 15: Proportion of cells undergoing apoptosis and annexin V positive after 
exposure to glycated albumin, hypoxia and minocycline 5µm. Cells were 
exposed to each experimental condition for 24 hours. Three independent 
experiments were performed in triplicate for each condition investigated. Results 
show the mean±SD. A Krushkal wallis test did not demonstrate a difference 
between the four experimental conditions. C=Control. Data shown in Appendix C 
(page 202) 
 
 
Figure 15 shows that apoptosis rates did not differ when ARPE-19 cells were 
exposed to experimental conditions of glycated albumin, combined with  
hypoxia (2% oxygen) for 24 hours and minocycline 5µm. 
 
Increased doses of minocycline above 5µM and increasing the length of 
exposure to hypoxia (2% O2) to 48 hours resulted in the majority of cells 
becoming non viable. Therefore, further hypoxic experiments were performed 
with 24 hours exposure to 2% oxygen and minocycline concentrations of 5µM 
C 
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were used. These conditions were used to investigate IL-8 and MCP-1 cytokine 
production from ARPE-19 cells and the effects of minocycline.  
3.6 IL-8 ELISA  
A standard curve was constructed from the results of duplicate standard 
dilutions as per instructions provided by the manufactor (Invitrogen, UK). The 
absorbance of the standards against the standard concentrations was plotted 
on a logarithmic scale.  
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Figure 16: IL-8 standard curve Results show Optical densities (OD) measured at 
450nm plotted against IL-8 concentration in picogrammes per millilitre (pg/ml). 
Results are plotted using a logarithmic scale. Each point represents the 
mean±standard deviation of standard dilutions of IL-8 measured in duplicate.  
 
3.6.1 Reproducibility of IL-8 ELISA 
Intraplate and interplate reproducibility  tests were performed. A pair of positive 
and negative controls were tested 30 times in the same plate (intraplate) and 
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this was then repeated in different plates (interplate) on different dates. Mean, 
standard deviation and coefficient of variation were calculated from both 
interplate and intraplate optical densities (ODs).  Results are shown in table 2 
below. 
Table 2: Reproducibility of IL-8 ELISA 
  Intraplate 
precision 
  Interplate 
precision 
 
IL-8     n OD(Mean±SD) CV(%)    N OD(Mean±SD) CV(%) 
0 pg/mL    30    1.176±0.088 7.4   30 1.301±0.391 30.1 
1000pg/mL    30    4.74±0.691 14.6   30 4.934±0.369 7.5 
 
 
The IL-8 concentrations from unknown samples were calculated using 
graphpad prism version 6.2 analysis software (Graphpad software Inc. San 
Diego California, USA).  
The results of flow cytometry presented in figures 12 to 15  earlier in this 
chapter did not demonstrate a statistical difference in numbers of viabile cells  
or apoptosis rates when ARPE-19 cells were exposed to various combinations 
of hypoxia (2% oxygen) for 24 hours, glycated albumin 500µg/ml or minocycline 
5µM. Therefore, these conditions were selected to investigate the effects of 
hypoxia, glycated albumin and minocycline on IL-8 and MCP-1 production 
utilising enzyme linked immunosorbant asssy (ELISA). 
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3.6.2 Effects of hypoxia and minocycline on glycated albumin induced IL-8 
production from ARPE-19 cells 
 
 
Figure 17: The figure above shows the results of exposure of ARPE-19 cells to 
four experimental conditions, glycated albumin (GA) and normoxia; GA, 
normoxia and minocycline 5µM; GA and hypoxia; and GA hypoxia and 
minocycline 5µM. The results shown are the mean ± standard deviation of each 
experimental conditions repeated in duplicate.  One way ANOVA and Tukey’s 
multiple comparions test was used to assess differences between experimental 
groups. Statistical significance is indicated in the results shown as **** (p < 
0.0001), *** (p = 0.0001 to 0.001) and ** (p = 0.001 to 0.01) 
C= Control. Data shown in Appendix C (page 203) 
 
The results from Figure 17 show that there was a statistically significant 
decrease in glycated albumin stimulated IL-8 production from ARPE-19 cells 
associated with minocycline. This effect occurred in both normoxic and hypoxic 
experimental conditions. 
C 
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3.6.3 Effects of minocycline on IL-1β stimulated IL-8 production in 
normoxia and hypoxia 
 
 
Figure 18: The figure above shows the results of exposure of ARPE-19 cells to 
four experimental conditions, IL-1β and normoxia; IL-1β, normoxia and 
minocycline 5µM; IL-1β and hypoxia; and IL-1β, hypoxia and minocycline 5µM. 
The results shown are the mean±standard deviation of each experimental 
conditions repeated in duplicate.  One way ANOVA and Tukey’s multiple 
comparisons test was used to assess differences between experimental groups. 
Statistical significance is indicated in the results shown as *** (p = 0.0001 to 
0.001), ** (p = 0.001 to 0.01) and * (p = 0.01 to 0.05) C=Control 
Data shown in Appendix C (page 205) 
 
The results in Figure 18 show that minocycline was associated with a 
statistically significant decrease in IL-1β induced IL-8 production from ARPE-19 
cells in normoxic conditions but not in hypoxia. 
   
 
 
 
C 
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3.6.4 Effects of individual biochemical inhibitors on glycated albumin 
stimulated IL-8 production from ARPE-19 cells in normoxia and hypoxia  
The exact mechanisms by which minocycline may produce abrogation of IL-8 
production from glycated albumin stimulated ARPE-19 cells remains unclear.  
Biochemical pathway inhibitors, Ly294002, SB202190 and JSH-23 were 
therefore studied  individually and in combination and the results are shown in 
figures 19 and 20. 
 
 
Figure 19: The figure above shows the results of exposure of ARPE-19 cells to 
six experimental conditions: (1) glycated albumin (GA), Ly294002 and normoxia; 
(2) GA, SB202190 and normoxia; (3) GA, JSH-23 and normoxia; (4) GA, hypoxia 
and Ly294002; (5) GA, hypoxia and SB202190 and (6) GA, hypoxia and JSH-23. 
The results shown are the mean ± standard deviation of each experimental 
condition repeated in duplicate.  One way ANOVA and Tukey’s multiple 
comparisons test was used to assess differences between experimental groups. 
Statistical significance is indicated in the results shown as **** (p = < 0.0001), *** (p 
= 0.0001 to 0.001), ** (p = 0.001 to 0.01) and * (p = 0.01 to 0.05) 
C = Control. Data shown in Appendix C (page 206) 
 
C 
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The results in Figure 19 show individual biochemical inhibitors all suppressed 
glycated albumin induced IL-8 production both in normoxic and hypoxic 
conditions.   
3.6.5 Effects of combination of biochemical inhibitors on glycated albumin 
induced IL-8 production 
  
 
 
Figure 20: The figure above shows the results of exposure of ARPE-19 cells to 
four experimental conditions: (1) glycated albumin (GA), Ly294002, SB202190 
and JSH-23; (2) GA, Ly294002 and SB202190; (3) GA, SB202190 and JSH-23; (4) 
GA, Ly294002 and JSH-23. The results shown are the mean ± standard deviation 
of each experimental condition repeated in duplicate.  One way ANOVA and 
Tukey’s multiple comparisons test was used to assess differences between 
experimental groups. Statistical significance is indicated in the results shown as 
*** (p = 0.0001 to 0.001), ** (p = 0.001 to 0.01) and * (p = 0.01 to 0.05) 
C= Control. Data shown in Appendix C (page 208) 
 
C 
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The results shown in Figure 20 show that biochemical inhibitors in combination 
all demonstrate a statistically significant decrease in glycated albumin induced 
IL-8 production from ARPE-19 cells. 
 
 
 
 
 
3.7 MCP-1 ELISA 
 
A standard curve was constructed from the results of duplicate standard 
dilutions as per instructions provided by the manufactor (Invitrogen, UK). The 
absorbance of the standards against the standard concentrations was plotted 
on a logarithmic scale. 
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Figure 21: MCP-1 standard curve. Results show Optical densities (OD) measured 
at 450nm plotted against MCP-1 concentration in picogrammes per millilitre 
(pg/ml). Results are plotted using a logarithmic scale. Each point represents the 
mean±standard deviation of standard dilutions of MCP-1 measured in duplicate. 
 
3.7.1 Reproducibility of MCP-1 ELISA 
Intraplate and interplate reproducibility  tests were performed. A pair of positive 
and negative controls were tested 30 times in the same plate (intraplate) and 
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this was then repeated in different plates (interplate) on different dates. Mean, 
standard deviation and coefficient of variation were calculated from both 
interplate and intraplate optical densities (ODs).  Results are shown in table 3 
below. 
Table 3: Reproducibility of MCP-1 ELISA 
  Intraplate 
precision 
  Interplate 
precision 
 
MCP-1     n OD(Mean±SD) CV(%)    n OD(Mean±SD) CV(%) 
0 pg/mL    30    1.593±0.148 9.3   30 1.188±0.223 18.8 
1000pg/mL    30    4.098±0.271 6.61   30 4.267±0.314 7.4 
 
 
3.7.2 Effects of hypoxia and minocycline on glycated albumin induced 
MCP-1 production 
 
Figure 22: The figure above shows the results of exposure of ARPE-19 cells to 
four experimental conditions, (1) glycated albumin (GA) and normoxia; (2) GA, 
normoxia and minocycline 5µM; (3) GA and hypoxia; and (4) GA, hypoxia and 
minocycline 5µM. The results shown are the mean ± standard deviation of each 
experimental conditions repeated in duplicate.  One way ANOVA and Tukey’s 
multiple comparions test was used to assess differences between experimental 
groups. Statistical significance is indicated in the results shown as **** (p < 
0.0001), and  ** (p = 0.001 to 0.01) C= Control. Data shown in Appendix C (page 
210) 
C 
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The results in Figure 22 show that minocycline statistically significantly 
decreased glycated albumin induced MCP-1 production. The effects were 
greater in normoxic conditions compared to hypoxia. Hypoxia increased 
glycated albumin induced MCP-1 production. 
 
3.7.3 Effects of minocycline on IL-1β induced MCP-1 production in 
normoxia and hypoxia 
One way ANOVA and Tukey’s multiple comparisons test was used to assess 
the differences between experimental groups. No meaningful statistical 
differences were demonstrated. The data and related statistical analysis is in 
Appendix C (tables 31 and 32, page 215). 
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3.7.4 Effects of individual biochemical inhibitors on glycated albumin 
stimulated MCP-1 production from ARPE-19 cells in normoxia and 
hypoxia  
 
 
 
Figure 23: The figure above shows the results of exposure of ARPE-19 cells to 
six experimental conditions: (1) glycated albumin (GA), Ly294002 and normoxia; 
(2) GA, SB202190 and normoxia; (3) GA, JSH-23 and normoxia; (4) GA, hypoxia 
and Ly294002; (5) GA, hypoxia and SB202190 and (6) GA, hypoxia and JSH-23. 
The results shown are the mean ± standard deviation of each experimental 
condition repeated in duplicate.  One way ANOVA and Tukey’s multiple 
comparisons test was used to assess differences between experimental groups. 
Statistical significance is indicated in the results shown as **** (p < 0.0001) 
C=Control. Data shown in Appendix C (page 212) 
 
Individual biochemical inhibitors all statistically significantly decreased glycated 
albumin induced MCP-1 production from ARPE-19 cells. 
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3.7.5 Effects of combination of biochemical inhibitors on glycated albumin 
induced MCP-1 production 
 
Figure 24: The figure above shows the results of exposure of ARPE-19 cells to 
four experimental conditions: (1) glycated albumin (GA), Ly294002, SB202190 
and JSH-23; (2) GA, Ly294002 and SB202190; (3) GA, SB202190 and JSH-23; (4) 
GA, Ly294002 and JSH-23. The results shown are the mean ± standard deviation 
of each experimental condition repeated in duplicate.  One way ANOVA and 
Tukey’s multiple comparisons test was used to assess differences between 
experimental groups. Statistical significance is indicated in the results shown as  
*** (p = 0.0001 to 0.001), ** (p = 0.001 to 0.01) and * (p = 0.01 to 0.05) 
C= Control. Data shown in Appendix C (page 214) 
 
The results in Figure 24 show that a combination of biochemical inhibitors 
varied in the response to suppression of MCP-1 production from ARPE-19 cells. 
SB202190 in combination with JSH-23 was most effective at suppressing 
glycated albumin induced MCP-1 production.  
 
 
 
C 
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3.8 Discussion 
 
3.8.1 Effects of glycated albumin and hypoxia on ARPE-19 cell growth 
The results of the growth curves in figure 10 show that glycated albumin 
(500µg/ml) did not impair cell growth. Hypoxia caused a flattening of the growth 
curve. This suggests that hypoxia acts by inhibition of cell division, or a 
combination of inhibited cell division and promotion of cell loss by inducing 
apoptotis or necrosis.  
The cell growth curves were constructed after cell counts were obtained after 
culturing ARPE-19 cells in media containing 10% foetal bovine serum. In 
physiological conditions, RPE cells are non dividing cells that form the external 
blood retinal barrier between the neural retina and the choroidal circulation. In 
vivo, RPE cells are not directly exposed to serum as Bruch’s membrane forms a 
barrier between the RPE cell layer and the blood within the choroidal 
vasculature. As such, measurement of cell growth parameters may be 
considered not directly applicable to conditions in vivo. However, in 
pathophysiological inflammatory conditions, such as autoimmune uveitis, RPE 
cells are activated and participate in recruitment and stimulation of inflammatory 
cells into the eye. 261 In neovascular AMD, a low grade inflammatory response 
is suggested to be the start of the pathophysiological process. This may 
progresses through recruitment of inflammatory cells and release of cytokines, 
the pathological endpoint being choroidal neovascularisation extending into the 
subretinal space and retina. 
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3.8.2 Effects of minocycline and hypoxia on cell viability 
Figure 12 showed that flow cytometry did not demonstrate statistical differences 
in cells staining propidium iodide positive when exposed to hypoxia (2% 
oxygen) for 24 hours or minocycline 5µM. Udono et al 262 reported that hypoxia 
decreased ARPE-19 cell viability by approximately 20% compared to normoxic 
conditions. However, the hypoxic conditions used in their study were 1% 
oxygen compared to 2% oxygen used in this study. Also, their method262 of cell 
counting used a modified 3-(4,5-dimetylthiazone-2yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. The MTT assay measures the ability of cells to reduce 
the tetrazolium dye, MTT to its insoluble formazan, resulting in a purple colour. 
As this effectively requires functioning mitochondria, the MTT effectively 
measures the metabolic activity of live cells. This does not necessarily correlate 
with cell viability. Some cells may be viable but not necessarily very 
metabolically active. The metabolic status of cells cultured in hypoxia is likely to 
be different to normoxic conditions therefore rendering the MTT assay as a 
measure of cell viability unreliable. In this study, it was therefore decided to use 
a technique that directly measured cell necrosis and apoptosis. Udono et al260 
used the modified TdT-mediated dUTP nick end labelling (TUNEL) method. 
This detects DNA fragmentation representing late stage apoptosis. It is unclear 
from their study 262 how the methodology used to detect cells undergoing 
apoptosis differentiated necrotic cells.  Therefore, in this study, annexin V and 
propidium iodide staining were used to distinguish apoptotic and necrotic cells.  
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3.8.3 Assessment of cell viability 
The method used to determine cell viability and so the definition of viability is 
often related to the phenomenon studied. Cell viability may be judged by 
morphological changes or by changes in membrane permeability and/or 
physiological state inferred from the exclusion of certain dyes or the uptake and 
retention of others. 263 
Live cells with intact membranes are distinguished by their ability to exclude 
dyes that easily penetrate dead or damaged cells. Staining of nonviable cells 
with propidium iodide (PI) has been performed on most cell types. The stained 
cells are bright red and easy to identify. 263 
The basal level of apoptosis and necrosis varies considerably within a 
population. Thus, even in the absence of induced apoptosis, most cell 
populations contain a minor percentage of cells that are positive for apoptosis 
(FITC Annexin V positive, PI negative or FITC Annexin V positive, PI 
positive).263 
The untreated population is used to define the basal level of apoptotic and dead 
cells. Since cell death is the eventual outcome of cells undergoing apoptosis, 
cells in the late stages of apoptosis will have a damaged cell membrane and 
stain positive for PI as well as for FITC Annexin V. Thus, the assay does not 
distinguish between cells that have already undergone an apoptotic cell death 
and those that have died as a result of necrotic pathway, because in either case 
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the dead cells will stain with both FITC Annexin V and PI. 263 This represents 
one on the limitations of the methodology used in this study. 
3.8.4 Differences in vitro and in vivo 
Many of the differences in cell behaviour between cultured cells and their 
counterparts in vivo stem from the dissociation of cells from a three-dimensional 
geometry and their propagation on a two dimensional substrate. Specific cell 
interactions characteristic of the histology of the tissue are lost, and as the cells 
spread out, become mobile, and start to proliferate, so the growth fraction of the 
cell population increases. 263 
The culture environment also lacks the several systemic components involved 
in homeostatic regulation in vivo, prinicipally those of the nervous and endocrine 
systems. Without this control, cellular metabolism may be more constant in vitro 
than in vivo, but may not be truly representative of the tissue from which the 
cells were derived. Energy metabolism in vitro occurs largely by glycolysis, and 
although the citric acid cycle is still functional, it plays a lesser role. 263 
3.8.5 Pharmacokinetics 
The measurement of toxicity in vitro is generally a cellular event. It is very 
difficult to recreate the complex pharmacokinetics of drug exposure in vitro, and 
between in vitro and in vivo experiments there usually are significant differences 
in exposure time to and concentration of the drug, rate of change of the 
concentration, metabolism, tissue penetration, clearance, and excretion.264 It 
may be possible to simulate these parameters, for example using multicellular 
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tumour spheroids for drug penetration or timed perfusion to simulate 
concentration and time (C x T) effects- most studies concentrate on a direct 
cellular response, therby gaining simplicity and reproducibility.262 This approach 
was utilised in this study. 
A toxic response in vitro may be measured by changes in cell survival or 
metabolism. 264 This may not accurately reflect the situation in vivo which may 
be a tissue response (eg. inflammatory reaction, fibrosis, kidney failure) or a 
systemic response (eg. pyrexia, vascular dilatation). This is a limitation of the 
work presented in this thesis. 
3.8.6 Conclusions of cell viability and apoptosis experiments 
ARPE-19 cells were exposed to varying concentrations of minocycline ranging 
from 1µM to 20µM as previous studies 265 have indicated a potential narrow 
therapeutic window for minocyline. Doses higher than 5µM affected ARPE-19 
cell viability. Hollborn et al 264 investigated the effects of minocycline on the 
viability and physiological properties of human ARPRE cells. Cell viability was 
determined by trypan blue assay. Their results 265 showed that minocycline at 
high concentrations (above 5µM) decreased the viability of human RPE cells 
through induction of cell necrosis.  Assessment of cell viability under the 
microscope utilising trypan blue and cell counting with haemocytometers is a 
widely used technique. Viable cells have intact membranes and exclude the 
dye. Limitations of this method are that the technique of cell counting is time 
consuming, and hence prone to errors with impact on the accuracy of the 
results. After staining with trypan blue cell counts are usually performed within 5 
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minutes. This is because on standing, some viable cells may become 
permeable and take up the dye. This may result in some cells being counted as 
falsely non viable.   
In this study, because of these limitations, trypan blue staining was not utilised. 
Whilst there are limitations of an vitro approach, the results of this study 
demonstrate that concentrations of minocycline below 5µm do not have an 
adverse effect on ARPE-19 cell viability and apoptosis. The results of this study 
utilising 2% oxygen for 24 hours to simulate hypoxic effects. The effects of 
hypoxia in this study did not demonstrate a significant decrease  in ARPE-19  
cell viability or increase in apoptosis suggesting that this cell line is relatively 
resistant to hypoxia.  
3.8.7 Effects of hypoxia, minocycline and biochemical inhibitors on GA 
induced IL-8 production from ARPE-19 cells 
The results showed that minocycline abrogated glycated albumin induced IL-8 
production from ARPE-19 cells under both normoxic and hypoxic conditions. 
Minocycline decreased IL-1β stimulated IL-8 production in normoxia but not in 
hypoxic conditions. With regard to biochemical inhibitors, the effects of 
Ly294002, SB202190 and JSH-23 individually were no different in suppressing 
IL-8 production in normoxia compared to hypoxia.  JSH-23 supressed IL-8 
production more than SB202190 and JSH-23 in both normoxic and hypoxic 
conditions. Ly294002 did not suppress glycated albumin induced IL-8 
production to the same extent as SB202190 and JSH-23. 
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In terms of various combinations of biochemical inhibitors, these experiments 
were all conducted in normoxia as hypoxic conditions did not show significant 
differences between individual inhibitors in suppressing IL-8 production. 
Ly294002 in combination with JSH-23 inhibited glycated albumin induced IL-8 
production more than a combination of all three inhibitors.  
Biochemical inhibitors, whether used individually or in combination suppressed  
glycated albumin induced IL-8 production more than minocycline. 
3.9.7 Effects of hypoxia, minocycline and biochemical inhibitors on GA 
induced MCP-1 production from ARPE-19 cells 
Hypoxia increased glycated albumin induced MCP-1 production. Minocycline 
suppressed this response, however, minocycline’s effect on reducing induced 
MCP-1 production was greater in normoxic conditions. 
Ly294002 inhibited glycated albumin induced MCP-1 production more than 
SB202190 and JSH-23 in normoxia and hypoxia. When biochemical inhibitors 
were  combined JSH-23 and SB202190 had the most effect on reducing MCP-1 
levels. 
Use of the biochemical inhibitor Ly294002 inhibited glycated albumin induced 
MCP-1 production more than minocycline, however, the other biochemical 
inhibitors when used individually in normoxia or hypoxia elicited a similar effect 
to minocycline. In combination, only SB202190 and JSH-23 together had a 
greater effect than minocycline suppressing glycated albumin induced MCP-1 
production. 
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3.9.8 Biochemical pathways for IL-8 and MCP- 1 production 
When exposed to GHSA, hRPE cells actively secrete IL-8 and MCP-1.266 Bian 
et al266 found that AGE does not stimulate hRPE IL-8 and MCP-1 production. 
This is the reason why GHSA was used to stimulate MCP-1 and IL-8 secrection 
from ARPE-19 cells in this study rather than AGE. 
The results of this study show that minocycline suppresses glycated albumin 
induced MCP-1 and IL-8 production from ARPE-19 cells. During autoimmune 
uveitis, RPE cells are activated and participate in recruitment and stimulation of 
inflammatory cells into the eye. 267 In vitro, RPE cells have been shown to 
produce different chemokines such as interleukin 8.268 It has been extensively 
described that cytokines such as TNF-α and IL-1β strongly activate RPE cells to 
secrete various inflammatory mediators including IL-8. 268 It is likely that other 
stimuli play a role triggering RPE cell activation.   
In AMD, macrophages and lymphocytes as well as reactive, migrating or 
proliferating hRPE cells are often found adjacent to newly formed vessels in the 
sub-retinal space. 269, 270  
IL-8 has been shown to induce angiogenesis and is present in the vitreous of 
patients with retinal neovascularisation.271 MCP-1 involvement in 
neovascularisation of the posterior segment of the eye has been suggested by 
several studies. High levels of MCP-1 in vitreous have been detected in 
proliferative diabetic retinopathy (PDR).272 Proliferation of RPE cells is 
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associated with upregulation of MCP-1 expression. 273   Intravitreal injections of 
anti MCP-1 significantly reduce ischaemia induced retinal neovascularisation.274 
Human RPE cells respond to monocytes binding to their cell surfaces by 
secreting IL-8 and MCP-1.266 Bian et al 266 suggest that MAPK activation and 
nuclear translocation of NF-ĸB may represent the major pathway for GHSA 
signalling in hRPE cells. However, the signal cascades leading to activation of 
IL-8 and MCP-1 expression remain complicated.  Extracellular signal regulated 
kinase ERK1/2 and p38 mitogen activated protein kinase (MAPK) pathways, 
and NF-ĸB induced kinase  (NIK) are the major signalling pathways. 
MCP-1 belongs to the C-C chemokine family which are named as such because 
of two adjacent cysteines (amino acids) near their amino terminus. MCP-1 
functions as a chemoattractant and as an activator for lymphocytes and 
monocytes and causes monocyte/macrophage infiltration into tissues. 275 IL-8 is 
a member of the CXC chemokine family, named as the two terminal cysteines 
are separated by one amino acid represented in this name by an X. IL-8 is a 
potent activator and chemoattractant of neutrophils.276 Transcription factors NF-
ĸB and AP-1 binding motifs are found in MCP-1 and IL-8 gene promoters hence 
both these chemokines are coinduced in different cells by several stimuli. 276,277 
MCP-1 directed monocyte extravasation and cell-cell contact between 
monocytes/ macrophages and hRPE cells are important sequential events in 
retinal diseases, such as proliferative vitreoretinopathy (PVR), AMD and uveitis. 
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Induced hRPE MCP-1 may initiate and perpetuate ocular inflammation by 
recruiting and activating monocytes and lymphocytes in diseased retinal tissue. 
Bian et al 266 investigated the signal mediators involved in GHSA stimulation of 
IL-8 and MCP-1 secretion in hRPE cells. hRPE cells were stimulated by GHSA 
in the presence or absence of a series of kinase inhibitors. Induced IL-8 and 
MCP-1 mRNA and proteins were determined by reverse transcriptase 
polymerase chain reaction (RT-PCR) and enzyme linked immunosorbent assay 
(ELISA). It has been shown 267, 278 that mitogen activated protein kinases 
(MAPK) plays an important role in AGE signalling. The involvement of 
extracellular signal regulated protein kinases (ERK) 1/2 was investigated by 
Bian et al. 266 Two subclasses of MAP kinases are associated with cellular 
stress response: 
1. p38 high osmolarity glycerol (HOG) kinase and c-Jun N-terminal kinase 
(JNK)/ stress activated MAP kinase (SAPK) 
2. Janus kinase (jak) signal transducers and activation of the transcription 
(STAT) pathway 
Bian et al 266 used specific inhibitors of ERK 1/2, p38 and Jak2 to block GHSA 
stimulation of IL-8 and MCP-1. Inhibitors were used alone and also in 
combination. The results suggested that GHSA stimulation of MCP-1 
expression is mediated by at least three signalling pathways, ERK 1/2, p38 and 
jak; this contrasts with predominant mediation of IL-8 expression by ERK 1/2. 
Activation of p38 is required for both IL-8 and MCP-1 induction by GHSA, p38 
activation is more effective for inducing MCP-1 than IL-8. Relative contributions 
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of p38 to IL-8 expression may be cell type dependent. In monocytes, LPS and 
osmotic stress induced IL-8 expression have been shown to be entirely 
mediated by p38. 279, 280 In other cell types p38 is insufficient for maximal 
stimulation of IL-8 production. 281 
The activation of jak appears to be involved in GHSA induction of MCP-1, but 
not IL-8. 266 Complete blockade of GHSA stimulated MCP-1 production 
occurred with simultaneous administration of inhibitors for ERK 1/2, p38, and 
jak2. However, IL-8 production induced by GHSA was insensitive to the jak2 
inhibitor AG490 and was not completely inhibited by blocking ERK 1/2 and p38. 
This suggests that there may be a jak independent mechanism accounting for 
remaining production of IL-8 in these cells. These mechanisms may be driven 
by activation of other transcription factors apart from NF-ĸB such as AP-1.282 
NF-ĸB is one of the transcription factors involved in IL-8 and MCP-1 gene 
expression. 268, 283  
Activation of NF-ĸB is required for MCP-1 gene expression in hRPE cells.284 
Activation of NF-ĸB occurs in response to a wide variety of stimuli such as IL-
1β, TNF-α, LPS and many other stress or injury related factors. 285 NF-ĸB is a 
pleiotropic transcription factor that regulates activation of various inflammatory 
genes. 286 
Bian et al 266 determined the involvement of NF-ĸB in GHSA stimulated hRPE 
IL-8 and MCP-1 expression in their study. 
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Their study266 described four approaches. First, anti NF-ĸB was used to stain 
hRPE monolayers immunohistochemically. In unstimulated cells NF-ĸB was not 
detected in the nuclei. This contrasted with nuclear translocation of NF-ĸB that 
was evident after hRPE cells were treated with 500µg/ml of GHSA for 3 hours. 
Secondly, three inhibitors of of NF-ĸB were utilised.266 These were BAY 11-
7085, caffeic acid phenethyl ester (CAPE), and parthenolide. These act on 
components of NF-ĸB in different ways. BAY 11-7085 inhibits IĸBα 
phosphorylation.287 CAPE is a potent and specific inhibitor of of NF-ĸB 
activation.288 Parthenolide is one of sesquiterpene lactones obtained from 
varieties of Mexican Indian plants, and prevents the degradation of IĸBα and 
IĸBβ.284 hRPE cells were preincubated with inhibitors, then challenged with 
GHSA (500µg/ml) for 24 hours. Supernatants were collected for ELISA for IL-8 
and MCP-1. All inhibitors completely blocked hRPE IL-8 and MCP-1.  
Thirdly, Western blot analysis showed the p65 subunit of NF-ĸB appeared in 
nuclear extracts after 3 hours exposure to GHSA (500µg/ml), yet was 
undetectable in nuclear extracts from unstimulated cells. 266 
The fourth approach described by Bian et al 266 measured activation of NF-ĸB 
using an electrophoretic mobility shift assay. Binding of specific probes to the 
NF-ĸB binding site of the promoter region in the IL-8 gene was observed 3 
hours after induction with GHSA (500µg/ml). 
Curcumin is a naturally occurring yellow pigment, isolated from the rhizomes of 
the plant Curcuma longa (Linn), that is commonly used in Asian cooking as a 
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flavouring and colouring agent.289 It has been used in Oriental and Ayurvedic 
medicine since ancient times. 289 Curcumin has been demonstrated to block a 
signal leading to activation of NF-ĸB inducing kinase (NIK). 290, 291 Curcumin was 
shown by Bian et al 266 to reduce production of IL-8 and MCP-1 in a dose 
dependent manner.  
The phosphatidyl-inositol-3-OH-kinase (P13K)/Akt pathway and the 
transcription factor AP-1 have been shown to be involved in MCP-1 291-293 and 
IL-8 294-296 expression in cell types other than RPE cells, whereas P13K also 
activates the NIK pathway. 297 
To investigate differential involvement of phosphoinositide 3 kinase/ Akt in 
human RPE MCP-1 and IL-8 expression, researchers stimulated hRPE cells 
with IL-1β and TNF-α by co-culturing with monocytes in the presence or 
absence of a series of kinase inhibitors. 298   MCP-1 and IL-8 mRNA and protein 
production were determined by RT-PCR and ELISA.  
PI3K comprises a family of lipid signalling enzymes that promote 
phosphorylation of phosphoinositides. Among them are second messengers 
that bind to Akt, (also known as protein kinase B, PKB). IL-1, TNF and cell to 
cell contact have been shown to activate the P13K pathway. 291,294, 299 The 
specific molecular inhibitor of P13K has been identified as Ly294002. 300 Bian et 
al 301 demonstrated the important role of the P13K/Akt pathway in the 
expression of hRPE MCP-1. However, hRPE IL-8 expresion induced by the 
same stimuli was completely insensitive to Ly294002.302 This contrasted with 
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concominant inhibition of both MCP-1 and IL-8 expression by blocking NIK and 
MAPK pathways.302 Selective stimulation of either IL-8 or MCP-1 by a given 
stimulus has been reported in various cell types, however, selective induction of 
MCP-1, but not IL-8, by a particular signalling pathway is rare. This is similar to 
observations that GHSA induced MCP-1, but not IL-8 was susceptible to 
inhibition by AE490, a selective inhibitor of jak2.266 Ly294002 sensitive P13K is 
thus a second signalling pathway observed in hRPE cells that selectively 
stimulates MCP-1. Stimuli may specifically trigger downstream effectors 
regulating MCP-1 gene expression. 
Joint stimulation of IL-8 and MCP-1 mRNA expression is consistent with the 
finding that both IL-8 and MCP-1 promoters contain common sites for 
transcription factors NF-ĸB and AP-1, both of which may be activated by IL-1 
and TNF.298  
NF-ĸB functions as a dimer, composed of a family of subunits including NF-ĸB1 
(p50), NF-ĸB2 (p52), c-REL, REL-A (p65) and REL-B .296 The transcription 
factor AP-1 is a homo or heterodimer formed by c-Jun, Jun-D, Jun-B, ATF-2, c-
Fos, FRA-1, FRA-2 and other members of this family. 296  
Molecular studies of MCP-1 and IL-8 promoters reveal differences between the 
two genes. In the IL-8 promoter, there is a single NF-ĸB binding site with high 
affinity for p65, whereas two NF-ĸB binding sites A1 and A2 have been found in 
the human MCP-1 promoter. The A2 site, which has high affinity for c-Rel/p65 is 
the most important NF-ĸB binding site for MCP-1 expression.303 The different 
  
118 
 
structure and properties of NF-ĸB sites in the promoters of the two chemokine 
genes suggests that selective inhibition of MCP-1 expression may result from 
blocking one of two NF-ĸB sites through a Ly294002 sensitive P13K pathway. 
In addition, another mechanism accounting for the selective inhibition of MCP-1 
expression by PIK3 inhibitors is that the P13K pathway may activate certain 
transcription factors required for MCP-1.  
The P13K pathway in hRPE MCP-1 induction, but not IL-8, provides putative 
targets for the selective regulation of hRPE chemokines.  
3.9.81 Nucleotide biochemical pathways 
Stimuli may arise from pathogens but also from stressed or necrotic cells, and it 
is now accepted that inflammatory cells respond to molecules normally found 
inside cells. 304 Among these molecules, nucleotides have been shown to be 
involved in immune regulation.305 Nucleotides are released into extracellular 
fluid through cell lysis, exocytosis of nucleotide concentrating granules, 
vesicular trafficking or membrane transport proteins. 306 Extracellular 
nucleotides have autocrine and paracrine roles by activating two families of 
receptors: P2X receptors, which are ATP gated ion channels and P2Y 
receptors, coupled to G proteins.306 P2Y2 receptors have been identified in RPE 
cells and their activation has been shown to stimulate fluid reabsorbtion and 
retinal reattachment in a rat model of retinal detachment. 307,308 The presence of 
P2Y subtypes P2Y1 and P2Y6 has also been demonstrated. 309  
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Relvas et al 304 cultured ARPE-19 cells with P2Y2 and P2Y6 receptor ligands 
ATPγS, UTP, and UDP and also TNF. IL-8 gene transcription and protein 
production were measured by semiquantative RT-PCR and ELISA. Western 
blot analysis and RT-PCR were used to investigate ERK 1/2 activation and P2Y 
expression. Changes in intracellular calcium and cAMP concentration were 
analysed by spectrofluorometry and radioimmunoassay.  
The results demonstrated that ATPγS, UTP, and UDP stimulated both basal 
and TNF-α induced IL-8 secretion in RPE cells through an ERK 1/2 dependent 
pathway and that these effects were mediated by P2Y2 and P2Y6 receptors. IL-
8 attracts and activates neutrophils.298 Although the main stimuli of IL-8 
secretion in vitro has been TNF-α and IL-1β, stimulation of Toll like receptors 3 
and 9 has also been found to induce IL-8 secretion by RPE cells. 310, 311 Toll like 
receptors recognise pathogen associated patterns and hence “danger signals”.  
As nucleotides are normally found within cells and are released during tissue 
damage, extracelluar nucleotides are also considered danger signals. 
Therefore, RPE cells may act as sentinels that can be alerted when the eye is 
responding to the threat of pathogen associated infection or inflammatory 
stress. As there is basal secretion of IL-8 by RPE cells, nucleotide release may 
help to recruit inflammatory cells from the choroid to the retina. 312 This is an 
advantage during infection to clear the retina from pathogens. However, if this 
response becomes dysregulated the eye can be exposed to abnormal IL-8 
production and may be involved in the pathophysiology of inflammatory retinal 
disease. The specific inhibition of MAPK kinase by PD98059 abrogates IL-8 
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secretion induced by ATPγS, UTP, and UDP in RPE cells. 304 All tested 
nucleotides induced a strong activation of ERK 1/2. Results suggest that these 
effects are mediated by P2Y2 and P2Y6 receptors. 304 This suggests that the 
mechanisms for IL-8 production in RPE cells are multiple and complex and 
minocycline may not fully suppress GHSA induced IL-8 production due to 
effects of other biochemical pathways. 
3.9.82 Hypoxic inflammation in AMD 
The aetiology of AMD is complex and multifactorial. The local regulatory 
mechanisms of hypoxia, ROS, inflammation and interactions with environmental 
and life style factors leading to the development of AMD are not yet clearly 
understood. The hypoxic conditions during inflammation in the retina may be 
the result of either increased consumption of oxygen due to the increased 
metabolic activity of the inflamed retina or due to the poor perfusion in the 
central macula as a consequence of vessel stenosis and microthrombosis197, 198 
This pathological state may elicit drusen formation, increase oxidative stress 
and inflammation and lead to the degeneration of RPE cells and progression of 
AMD.  
Cellular damage by oxygen free radicals is the primary driving force for ageing 
and the expression of transcription factors such as NF-ĸB that regulate the 
expression of proinflammatory molecules. The NF-ĸB protein complex is a 
critical regulatory mechanism that controls a variety of external and internal 
danger signals including oxidative stress and inflammation.232 In its inactive 
  
121 
 
state the NF-ĸB complex is retained in the cytoplasm with an IĸB protein. In the 
presence of a stress stimulus, IĸB becomes degraded in the ubiquitin- 
proteasome system, the released NF-ĸB complex translocates to the nucleus 
and binds to the promoter area of the target genes that are mostly involved in 
the regulation of inflammation during ageing. 232 
The elevated levels of ROS strongly linked to AMD pathology are able to 
activate NF-ĸB signalling. 313, 314 A binding site for NF-ĸB has been identified 
within the HIF-1α promoter. 315 Hypoxia has been shown to to result in 
activation of NF-ĸB which can bind to the HIF-1α promoter. Overexpression of 
the NF-ĸB complex proteins p50 and p65 may increase HIF-1α promoter 
activity. 316 Mutation of the NF-ĸB site in the HIF-1α promoter at -197/-188 base 
pairs prevents hypoxic induction of HIF-1α promoter activity.317This indicates 
that NF-ĸB binding to the HIF-1α promoter is a prerequisite for transcriptional 
activation of HIF-1α by hypoxia. 
Hypoxia can also activate the P13K/Akt pathway subsequently leading to the 
simultaneous activation of the transcription of both NF-ĸB and HIF-1α genes.317 
ERK 1/2 does not seem to be involved in the NF-ĸB induced transcriptional 
activation of the HIF-1α gene. However, ERK 1/2 may be involved in HIF-1α 
protein stability and/or transactivation without the need for NF-ĸB activation. It 
appears that hypoxia leads to activation of NF-ĸB through a P13K dependent 
pathway. NF-ĸB binds to the HIF-1α promoter resulting in an increase in 
transcription and translation of HIF-1α.317 
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The pathogenesis of AMD is thought to involve reduced oxygen availability 
together with a chronic low grade inflammatory response. During the 
pathological ageing process, homeostatic mechanisms may fail in RPE cells. 
The P13K pathway in conjunction with other members of the NF-ĸB complex 
which may modulate HIF-1α target genes may represent a new therapeutic 
strategy.317 
Kumar et al 318 cultured human retinal progenitor cells (HRPC) and human 
umbilical vein endothelial cells (HUVEC) in monolayers of each cell type 
maintained alone and also co-cultured with the two cell lines. The aim of their 
study318 was to elucidate the mechanism of action between the two cell lines 
that modulates a neovascularisation response. Culture and co-culture was 
carried out under normoxia (control) or hypoxic (1% O2) conditions for 24 hours.  
The secretion of VEGF was examined by ELISA and the expression of VEGF, 
VEGFR-2, NF-ĸB and HIF-1α by PCR and Western blotting. The cellular 
localization of NF-ĸB and HIF-1α were studied by immunofluorescence and 
Western blotting. The results 318 showed that hypoxia increased exogenous 
VEGF expression by 4 fold in HRPC cells with a further 2 fold increase when 
HRPC was co-cultured with HUVEC. Hypoxia resulted in an increase in NF-ĸB 
and HIF-1α, there was a 4 and 6 fold increase during co-culture. Hypoxia 
induced nuclear translocation of NF-ĸB in HRPC when exposed to HUVEC 
hypoxic conditioned media. As nuclear translocation of NF-ĸB is considered 
equivalent to activation the findings 318 suggest that direct or indirect 
communication between HRPC and HUVEC cells results in expression and 
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activation of transcription factors associated with enhanced expression of pro-
angiogenic factors under hypoxic conditions. 
Udono et al 262 investigated the effects of hypoxia on the production and 
secretion of adrenomedullin and endothelin in human retinal pigment epithelial 
cells. Adrenomedullin (ADM) is a vasorelaxant peptide originally identified from 
human phaeochromocyctoma. Hypoxia significantly decreased the numbers of 
ARPE-19 cells and this effect was ameliorated with ADM. 262 
Significant increases in the index of apoptosis were observed in ARPE-19 cells 
cultured under hypoxic conditions.262 ADM did not affect the apoptosis rate of 
ARPE-19 cells exposed to hypoxia. This suggests that the effects of ADM on 
the cell number of RPE cells under hypoxic conditions are independent of 
antiapoptotic actions.   
3.9.83 Mechanisms for minocyline induced suppresion of IL-8 and MCP-1 
production 
Pang et al 319 studied the effects of minocycline on LPS stimulated human 
circulating monocytes in culture. Incubation of primary human monocytes with 
LPS increased p38 MAPK phosphorylation and this effect was significantly 
reduced by minocycline in a concentration dependent manner. 319 The effects of 
minocycline were mediated, at least, in part, by inhibition of NF-ĸB and p38 
activation, the later being completely dependent on the stimulation of the 
P13K/Akt pathway. This indicates that the effect of minocycline on p38 MAPK 
activity is exclusively dependent on P13K/Akt signalling. Therefore, minocycline 
activation of the P13K/Akt pathway plays a significant role in its anti- 
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inflammatory effects. Minocycline substantially reduced LPS induced NF-ĸB 
activation, demonstrating that this pathway is an important target for its anti-
inflammatory effects. 319 
The anti-inflammatory effects of minocycline were apparent at a low 
concentration of 10µM used in the study by Pang et al. 319 This is in the same 
range of the peak plasma concentrations of 6mg/l (equivalent to 13µM) 
achieved after a single oral administration of 100 to 200mg of minocycline in 
humans. 320 However, the plasma concentrations may not accurately reflect 
minocycline concentrations reaching the retina after crossing the blood retinal 
barrier.  
The studies described above 318, 319 suggest that during hypoxia there may be 
overexpression of the p65 subunit of the NF-ĸB transcription factor which may 
lead to activation of hypoxia inducible factor. Evidence for minocycline 
suppressing p65 phosphorylation and nuclear translocation of NF-ĸB 
accompanied by downregulation of NF-ĸB activity has been shown by a recent 
study 321 in ovarian carcinoma cells. 
The biochemical inhibitors that were used in the study presented in this thesis 
were chosen as they specifically inhibited pathways or components of pathways 
considered to be important mediators of minocycline’s action. These were 
Ly294002 a specific inhibitor of the P13K pathway, SB202190, a p38 inhibitor 
and JSH-23, an inhibitor of the p65 subunit of NF-ĸB. As described above, 
these pathways are interconnected and complex. The mechanisms for glycated 
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albumin induced MCP-1 production appear to involve the p38 and P13K 
pathways to a greater extent than the pathways for IL-8 production. Minocycline 
appears to exert its anti-inflammatory effects through specific targeting of the 
P13K pathway and also p38. This explains the results of this study where the 
effects of minocycline in suppressing glycated albumin induced MCP-1 
production were greater than similar experiments involving IL-8 production. 
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Figure 25: Schematic representation of mechanisms of actions of minocycline, 
and biochemical inhibitors Ly294002, SB202190 and JSH-23 in suppression of 
glycated human serum albumin (GHSA) induced IL-8 and MCP-1 production from 
ARPE-19 cells 
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Figure 26: Schematic representation of effects of minocycline and biochemical 
inhibitor JSH-23 on putative effects of hypoxia and hypoxic inducible factor (HIF) 
in ARPE-19 cells 
 
3.9.84 Conclusions of preclinical study 
The results suggest that minocycline inhibits glycated albumin induced MCP-1 
and IL-8 production from ARPE-19 cells in vitro. Minocycline also inhibits MCP-
1 and IL-8 production to a lesser extent in hypoxia. The aetiology of 
neovascular AMD is recognised to be complex and both inflammation and 
hypoxia contribute to the pathological process culminating in 
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neovascularisation. This study supports a therapeutic role for minocycline in 
suppressing IL-8 and MCP-1 production arising from inflammatory and hypoxic 
pathological processes occurring in neovascular AMD. 
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Chapter 4 
4.0 Clinical Study 
4.1 Introduction 
The exudative (wet) type of AMD is characterised by the presence of choroidal 
neovascularisation (CNV).19 The pathogenesis of neovascular AMD is widely 
regarded to be complex, involving several intricately linked pathways including 
oxidative stress, inflammation, immune mechanism and angiogenesis. Inhibition 
of vascular endothelial growth factor is now in widespread use for treating 
exudative AMD. Combination therapy in exudative AMD is aimed at targeting 
the different pathways in the disease process whilst reducing or counteracting 
the adverse effects of individual therapeutic agents.  
4.2 Aims and rationale 
The aims were to assess the safety and efficacy of the combined treatment of 
reduced fluence verteporfin photodynamic therapy (PDT), intravitreal 
ranibizumab, intravitreal dexamethasone and oral minocycline for choroidal 
neovascularisation (CNV) secondary to age related macular degeneration 
(AMD). The hypothesis was that by combining ranibizumab with other CNV 
modulating agents, the need for ranibizumab retreatment could be reduced 
while remaining both efficacious and safe. 
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4.3 Ethics and regulatory approval 
The trial was conducted in compliance with the principles of the Declaration of 
Helsinki (1996), the Principles of Good Clinical Practice, and all of the 
applicable regulatory requirements. King’s College hospital NHS Research 
Ethics Committee reviewed and approved this research trial. 
4.4 Quality Assurance and data handling 
Copies of protocols, case report forms, physiological test results, 
correspondence, informed consents, and other documents relevant to the study 
were kept on file by the Principal Investigator and archived after completion of 
the study. The results of the study have been disseminated and presented at 
scientific conferences and published. 248 
4.5 Methods 
4.5.1 Trial design 
This was a prospective open label interventional clinical trial of eyes with recent 
onset CNV secondary to AMD. Patients had to be willing to given written 
informed consent, undertake the necessary medical tests and treatments and 
be willing to be followed up.  Patients with active medical conditions or a history 
of a medical condition that would be likely to preclude scheduled study visits 
such as unstable angina, dialysis and active cancer were excluded. Also, 
patients who were unable to sign or understand the consent process were 
excluded. 
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4.5.2 Eligibility criteria 
The inclusion criteria were (1) age ≥ 50 years, (2) clinical diagnosis of wet AMD 
(3) any active subfoveal CNV (classic and occult) and (4) logMAR best 
corrected visual acuity (BCVA) of 24-73 letters on the Early Treatment Diabetic 
Retinopathy Study (ETDRS) chart. Activity of the CNV was determined by 
recent decline in vision, presence of subretinal fluid or haemorrhage and 
leakage on fundus fluorescein angiogram. Only one eye of each patient was 
included in the study. The main exclusions were (1) eyes with CNV from causes 
other than AMD (myopia, angioid streaks, choroidal rupture, chorioretinal 
scarring), (2) previous treatment for CNV (PDT, argon laser, anti-VEGF agents, 
steroids), (3) open angle glaucoma or risk of developing glaucoma and (4) 
myopia > -8.00 dioptre. Further exclusion criteria were (5) Inability to have a 
good quality fluoroscein angiogram taken for example, due to head tremor or 
media opacity (6) Allergy to fluoroscein or verteporfin (7) Previous treatment for 
retinal detachment (8) Judged by the examining clinician to be at increased risk 
of retinal detachment due to weaknesses in the peripheral retina (9) Previous 
photodynamic therapy or other therapy for CNV such as argon laser treatment 
(10)Patient has currently parcipated in a clinical trial that utilised an 
investigational drug or treatment within 30 days prior to enrolment in this study 
(11) Patient taking anticoagulation therapy such as warfarin, with the exception 
of aspirin and other anti-platelet therapy (12) Exclusion of women of child 
bearing potential (13) Exclusion of pregnant or lactating women 
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4.5.3 Ophthalmic assessment schedule 
The logMAR BCVA was measured in both eyes after refraction using the 
modified ETDRS charts. The BCVA, slitlamp biomicroscopic examination of the 
anterior segment, intraocular pressure measurement and dilated fundus 
examination of the posterior pole were perfomed at baseline and monthly visits. 
Baseline and monthly OCT imaging was carried out on the Stratus OCT (Carl 
Zeiss Meditec) using the fast macular thickness map protocol. Colour fundus 
photography and fluorescein angiography were performed at baseline, month 6 
and month 12. 
Table 4: Study visit protocol (X represents procedures completed at visits, X1 
ranibizumab was administered if retreatment criteria met) 
Visit number Visit 1 
Screening 
and 
treatment 
Visit 
2 
Visit 
3 
Visit 
4 
Visit 
5 
Visit 
6 
Visit 
7 
Visit 
8 
Visit 
9 
Visit 
10 
Visit 
11 
Visit 
12 
Study month 0 1 2 3 4 5 6 7 8 9 10 11 
Procedure             
Informed 
Consent 
X            
Medical history X            
BCVA X X X X X X X X X X X X 
Ophthalmic 
examination 
X X X X X X X X X X X X 
Tonometry X X X X X X X X X X X X 
OCT X X X X X X X X X X X X 
Colour fundus 
photo 
X      X      
FFA X      X      
BP X            
Weight X            
Height X            
PDT & 
Visudyne 
X            
Minocycline X            
Dexamethasone X            
Ranibizumab X X1 X1 X1 X1 X1 X1 X1 X1 X1 X1 X1 
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4.5.4 Treatment schedule at baseline 
Reduced fluence PDT was administered at baseline. Verteporfin (6mg/m2) was 
administered as a standard 10 minute infusion, and the PDT laser was applied 
with a reduced fluence (25 J/cm2, 300mW/cm2) 5 minutes after the infusion of 
the drug for 83 seconds. This was followed by a single intravitreal injection of 
ranibizumab 0.3mg/ 0.05ml and dexamethasone 200µg in 0.05ml that were 
combined in the same syringe (total volume 0.1ml). 
The intravitreal injection was administered using a standard sterile technique. 
Measurement of intraocular pressure was performed prior to and 30 minutes 
after the injection. A post injection course of ofloxacin eyedrops 3 times a day 
for 4 days was prescribed. 
4.5.5 Subsequent treatment regimen 
All subsequent intravitreal injections of ranibizuma were only administered if 
they fulfilled the retreatment criteria. Oral minocycline 100mg daily was started 
the next day after the baseline treatment was administered and continued for 3 
months. Patients were instructed to return all used and unused drug packages 
to ascertain compliance. 
4.5.6 Retreatment criteria 
Re-injection with ranibizumab was indicated if any of the following were present 
at the monthly follow up visits: 
  
134 
 
1. A loss of > 5 letters of refracted logMAR BCVA recorded on the modified 
ETDRS chart when compared to the previous month 
2. An increase in central retinal thickness (CRT) of >100µm measured on a 
fast macular thickness map when compared to the previous month 
3. Fresh macular haemorrhage on dilated fundus biomicroscopy 
 
4.5.7 Outcome measures 
The primary efficacy outcome measures were: 
1. The mean changes in BCVA from baseline to study completion  
2. The proportion of patients with stable vision (a loss or gain of less than 
15 letters) 
3. The mean ranibizumab retreatment rate per study eye over the follow up 
period 
The secondary outcome measures were: 
1. The proportion of study eyes which gained ≥ 5 letters of BCVA 
2. The proportion of study eyes which lost ≥15 letters of BCVA 
3. Mean final BCVA 
4. The mean change in the CRT on OCT 
The safety profile was assessed by visual acuity, tonometry, ophthalmic 
examinations, adverse events and vital signs. 
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4.5.8 Statistical analysis 
The proof of concept safety hypothesis used in other combination studies to 
measure possible safety implications and the relationship between the 
concomitant administration of two drugs was used in this study (FOCUS and 
PROTECT). 322, 323 Enrolment of 19 patients was needed to allow a 95% chance 
of observing at least 1 adverse event with a true rate of occurrence of ≥4% 
within the treatment period, based on the 3% rate of moderate visual loss 
reported in the PROTECT study322, the study that assessed safety of same day 
standard PDT and ranibizumab and the study that assessed outcomes of 
combined bevacizumab and dexamethasone with PDT that showed 3.8% lost 3 
or more lines. 324 These safety assessments included the incidence of severe 
vision loss (number of patients losing 30 letters of BCVA from baseline) and the 
incidence of moderate vision loss (number of patients losing 15 letters of BCVA 
from baseline). 
4.6 Results 
Nineteen eyes of 19 patients were recruited into the study. One patient was 
withdrawn from the study as a result of epidural haematoma after a retreatment 
at month 2. Three patients were retreated with 0.5mg/ 0.05ml of commercially 
available ranibizumab (2 from visit 10 and 1 from visit 8) due to non availability 
of the study specific ranibizumab (0.3mg/0.05ml) preparation. The baseline 
characteristics are described in table 5. 
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Table 5: The baseline characteristics of the study cohort 
Baseline characteristics Number of eyes (total n = 18) 
Mean age, years 79.2±6 
Laterality (OD:OS) 11:7 
CNV type  
      Predominantly classic 3 (15.7%) 
      Minimally classic 3 (15.7%) 
      Occult not classic 12 (63.2%) 
      Retinal angiomatous  proliferation 1 (5.3%) 
  
Mean baseline visual acuity (ETDRS) 58±11.4 
Mean baseline CRT (microns) 315.1±65.4 
Mean angiographic lesion size mm2 6.75±2.78 (range 1.9 to 10.9) 
 
4.6.1 Visual acuity outcomes  
The mean change in BCVA at the final follow up was -5.0 (± 10.5) ETDRS 
letters (figure 27). The final mean BCVA was 52.6 ± 16 ETDRS letters (range 7-
76). Eighty nine percent (16/18 eyes) had stable vision losing fewer than 15 
ETDRS letters. None of the study eyes gained more than 15 ETDRS letters, 
although 3/15 eyes gained more than 5 ETDRS letter (7, 11 and 12 letter gain). 
One eye suffered a moderate visual loss of 24 letters, and another eye had 
severe visual loss of 30 letters. 
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Figure 27: Mean final visual outcome at the final follow up at 12 months. The final 
mean BCVA was 52.6± 16 ETDRS letters. Mean change in BCVA was -5.0 (±10.5) 
ETDRS letters.  This was not significant (p = 0.06). 
 
4.6.2 OCT outcomes 
The mean reduction in CRT was 66.3 (±75) µm. The mean final CRT on OCT 
was 248 ± 52µm. The greatest reduction in CRT measurements occurred 1 
month after the combined treatment was administered after which it remained 
relatively stable (figure 28). 
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Figure 28: Mean change in central retinal thickness (CRT) during the study 
period. The mean final CRT on OCT was 248 ± 52µm. The mean reduction in CRT 
was 66.3 ±75µm. The greatest reduction in CRT measurements occurred 1 month 
after the combined treatment was administered after which it remained relatively 
stable 
 
 
4.6.3 Retreatment outcomes 
The mean total number of ranibizumab injections given was 3.4 (baseline 
ranibizumab + ranibizumab retreatments). The average number of months from 
baseline treatment with combined reduced fluence verteporfin PDT, 
ranibizumab, dexamethasone and minocycline to retreatment with ranibizumab 
monotherapy was 2.6 months (range 1-6). Two eyes required 5 ranibizumab 
retreatments, and the mean changes in visual acuity in these eyes were -12 and 
-6 ETDRS letters, respectively. Three eyes required only 1 additional 
ranibizumab retreatment, while the rest of the cohort needed 2-3 injections. 
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4.6.4 Safety assessment 
One eye suffered a moderate visual loss of 24 letters. This 73 year old patient 
had a predominantly classic lesion with a pretreatment baseline visual acuity of 
31 letters, CRT of 319µm and lesion size of 9.08mm2. In the first month 
following baseline combination treatment, the vision improved to 37 letters and 
CRT was reduced to 182µm. Two additional ranibizumab retreatments were 
given at follow up months 3 and 5. However, the visual acuity dropped by 16 
letters compared to the previous month and continued to progressively 
deteriorate. The final visual acuity was 7 letters and CRT was 267µm. The 
visual loss was attributed to central subretinal fibrosis, and the final size of the 
fibrotic lesion was 14.502mm2. 
Severe visual loss of 30 letters was reported in 1 eye. This 71 year old patient 
had an occult lesion with a baseline visual acuity of 62 letters, CRT of 279µm 
and lesion size of 9.266mm2. Baseline combination therapy and 1 ranibizumab 
retreatment at follow up month 3 stabilised the vision for 5 months. Despite 2 
further ranibizumab injections, the vision progressively deteriorated from month 
6 to a final visual acuity of 32 letters. The final size of the fibrotic lesion was 
16.037mm2. 
None of the patients had any inflammatory response, raised intraocular 
pressure or cataract extraction during the study period.  There was 1 case of 
mild gastrointestinal disturbance secondary to oral minocycline, but the patient 
was able to complete the 3 month course. There was 1 study related death. 
This 89 year old patient had received both the combination treatment regime at 
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baseline and a retreatment with ranibizumab at month 2. She then died of an 
epidural haematoma a week following the treatment. This was reported as a 
suspected unexpected serious adverse reaction (Appendix F, page 225). 
4.7 Discussion 
This pilot study was powered to determine the adverse events when a 
quadruple therapy of reduced fluence PDT, intravitreal ranibizumab and 
dexamethasone and oral minocycline are used as a treatment option for 
neovascular AMD. The efficacy of individual components of the combination 
therapy was not evaluated in this study.  
The study showed that quadruple therapy can be delivered safely. Reduced 
fluence PDT with 25 J/cm2 reduces the choroidal hypoperfusion, inflammation, 
vascular leakage and VEGF upregulation that is associated with standard 
fluence PDT. 322-325 It was used only once during the course of treatment in 
combination with ranibizumab and dexamethasone. Dexamethasone provided 
additional anti-inflammatory, antifibrotic, anti-proliferative and anti-VEGF effects. 
It is more rapidly cleared from the vitreous that triamcinolone with a lower risk of 
raised intraocular pressure and cataract formation. 246, 247 Oral minocycline, a 
semi synthetic tetracycline derivative, was used for its immunomodulatory, anti-
angiogenic, antimetalloproteinase, anti-oxidant and anti-apoptotic effects. 254 A 
reduced dose of ranibizumab (0.3mg in 0.05ml) was used, given the combined 
angio-occlusive effect of PDT and the anti-angiogenic effects of dexamethasone 
and minocycline. No angiographic evidence of choroidal non perfusion was 
noted at 6 months in any of the patients in this case series, unlike other 
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combination studies. 326 This may be because choroidal perfusion defects are 
noted within a week of combination treatment while this study’s protocol was 
monthly visits. 
Two of the 18 patients (11%) lost more than 3 lines of vision due to subretinal 
fibrosis. In contrast, the PROTECT study 322 showed that only 1/32 lost more 
than than 15 letters at 9 months. The difference between the two studies was 
that intravitreal ranibizumab was given monthly for 4 months in the induction 
phase and PDT was administered at 12 weekly intervals if angiographic leakage 
was present at 3, 6 and 9 months in the PROTECT study 322 compared to an ‘as 
needed’ strategy for re-injection with ranibizumab and no further PDT in this 
study.  
Both patients in this study lost the vision due to subretinal fibrosis, and the 
increase in fibrosis was noted at the 5th and 8th months, respectively. The 
second injection of intravitreal ranibizumab was only given at 3 months in both 
cases, and the change in vision at that point was 0 and +2 and re-injection of 
ranibizumab was given for recurrence of fluid. This suggests that in combination 
treatment, retreatment with intravitreal ranibizumab based on recurrent fluid is 
an insufficient retreatment criterion. This trial was designed before OCT guided 
dosing schedules were published. Clearly, this study shows that it is insufficient 
to treat recurrent fluid only. 
This study did not show the initial steep gradient of gain in vision noted in the 
PROECT study 322 and the ranibizumab monotherapy trials (MARINA104 and 
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ANCHOR 105), suggesting that the quadruple therapy at baseline (or only 1 
intravitreal ranibizumab injection) is insufficient to improve vision. Repeated 
injections of ranibizumab in the induction phase are required to achieve an 
improvement in vision. 
The study results correlate well with the observation that reduced levels of 
aqueous VEGF and pigment epithelium derived factor are associated with 
ranibizumab therapy regardless of combined therapy with PDT. The reduction 
levels of VEGF and pigment epithelium derived factor also correlated with 
anatomical improvements in the macula, suggesting that ranibizumab is the 
main driver of outcomes. 327 
This study mirrors the outcomes of other multicentre trials on combination 
treatments of ranibizumab and PDT such as the FOCUS study. 323 
The MONT BLANC study 328 that evaluated the superiority of standard PDT with 
ranibizumab compared to ranibizumab monotherapy also showed that an 
induction of 3 injections of intravitreal ranibizumab is required for an 
improvement of vision (+7.1 ETDRS letters). The study also showed that a PRN 
schedule in the maintenance phase of either ranibizumab monotherapy or the 
combination of standard PDT with ranibizumab booster is insufficient to sustain 
the improvement of vision. 328 
This study reiterates that aggressive retreatment strategies have to be initiated 
to improve and sustain the effect. 329 Although ranibizumab monotherapy is a 
burden to patient, treating physicians and health care systems, it is the only 
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treatment that can sustain an improved vision obtained at induction if strict re-
treatment criteria are implemented. 
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Chapter 5  
5.0 Current Treatment Approaches for neovascular AMD 
Following the results of pivotal clinical trials (MARINA104 and ANCHOR105) 
published in 2006, and NICE approval of Ranibizumab in 2007 and Aflibercept 
in 2013 current standard NHS treatment for neovascular age related macular 
degeneration involves intravitreal injections of ranibizumab or afilbercept at 
regular intervals. Various studies have been published (PIER113, PRONTO117) in 
an attempt to demonstrate vision can be maintained with a less intensive 
injection regimen. The results of the VIEW studies 330 with aflibercept offered a 
direct comparision between 2 monthly aflibercept and monthly ranibizumab and 
showed equivalent visual gains. However, the VIEW study did not include a 
comparision group of two monthly ranibizumab. 330 
5.1 Radiation therapy 
The underlying pathological mechanisms in neovascular age related macular 
degeneration have been postulated to be similar to those of a proliferative 
wound healing response.331 Radiation therapy targets proliferating cells in 
neovascular age related macular degeneration including fibroblastic, 
inflammatory and endothelial cells.331 
Radiation therapy for medical use is usually divided into two main categories 
depending on its method of delivery to the tissue.  Brachytherapy uses a 
radiation source which produces ionising radiation as it decays and emits 
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energy. The radiation source is delivered directly to the lesion by surgery. 
External beam therapy is delivered from an external source in which radiation is 
formed into beams which can be projected at an internal body tissue. 331 
Two main approaches to radiation therapy in neovascular AMD are under 
investigation, epimacular brachytherapy (VIDION; NeoVista Inc. Fremont,CA) 
and stereotactic radiosurgery (IRay system; Oraya Therapeutics Inc 
Newark,CA)331 
The beta radiation (approximately 24 gray delivered to the macular lesion) in 
epimacular brachytherapy is delivered via a probe through a pars plana 
vitrectomy. Potential risks of intraocular radiation include retinopathy, optic 
neuropathy and cataract. 331However, the dose delivered to nearby structures is 
reported to be below the safety threshold to cause damage. Vitrectomy is 
postulated to improve the oxygenation of the inner retina via diffusion from the 
aqueous humour.332 Reduced oxygen tension within the inner retina may 
instigate CNV formation. The MERITAGE study333 was a multicentre study to 
evaluate the safety and efficacy of focal delivery of radiation in patients that 
require persistent injections of anti VEGF therapy. Fifty three eyes of fifty three 
participants with neovascular AMD were included. Patients underwent pars 
plana vitrectomy with a single dose of 24Gy of epimacular brachytherapy 
delivered via an intraocular handheld cannula containing a strontium 90/ yttrium 
90 source positioned over the active lesion. Retreatment with ranibizumab was 
administered monthly as needed, using predefined retreatment criteria. Optical 
coherence tomography (OCT) was undertaken monthly. Primary outcome 
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measures at 12 months were proportion of patients with stable vision (losing < 
15 letters on the ETDRS chart), and mean number of anti-VEGF injections. 
Prior to commencement of the trial patients had received a mean number of 
12.5 anti-VEGF injections. After a single treatment with epimacular 
brachytherapy, 81% maintained stable vision, the mean number of anti-VEGF 
retreatments was 3.49 in 12 months. Mean change in vision was -4.0 ETDRS 
letters with a standard deviation of ±15 letters. Cataract was documented in 16 
(30%) patients. The conclusions were that EMB produced stable vision in most 
patients with previously treated active disease and may have a role to decrease 
the need for frequent anti-VEGF retreatment.333 
CABERNET334 was a multicentre randomised controlled trial evaluating the 
safety and efficacy of epimacular brachytherapy in treatment naive patients. 494 
patients with treatment naive classic, minimally classic, and occult lesions with 
neovascular AMD were randomised 2:1 into EMB or ranibizumab control arm. 
The EMB arm received two mandatory monthly loading injections of 0.5mg of 
ranibizumab. The control arm received three mandatory monthly loading 
injections of ranibizumab then quarterly injections. Both arms received monthly 
as needed (PRN) retreatment. The main outcome measures at 24 months were 
the proportion of patients losing or gaining 15 letters of vision on the ETDRS 
chart from baseline vision.334 
Results334 demonstrated that 77% of the EMB arm and 90% of the control arm 
lost fewer than 15 letters. This difference did not meet the prespecified 10% non 
inferiority margin. EMB did not meet the superiority end point for the proportion 
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of patients gaining more than 15 letters (16% EMB versus 26% for the control 
group). The differences were statistically significant for occult lesions (favouring 
controls) but not for classic and minimally classic lesions. 334 End change in 
vision was -2.5 letters in the EMB arm and +4.4 letters in the control arm. 
Patients in the EMB arm received a mean number of 6.2 ranibizumab injections 
versus 10.4 in the control arm. Postvitrectomy cataract occurred in 54% of the 
EMB arm versus 18% in the control arm. Mild non vision threatening radiation 
retinopathy occurred in 3% of the EMB arm. Despite an acceptable safety 
profile, the conclusions of the trial were that the two year data do not support 
the routine use of EMB for treatment naive neovascular AMD.334 
MERLOT is a UK multicentre randomised controlled trial in patients who have 
already commenced anti-VEGF therapy. The aim is to compare epimacular 
brachytherapy and as required ranibizumab with ranibizumab monotherapy. 
This study has an estimated enrollment of 363 patients and results are yet to be 
published. 
Sterotactic radiotherapy is a technique for targeting beams from different angles 
onto the target area thereby avoiding exposure to surrounding healthy tissue. 
331 The IRay system utisilises a low energy X-ray source so avoiding the need 
for a high degree of radiation shielding. The patient is secured in place with a 
head restraint with lead backing preventing radiation travelling beyond the 
patient. A robotically controlled delivery system connects the radiation source to 
the patient using a contact lens and 25mmHg suction. Two to three beams of 
radiation are delivered to overlap on the foveal centre through the inferior pars 
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plana region of the sclera (5, 6 and 7 o’clock ), dispersing the scleral entry dose 
and minimising exposure of the lens and optic nerve. The eye is continually 
tracked during treatment and an inbuilt safety feature interrupts the radiation 
treatment if the eye moves out of position. 331 
The safety and efficacy of low voltage external beam stereotactic radiotherapy 
(SRT) for neovascular age related macular degeneration was studied in a 
randomised, double masked sham controlled multicentre clinical trial. 335 Two 
hundred and thirty patients with onset of neovascular AMD within the previous 
three years who had received three or more injections of ranibizumab or 
bevacizumab within the preceeding year and needed continual treatment were 
recruited. Patients were randomised 2:1:2:1 to 16 Gy SRT plus PRN 
ranibizumab, sham SRT 16 Gy plus PRN ranibizumab, 24 SRT Gy plus PRN 
ranibizumab and sham SRT 24 Gy plus PRN ranibizumab respectively.335 The 
primary efficacy end point was the mean number of ranibizumab injections at 
week 52. Secondary endpoints were change in mean BCVA, loss or gain of 15 
letters of vision on the ETDRS chart, and change in angiographic total lesion 
size and choroidal neovascularisation (CNV) lesion size. The results335 
demonstrated that both the 16Gy and 24 Gy SRT treatment arms received 
significantly fewer ranibizumab treatments compared to the sham arms, 
however, in terms of clinical impact this only equates to an equivalent mean 
reduction of 1.5 injections per year. Change in mean VA was -0.28, +0.40 and -
1.57 letters for the 16 Gy, 24 Gy and sham arms respectively. Across all arms 
vision was maintained with approximately 90% of patients losing fewer than 15 
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letters of vision. Ony 4% of patients across all arms gained 15 letters of vision. 
The numbers of adverse events were similar across all arms and no adverse 
events were attributed to radiation. The conclusions were that a single dose of 
SRT reduces ranibizumab retreatment for patients with neovascular AMD and 
there were no concerns over patient safety effects over a one year period. SRT 
was associated with relatively well preserved vision over a one year period. 335  
5.2 Combination studies 
Research has also been conducted to examine treatment outcomes utilising a 
combination of PDT and anti-VEGF drugs. The aims were to attempt to reduce 
the treatment burden of anti VEGF monotherapy whilst maintaining the vision 
gains achieved with anti-VEGF monotherapy. The SUMMIT clinical trial 
programme evaluated the efficacy and safety of verteporfin PDT in combination 
with ranibizumab compared with ranibizumab montherapy in various forms of 
CNV. This comprised three studies, MONT BLANC 328, DENALI336 and 
EVEREST.337 
Polypoidal choroidal vasculopathy (PCV) is a distinct clinical entitity and 
regarded as part of the spectrum of neovascular age related macular 
degeneration. The condition is associated with recurrent macular serous 
leakage and haemorrhage.  It has been shown that this condition occurs more 
frequently in Asian populations.338 
The EVEREST trial337 was part of the SUMMIT program and conducted only in 
Asia. In the EVEREST trial337 treatment naive patients with ICG verified PCV 
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were randomised to verteporfin PDT (6mg/m2), ranibizumab, or a combination 
of both. The primary end point was the proportion of patients with ICG assessed 
complete regression of polyps at 6 months follow up. Results showed that the 
combination of PDT with ranibizumab or PDT alone was superior to 
ranibizumab monotherapy in achieving complete polyp regression (77.8 and 
71.4 versus 28.6%, p < 0.01). Combination treatment also showed superior 
improvements in vision (+10.9 letters compared to +7.5 letters for verteporfin 
PDT and +9.2 letters for ranibizumab monotherapy). 
As part of the SUMMIT program, the MONT BLANC 328(conducted in Europe) 
and DENALI336 (conducted in the USA and Canada) studies evaluated 
combination therapy in patients with CNV because of neovascular AMD. The 
DENALI study336 showed noninferiority of ranibizumab in combination with 
verteporfin PDT versus monthly ranibizumab monotherapy in patients with 
subfoveal CNV secondary to AMD.339 Clinically meaniful visual gains were 
maintained with fewer intravitreal injections over 12 months. Ranibizumab 
treatment free intervals of over 3 months were achieved in 92.6% and 83.5% of 
patients randomised to verteporfin standard fluence or verteporfin reduced 
fluence respectively associated with a mean of 5.1 and 5.7 ranibizumab 
injections respectively. Patients in the ranibizumab monotherapy arm received 
10.5 injections. 339 
Currently, combination therapy with PDT and anti-VEGF injections is used as 
second line therapy when patients do not respond to anti-VEGF monotherapy or 
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when the treatment burden of monthly injections is too great. Combination 
therapy is used as primary treatment for idiopathic PCV. 
Retinal angiomatous proliferation is a subtype of neovascular age related 
macular degeneration. This condition often requires repeated anti-VEGF 
injection treatment. Triple therapy involving a combination of verteporfin PDT, 
intravitreal anti VEGF and intravitreal steroid (dexamethasone or triamcinolone) 
has been used for these difficult to treat lesions. Small prospective randomised 
studies 340 of RAP lesions show vision was stabilised in all treatment groups but 
results were more favourable with a triple therapy regimen.  
5.2.1 Antiplatelet derieved growth factor and antivascular endothelial 
growth factor 
PDGF regulates cell growth and division and is an important factor in new blood 
vessel formation from existing vascular tissue. Several subtypes of PDGF exist 
as part of the PDGF family, such as PDGF-CC. This factor increases the 
survival of vascular endothelial cells and promotes the proliferation, survival and 
migration of fibroblasts and pericytes. Inhibition reduces macrophages 
infiltration during CNV formation. 341 Both choroidal and retinal vascularisation 
were shown to be suppressed when inhibition of PDGF-CC occurred in 
preclinical studies.342 This provides a rationale for combining anti-PDGF 
together with anti-VEGF agents to treat CNV. The aim of anti-PDGF treatment 
would be to strip pericytes from maturing neovascular tissue thus leading to 
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increased susceptibility to anti-VEGF therapeutic agents. Anti-PDGF treatment 
in isolation is unlikely to show an effect. 342 
A prospective randomised controlled trial 343 of patients with neovascular AMD 
was conducted to compare anti-PDGF (Fovista, Ophthotech New York, USA) 
administered in combination with ranibizumab to monthly ranibizumab. Patients 
receiving the combination regimen at monthly intervals gained significantly more 
vision ( mean gain +10.6 letters) at 24 weeks compared with patients receiving 
ranibizumab monotherapy (+6.5 letters, p=0.019). 343 
Future treatment approaches are likely to target an increasing number of growth 
factors in an attempt to reduce the treatment burden for individual patients and 
healthcare providers. 
5.3 General Conclusions 
The results of a pilot trial of combination therapy incorporating minocycline for 
neovascular age related macular degeneration have shown that this treatment 
is safe. However, the results were not superior than anti-VEGF monotherapy.  
The results of the pre-clinical research on a putative therapeutic role for 
minocycline in the treatment of neovascular age related macular degeneration 
have shown that there is a narrow therapeutic range for treatment. Minocycline 
appears to protect cells from hypoxia, the molecular mechanisms are complex 
and were not investigated in detail in this study. In this study minocycline was 
found to inhibit glycated albumin induced MCP-1 and IL-8 production from 
ARPE-19 cells in culture. The limitations of this study were that this model is 
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unlikely to accurately represent in vivo pathology in AMD due to the complex 
interacting molecular mechanisms involved. However, the results do support a 
therapeutic role for minocycline in the early inflammatory pathological process. 
Further studies will be required to determine the future therapeutic potential of 
minocycline in age related macular degeneration.  
5.4 Future work  
Future studies will be required to elucidate fully the detailed molecular 
mechanisms through which minocycline acts. Putative targets apart from 
inflammatory cytokine suppression include cellular tight junction proteins and 
signalling. A recent study by Abcouwer et al 344 demonstrated that minocycline 
prevented ischaemia reperfusion induced permeability and tight junction 
disorganisation in a rat model of retinal neurodegeneration. Similarly, a small 
clinical study of five patients with diabetic macular oedema found that 6 months 
of minocycline treatment reduced vascular fluoroscein leakage and diminished 
mean retinal thickness. 345 This indictates potential future roles for minocycline 
to prevent the vascular leakage associated with neovascular AMD. 
Autophagy is another process in which minocycline may have a future 
therapeutic role. 
During the last decade there has been a greater understanding of the process 
of autophagy. In normal physiological conditions, autophagy serves as a 
housekeeping process through which cytoplasmic proteins and damaged 
cellular organelles, such as dysfunctional mitochondria are removed.346 
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Autophagy plays a key role in cellular homeostasis and this process can be 
stimulated to cope with excessive organelle damage, aggregate removal, and 
pathogen defense.347 
As accumulation of proteins and damaged organelles are generally considered 
to occur in the aging RPE and in AMD, it is reasonable to postulate that a 
breakdown in the recycling capacity of autophagy may have a strong 
association. Starvation has been used as an inducer of autophagy in most 
studies, however, oxidative stress has also been acknowledged as a regulator 
of autophagy. 348 Autophagy proteins are strongly expressed in the RPE. 349 
Many of the pathogenic features of RPE in AMD such as lipofuscin 
accummulation, susceptibility to oxidative stress and lysosomal dysregulation 
have an association with autophagy. It is currently unclear whether changes in 
autophagy are a cause or consequence of disease. A recent study 350 utilising 
cultured RPE cells and AMD donor tissue showed that under conditions of 
increased mitochondrial damage, autophagy markers were upregulated and 
that drusen in AMD donor eyes contain markers for autophagy. This suggests 
that increased autophagy and release of intracellular proteins by the aged RPE 
may contribute to the formation of drusen. Ischaemia and hypoxia are 
considered to contribute towards the pathogenesis of neovascular AMD and 
hypoxia induced autophagy has been demonstrated 351 as a cell survival 
mechanism.  Induction of autophagy can be obtained through inhibition of the 
mitogen activated protein kinase/ extracellular signal regulated kinase, 
phosphoinositide 3-kinase-AKT and MTOR signalling pathways. Inhibitors of 
P13 kinases such as Ly2949002 can inhibit autophagy 352 and this same 
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pathway has been identified as a putative mechanism for the actions of 
minocycline. This suggests that minocycline is a plausible therapeutic option to 
target regulation of autophagy signalling pathways in AMD. However, the 
complexity of autophagy as a pharmacological therapeutic target in AMD 
therapy means, to date, there is no consenus as to whether autophagy 
inhibitors or activators would be beneficial in AMD therapy.
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                                                    Appendix A 
 
Detailed protocol for human IL-8 ELISA  
A Reconstitution and dilution of Hu IL-8 standard 
Glass or plastic tubes may be used for standard dilutions 
 
1. Reconstitute standard to 10.0ng/mL with Standard Dilutent Buffer. Refer to 
standard vial label for instructions. Swirl or mix gently and allow to stand for 10 
minutes to ensure complete reconstitution. Use standard within 1 hour of 
reconstitution. 
2. Add 0.100mL of the reconstituted standard to a tube containing 0.9mL 
Standard Dilutent Buffer. Label as 1000pg/mL Hu IL-8. Mix 
3. Add 0.300mL of Standard Dilutent Buffer to each of 6 tubes labelled 500, 
250, 125, 62.5, 31.2 and 15.6pg/mL Hu IL-8. 
4. Make serial dilutions of the standard as described in dilution table. Mix 
thoroughly between steps. 
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B Dilution of Hu IL-8 Standard 
Table 6: Dilution of IL-8 Standard 
Standard Add: Into: 
1000 pg/mL Prepare as described in step 2 
500 pg/mL 0.300 mL of the 1000 pg/ 
mL std. 
0.300 mL of the Diluent 
Buffer 
250 pg/mL 0.300 mL of the 500 
pg/mL std. 
0.300 mL of the Diluent 
Buffer 
125 pg/mL 0.300 mL of the 250 
pg/mL std. 
0.300 mL of the Diluent 
Buffer 
62.5 pg/mL 0.300 mL of the 125 
pg/mL std. 
0.300 mL of the Diluent 
Buffer 
31.2 pg/mL 0.300mL of the 62.5 
pg/mL std. 
0.300 mL of the Diluent 
Buffer 
15.6 pg/mL 0.300mL of the 31.2 
pg/mL std. 
0.300 mL of the Diluent 
Buffer 
0 pg/mL 0.300 mL of the Diluent 
Buffer 
An empty tube 
Discard all remaining reconstituted and diluted standards after completing the 
assay. 
Return the Standard Diluent Buffer to the refrigerator. 
C Storage and final dilution of streptavidin- HRP 
1. Dilute 10µl of this 100x concentrated solution with 1 mL of Streptavidin-
HRP Diluent for each 8 well strip used in the assay. Label as 
Streptavidin-HRP working solution.  
2. Table 7: Dilution of streptavidin- HRP 
# of 8 well strips Volume of streptavidin-
HRP concentrate 
Volume of Diluent 
(mL) 
2 20µl solution 2 
4 40µl solution 4 
6 60µl solution 6 
8 80µl solution 8 
10 100µl solution 10 
12 120 µl solution 12 
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2. Return the unused Streptavidin-HRP concentrate to the refrigerator. 
D Dilution of wash buffer 
Allow the Wash Buffer Concentrate (25X) to reach room temperature and mix to 
ensure that any precipitated salts have redissolved. Dilute 1 volume of the 
Wash Buffer Concentrate (25X) with 24 volumes of deionised water (eg. 50mL 
may be diluted up to 1.25 litres, 100mL may be diluted up to 2.5 litres). Label as 
Working Wash Buffer. 
Store both the concentrate and the Working Wash Buffer in the refrigerator. The 
diluted buffer should be used within 14 days.   
ASSAY METHOD: PROCEDURE AND CALCULATIONS 
Allow all reagents to reach room temperature before use. Gently mix all liquid 
reagents prior to use.  
A standard curve must be run with each assay 
1. Determine the number of 8 well strips needed for the assay. 
    Insert these in the frame(s) for current use. (Re-bag extra strips and     
    frame. Store these in the refrigerator for future use). 
2. Add 50µL of the Standard Diluent Buffer to zero wells. Well(s) reserved for 
chromogen blank should be left empty. 
3. Add 50µl of standards, samples or controls to the appropriate microlitre wells 
4. Pipette 50µl of biotinylated anti-IL-8 (Biotin Conjugate) solution into each well 
except the chromogen blank(s). Tap gently on the side of the plate to mix.  
5. Cover plate with a plate cover and incubate for 1 hour and 30 minutes at 
room temperature. 
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6. Thoroughly aspirate or decant solution from wells and discard the liquid. 
Wash wells 4 times. 
7. Add 100µl Streptavidin- HRP Working Solution to each well except the 
chromogen blank(s). (Prepare the working dilution as described in REAGENT 
PREPARATION AND STORAGE. 
8. Cover plate with a plate cover and incubate for 30 minutes at room 
temperature.  
9. Thoroughly aspirate or decant solution from wells and discard the liquid. 
Wash wells 4 times. 
10. Add 100µl of Stabilised Chromogen to each well. The liquid in the wells will 
begin to turn blue.  
11. Incubate for 30 minutes at room temperature and in the dark. Do not cover 
with Aluminium foil. The incubation time for the chromogen substrate is often 
determined by the microtitre plate reader used. Many plate readers have the 
capacity to record a maximal optical density (O.D.) of 2.0. The O.D values 
should be monitored and the substrate reaction stopped before the O.D. of the 
positive wells exceed the limits of the instrument.  The O.D. values at 450nm 
can only be read after the stop Solution has been added to each well. If using a 
reader that records only to 2.0 O.D. stopping the assay after 20 to 25 minutes is 
suggested. 
12. Add 100µl of Stop Solution to each well. Tap side of plate gently to mix. The 
solution in the wells should change from blue to yellow. 
13. Read the absorbance of each well at 450nm having blanked the plate 
reader against a chromogen blank composed of 100µl each of Stabilised 
Chromogen and Stop Solution. Read the plate within 2 hours after adding the 
Stop Solution. 
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14. Plot on graph paper the absorbance of the standards against the standard 
concentration. (Optimally, the background absorbance may be subtracted from 
all data points, including standards, unknowns and controls, prior to plotting). 
Draw the best smooth curve through these points to construct the standard 
curve. If using curve fitting software, the four parameter algorithm provides the 
best curve fit.  
15. Read the Hu IL-8 concentration for unknown samples and controls from the 
standard curve plotted in step 14. (Samples producing signals greater than that 
of the highest standard (1000 pg/mL) should be diluted in Standard Diluent 
Buffer and reanalyzed, multiplying the concentration found by the appropriate 
dilution factor).  
Detailed protocol for human MCP-1 ELISA  
Preparation of reagents 
1. Bring all reagents and samples to room temperature (18-25°C) before 
use. 
2. Sample dilution: 1X assay diluent buffer is used for dilution of cell culture 
medium dilution 
3. Assay diluent was diluted 5 fold with deionised or distilled water before 
use 
4. Preparation of standard: The vial was briefly spun, then 400µl 1X assay 
diluent was added to prepare a 100ng/ml standard. The powder was 
dissolved thoroughly by gentle mix. 5µl of this MCP-1 standard was 
added to a tube containing 995µ 1X assay diluent to prepare a 500pg/ml 
stock standard solution. 300µl of assay diluent was pipetted into 7 empty 
tubes. The stock standard solution was used to produce a a dilution 
series as shown in the table below. Each tube was mixed thoroughly 
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before the next transfer. Gentle vortex was used to mix each tube. The 1 
X assay diluent served as the zero standard (0pg/ml).    
Table 8: Dilution of MCP-1 standard 
Standard Add: Into: 
500 pg/mL Prepare as described in step 2 
500 pg/mL 200µl of the 500 pg/ mL 
std. 
300µl of the Diluent 
Buffer 
200 pg/mL 200µl of the 500 pg/mL 
std. 
300µl of the Diluent 
Buffer 
80 pg/mL 200µl of the 200 pg/mL 
std. 
300µl of the Diluent 
Buffer 
32 pg/mL 200µl of the 80 pg/mL 
std. 
300µl of the Diluent 
Buffer 
12.8 pg/mL 200µl of the 32 pg/mL 
std. 
300µl of the Diluent 
Buffer 
5.12 pg/mL 200µl of the 12.8 pg/mL 
std. 
300µl of the Diluent 
Buffer 
2.0 pg/mL 200µl of the 5.12 pg/mL 
std. 
300µl of the Diluent 
Buffer 
0 pg/mL 200µl mL of the 2.0 
pg/mL std. 
An empty tube 
5. The wash concentrate  (20x) was examined for visible crystals, warmed 
to room temperature and mixed gently until dissolved. 20ml of wash 
buffer concentrate was diluted into deionised or distilled water to yield 
400ml of 1x wash buffer. 
6. The detection antibody was briefly spun before use. 100µl of assay 
diluents was added to the vial to prepare a detection antibody 
concentrate. This mixture was pipetted up and down to mix gently. The 
detection antibody concentrate was diluted 80 fold with 1x assay diluent. 
7. The HRP-streptavidin concentrate vial was briefly spun and pipetted up  
and down to mix gently before use. HRP-streptavidin concentrate was 
diluted 400 fold with 1x assay diluent ie. 30µl of HRP-streptavidin 
concentrate was added into a tube with 12ml 1x assay diluent to prepare 
a final 400 fold diluted HRP- streptavidin solution. 
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MCP-1 ELISA Assay method 
1. Bring all reagents and samples to room temperature (18-25°C) before 
use.  
2. Add 100µl of each standard and samples into appropriate wells. Cover 
well and incubate for 2.5 hours at room temperature or overnight at 4°C 
with gently shaking. 
3. Discard the solution and wash 4 times with 1x wash solution. Wash by 
filling each well with wash buffer (300µl) using a multichannel pipette. 
Complete removal of liquid at each step is essential to good 
performance. After the last wash, remove any remaining wash buffer by 
aspirating or decanting. Invert the plate and blot it against clean paper 
towels. 
4. Add 100µl of 1x prepared biotinylated antibody to each well. Incubate for 
1 hour at room temperature with gently shaking. 
5. Discard the solution. Repeat the wash step as in step 3. 
6. Add 100µl of prepared streptavidin solution to each well. Incubate at 45 
minutes at room temperature with gentle shaking.  
7. Discard the solution. Repeat the wash step as in step. 
8. Add 100µl of TMB one-step substrate reagent to each well. Incubate for 
30 minutes at room temperature in the dark with gentle shaking. 
9. Add 50µl of stop solution to each well. Read at 450nm immediately. 
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                                       APPENDIX B 
Detailed protocol for reagent preparation 
Virkon- purchased as a powder from Fisher Scientific (UK). Store packs dry at 
room temperature. 
For protocol: make a 2x concentrate solution. This is a 2% stock solution in tap 
water for disinfection (ie 2g per 100ml). This is equivalent to 1 spoonful of 
Virkon in 500ml. 
PBS 
1 tablet added to 500ml distilled water and autoclaved 
Media  
Dulbecco’s modified eagle medium (DMEM GlutaMAX, Gibco, Invitrogen) 
supplemented with 10% Foetal bovine serum (FBS, Gibco, Invitrogen), 1% Pen-
Strep (5000 units/ml penicillin and 5000µl/ml streptomycin, Gibco, Invitrogen) 
Glycated albumin 
Main solution (10mg/ml): 25mg + 2.5ml PBS (Sigma Aldrich, UK) 
Stock solution (2mg/ml): 300µl main solution + 1200µl PBS 
Albumin 
Main solution (100mg/ml): 5g albumin + 50ml PBS (Sigma Aldrich, UK) 
Stock solution (2mg/ml): 30µl main solution + 1470µl PBS 
Recombinant human interleukin-1β 
Delivered as 10µg (10000ng) (Merck Millipore, UK) 
Centrifuged briefly 
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Reconstituted with dH2O to 100µl: equivalent to 100ng/µl 
Aliquoted into 2µl (200ng) samples and stored at -20°C 
For use: sample aliquots defrosted and diluted x10 
2µl sample + 18µl PBS equivalent to 20µl (200ng) 
2µl diluted sample equivalent to 20ng 
Recombinant human TNF-α 
Delivered as 50µg (50000ng) (Merck Millipore, UK) 
Centrifuged briefly 
Reconstituted with dH2O to 100µl: equivalent to 500ng/µl 
Aliquots of 4µl (2000ng) stored at -20°C 
For use: 
Samples defrosted and diluted x100 
4µl sample + 396µl PBS equivalent to 20ng 
Inhibitor preparations 
Ly294002- specific inhibitor of P13k pathway  
1mg MW 343.80 (Sigma Aldrich, UK) 
DMSO soluble >5mg/ml: require 50µM 
Add 1mg to 29ml DMSO equivalent to stock solution of 100µM/ml 
For  50µM use 500µl stock solution 
Cells pretreated for 1 hour then SFM changed and 500mg GHSA added for 24 
hours 
SB202190- p38 inhibitor 
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5mg MW 331.34 (Sigma Aldrich, UK) 
DMSO soluble 30mg/ml: require 30µM 
Add 5mg to 50ml DMSO equivalent to stock solution of 300µM/ml 
For 30µM use 100µl stock solution 
Cells pretreated for 1 hour then SFM changed and 500mg GHSA added for 24 
hours 
JSH-23- p65 subunit of NF-ĸB inhibitor 
5mg MW 240.34 (Sigma Aldrich, UK) 
DMSO soluble >10mg/ml: require 50µM 
Add 5mg to 41.5ml DMSO equivalent to stock solution of 500µM/ml 
For 50µM use 100µl stock solution 
Cells pretreated for 1 hour then SFM changed and 500mg GHSA added for 24 
hours 
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                            Appendix C: Statistical results 
  
Figure 12: Effects of minocycline and hypoxia on ARPE-19 cell viability 
 
 
Table 9: Statistical results relating to Figure 12 
Row Experimental 
condition 
Mean % SD N 
A Normoxia 4.4 1.18 3 
B Normoxia + Mino 4.2 0.40 3 
C Hypoxia 5.4 0.61 3 
D Hypoxia + Mino 3.4 0.67 3 
 
Kruskal-Wallis test 
 
Kruskal-Wallis statistic : 6.371 
P value: 0.0787 
Do the medians vary significantly (P < 0.05) : No 
P value summary: Not significant 
 
Table 10: Dunn’s multiple comparison test of data relating to Figure 12 
 
 Mean rank 
difference 
Significant Summary 
Row A and B 0.6667 No NS 
Row A and C -3.667 No NS 
Row A and D 3.667 No NS 
Row B and C -4.333 No NS 
Row B and D 3.000 No NS 
Row C and D 7.333 No NS 
 
Experimental condition 
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Figure 13: Effects of minocycline and hypoxia on ARPE-19 cell apoptosis 
 
Table 11: Statistical results relating to Figure 13 
 
Row Experimental 
condition 
Mean % SD N 
A Normoxia 4.2 2.48 3 
B Normoxia + Mino 1.8 0.45 3 
C Hypoxia 2.5 0.51 3 
D Hypoxia + Mino 1.9 0.36 3 
 
 
 
Kruskal-Wallis test 
Kruskal-Wallis statistic: 6.830 
P value: 0.0521 
Do the medians vary significantly (P < 0.05): No 
P value summary: Not significant 
 
Table 12: Dunn’s multiple comparison test of data relating to Figure 13 
 
 Mean rank 
difference 
Significant Summary 
Row A and B 6.667 No NS 
Row A and C 2.167 No NS 
Row A and D 5.833 No NS 
Row B and C -4.500 No NS 
Row B and D -0.8333 No NS 
Row C and D 3.667 No NS 
 
 
 
 
Experimental condition 
  
201 
 
Figure 14: Effects of glycated albumin on ARPE-19 cell viability after exposure to 
minocycline and hypoxia 
 
Table 13: Statistical results relating to Figure 14 
 
Row Experimental 
condition 
Mean % SD N 
A  GA + Normoxia 5.1 0.65 3 
B GA +Normoxia + 
Mino 
3.9 0.36 3 
C GA + Hypoxia 5.7 1.3 3 
D GA + Hypoxia + 
Mino 
3.8 0.53 3 
 
Kruskal-Wallis test 
Kruskal-Wallis statistic: 6.714 
P value: 0.0601 
Do the medians vary significantly (P < 0.05): No 
P value summary: Not significant 
 
Table 14: Dunn’s multiple comparison test of data relating to Figure 14 
 Mean rank 
difference 
Significant Summary 
Row A and B 4.667 No NS 
Row A and C -0.6667 No NS 
Row A and D 5.333 No NS 
Row B and C -5.333 No NS 
Row B and D 0.6667 No NS 
Row C and D 6.000 No NS 
 
 
 
 
 
Experimental condition 
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Figure 15: Effects of glycated albumin on ARPE-19 cell apoptosis after exposure 
to minocycline and hypoxia 
 
Table 15: Statistical results relating to Figure 15 
 
Row Experimental 
condition 
Mean % SD N 
A GA + Normoxia 6.8 0.95 3 
B GA +Normoxia + 
Mino 
5.9 0.20 3 
C GA + Hypoxia 11.5 2.93 3 
D GA + Hypoxia + 
Mino 
7.5 1.49 3 
 
Kruskal-Wallis test 
Kruskal-Wallis statistic: 6.832 
P value: 0.0506 
Do the medians vary significantly (P < 0.05): No 
P value summary: Not significant 
 
Table 16: Dunn’s multiple comparison test of data relating to figure 15 
 Mean rank 
difference 
Significant Summary 
Row A and B 2.333 No NS 
Row A and C -5.167 No NS 
Row A and D -1.167 No NS 
Row B and C -7.500 No NS 
Row B and D -3.500 No NS 
Row C and D 4.000 No NS 
 
 
 
Experimental condition 
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Figure 17: Effects of hypoxia and minocycline on glycated albumin induced IL-8 
production 
 
 
Table 17: Statistical results relating to Figure 17 
IL-8 
ELISA 
Experimental 
condition 
Mean 
Conc. 
SD N 
A normoxia 98.78 15.96 3 
B hypoxia 42.41 6.29 3 
C GA normoxia 375.89 26.76 3 
D GA normoxia + 
mino 
250.15 19.70 3 
E GA hypoxia 328.05 14.04 3 
F GA hypoxia + 
mino 
200.57 20.75 3 
 
ANOVA summary 
F value: 148.1 
P value: < 0.0001 
Are differences between means statistically different? (p<0.05): Yes 
R square: 0.9841 
 
 
 
 
Experimental condition 
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Table 18: Tukey’s multiple comparison test of data relating to Figure 17 
Test details Mean 
difference 
95% CI of 
difference 
Significant? Summary 
Row A and B 56.37 5.966 to 106.8 Yes * 
Row A and C -277.1 -327.5 to -226.7 Yes **** 
Row A and D -151.4 -201.8 to -101.0 Yes **** 
Row A and E -229.3 -279.7 to -178.9 Yes **** 
Row A and F -101.8 -152.2 to -51.39 Yes *** 
Row B and C -333.5 -383.9 to -283.1 Yes **** 
Row B and D -207.7 -258.1 to -157.3 Yes **** 
Row B and E -285.6 -336.0 to -235.2 Yes **** 
Row B and F -158.2 -208.6 to -107.8 Yes **** 
Row C and D 125.7 75.34 to 176.1 Yes **** 
Row C and E 47.84 -2.564 to 98.24 No NS 
Row C and F 175.3 124.9 to 225.7 Yes **** 
Row D and E -77.90 -128.3 to -27.50 Yes ** 
Row D and F 49.58 -0.8244 to 99.98 No NS 
Row E and F 127.5 77.08 to 177.9 Yes **** 
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Figure 18: Effects of Minocycline on IL-1β stimulated IL-8 production 
 
Table 19: Statistical results relating to Figure 18 
IL-8 
ELISA 
Experimental 
condition 
Mean 
Conc. 
SD N 
A Normoxia 98.78 15.96 3 
B Hypoxia 42.41 6.29 3 
C Normoxia + IL-1β 2075.7 558.5 3 
D Normoxia + IL-1β 
+ Mino 
1267.23 11.49 3 
E Hypoxia + IL-1β 681.94 15.74 3 
F Hypoxia + IL-1β + 
Mino 
617.81 36.62 3 
 
ANOVA summary 
F value: 33.92 
P value: <0.0001 
Are differences between means statistically significant? (p<0.05): Yes 
R square: 0.9339 
 
Table 20: Tukey’s multiple comparisons test of data relating to Figure 18 
Test details Mean 
difference 
95% CI of 
difference 
Significant? Summary 
Row A and B 56.37 -571.0 to 683.8 No NS 
Row A and C -1977 -2604 to -1350 Yes **** 
Row A and D -1168 -1796 to -541.1 Yes *** 
Row A and E -583.2 -1211 to 44.23 No NS 
Experimental condition 
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Row A and F -519.0 -1146 to 108.4 No NS 
Row B and C -2033 -2661 to -1406 Yes **** 
Row B and D -1225 -1852 to -597.4 Yes *** 
Row B and E -639.5 -1267 to -12.14 Yes * 
Row B and F -575.4 -1203 to 51.99 No NS 
Row C and D 808.5 181.1 to 1436 Yes ** 
Row C and E 1394 766.4 to 2021 Yes **** 
Row C and F 1458 830.5 to 2085 Yes **** 
Row D and E 585.3 -42.10 to 1213 No NS 
Row D and F 649.4 22.03 to 1277 Yes * 
Row E and F 64.13 -563.3 to 691.5 No NS 
 
 
Figure 19: Effects of individual biochemical inhibitors on glycated albumin IL-8 
production from ARPE-19 cells 
 
Table 21: Statistical results relating to Figure 19 
IL-8 
ELISA 
Experimental 
condition 
Mean 
Conc. 
SD N 
A GA and normoxia 375.89 26.77 3 
B GA and hypoxia 328.05 14.04 3 
C Ly294002 + GA 
normoxia 
190.09 5.97 2 
D SB202190 + GA 
normoxia 
149.86 3.18 2 
E JSH-23 + GA 
normoxia 
120.68 6.99 2 
F Ly294002 + GA 174.78 2.56 2 
Experimental condition 
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hypoxia 
G SB202190 + GA 
hypoxia 
122.58 2.59 2 
H JSH-23 + GA 
hypoxia 
116.79 4.15 2 
ANOVA summary 
F value: 134.1 
P value: < 0.0001 
Are differences among means statistically significant? (p<0.05): Yes 
R square: 0.9895 
 
Table 22: Tukey’s multiple comparison tests of data relating to Figure 19  
Test details Mean 
difference 
95% CI of 
difference 
Significant? Summary 
Row A and B 47.84 5.068 to 90.61 Yes * 
Row A and C 185.8 138.0 to 233.6 Yes **** 
Row A and D 226.0 178.2 to 273.9 Yes **** 
Row A and E 255.2 207.4 to 303.0 Yes **** 
Row A and F 201.1 153.3 to 248.9 Yes **** 
Row A and G 253.3 205.5 to 301.1 Yes **** 
Row A and H 259.1 211.3 to 306.9 Yes **** 
Row B and C 138.0 90.13 to 185.8 Yes **** 
Row B and D 178.2 130.4 to 226.0 Yes **** 
Row B and E 207.4 159.5 to 255.2 Yes **** 
Row B and F 153.3 105.4 to 201.1 Yes **** 
Row B and G 205.5 157.6 to 253.3 Yes **** 
Row B and H 211.3 163.4 to 259.1 Yes **** 
Row C and D 40.24 -12.15 to 92.62 No NS 
Row C and E 69.42 17.03 to 121.8 Yes ** 
Row C and F 15.31 -37.07 to 67.69 No NS 
Row C and G 67.52 15.13 to 119.9 Yes * 
Row C and H 73.30 20.92 to 125.7 Yes ** 
Row D and E 29.18 -23.20 to 81.56 No NS 
Row D and F -24.93 -77.31 to 27.46 No NS 
Row D and G 27.28 -25.10 to 79.66 No NS 
Row D and H 33.07 -19.32 to 85.45 No NS 
Row E and F -54.11 -106.5 to -1.720 Yes * 
Row E and G -1.900 -54.28 to 50.48 No NS 
Row E and H 3.885 -48.50 to 56.27 No NS 
Row F and G 52.21 -0.1799 to 104.6 No NS 
Row F and H 57.99 5.605 to 110.4 Yes * 
Row G and H 5.785 -46.60 to 58.17 No  NS 
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Figure 20: Effects of combination of biochemical inhibitors on glycated albumin 
induced IL-8 production 
 
 
Table 23: Statistical results relating to Figure 20 
IL-8 
ELISA 
Experimental 
condition 
Mean 
Conc. 
SD N 
A GA + normoxia 375.89 26.77 3 
B All inhibitors  
GA + normoxia 
41.65 1.0112 2 
C Ly294002 + 
SB202190 
GA + normoxia 
36.215 0.347 2 
D SB202190 + 
JSH-23 
GA + normoxia 
47.26 0.23 2 
E Ly294002 + 
JSH-23 
GA + normoxia 
32.795 1.549 2 
 
ANOVA summary 
F value: 258.1 
P value: < 0.0001 
Are differences among means statistically significant? (p<0.05): Yes 
R square: 0.9942 
 
Experimental condition 
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Table 24: Tukey’s multiple comparisons test of data relating to Figure 20 
Test details Mean 
Difference 
95% CI of 
difference 
Significant? Summary 
Row A and B 334.2 281.3 to 387.2       Yes **** 
Row A and C 339.7 286.7 to 392.7       Yes **** 
Row A and D 328.6 275.6 to 381.6       Yes **** 
Row A and E 343.1 290.1 to 396.1       Yes **** 
Row B and C 5.435 -52.61 to 63.48       No NS 
Row B and D -5.610 -63.65 to 52.43       No NS 
Row B and E 8.855 -49.19 to 66.90       No NS 
Row C and D -11.05 -69.09 to 47.00       No NS 
Row C and E 3.420 -54.62 to 61.46       No NS 
Row D and E 14.47 -43.58 to 72.51       No NS 
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Figure 22: Effects of hypoxia and minocycline on glycated albumin induced 
MCP-1 production 
 
 
Table 25: Statistical results relating to Figure 22 
MCP-1 
ELISA 
Experimental 
condition 
Mean 
Conc. 
SD  N 
A Normoxia  88.38 14.62 3 
B Hypoxia 132.8 10.7 3 
C GA normoxia 305.45 5.88 3 
D GA normoxia + 
mino 
123.67 5.27 3 
E GA hypoxia 546.66 10.69 3 
F GA hypoxia + 
mino 
498.58 24.06 3 
 
ANOVA summary 
F value: 671.7 
P value: <0.0001 
Are differences between means statistically significant? (p<0.05): Yes 
R square: 0.9964 
 
Table 26: Tukey’s multiple comparisons test of data relating to Figure 22 
Test details Mean 
difference 
95% CI of 
difference 
Significant? Summary 
Row A and B -44.42 -81.29 to -7.552 Yes * 
Row A and C -217.1 -253.9 to -180.2 Yes **** 
Experimental condition 
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Row A and D -35.29 -72.16 to 1.578 No NS 
Row A and E -458.3 -495.1 to -421.4 Yes **** 
Row A and F -410.2 -447.1 to -373.3 Yes **** 
Row B and C -172.7 -209.5 to -135.8 Yes **** 
Row B and D 9.130 -27.74 to 46.00 No NS 
Row B and E -413.9 -450.7 to -377.0 Yes **** 
Row B and F -365.8 -402.6 to -328.9 Yes **** 
Row C and D 181.8 144.9 to 218.6 Yes **** 
Row C and E -241.2 -278.1 to -204.3 Yes **** 
Row C and F -193.1 -230.0 to -156.3 Yes **** 
Row D and E -423.0 -459.9 to -386.1 Yes **** 
Row D and F -374.9 -411.8 to -338.0 Yes **** 
Row E and F 48.08 11.21 to 84.95 Yes ** 
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Figure 23: Effects of individual biochemical inhibitors on glycated albumin 
stimulated MCP-1 production from ARPE-19 cells 
 
 
Table 27: Statistical results relating to Figure 23 
 
MCP-1 
ELISA 
Experimental 
condition 
Mean 
Conc. 
SD N 
A GA and normoxia 305.45 5.87 3 
B GA and hypoxia 546.66 10.69 3 
C Ly294002 + GA 
normoxia 
84.94 16.24 2 
D SB202190 + GA 
normoxia 
150.01 4.89 2 
E JSH-23 + GA 
normoxia 
132.84 14.86 2 
F Ly294002 + GA 
hypoxia 
68.07 3.19 2 
G SB202190 + GA 
hypoxia 
143.58 0.91 2 
H JSH-23 + GA 
hypoxia 
117.59 2.43 2 
 
ANOVA summary 
F value: 837.3 
P value: <0.0001 
Are differences between means statistically significant? (p<0.05): Yes 
R square: 0.9 
Experimental condition 
  
213 
 
Table 28: Tukey’s multiple comparison tests of data relating to Figure 23 
Test details Mean 
difference 
95% CI of 
difference 
Significant? Summary 
Row A and B -241.2 -269.0 to -213.4 Yes **** 
Row A and C 220.5 189.4 to 251.6 Yes **** 
Row A and D 155.4 124.4 to 186.5 Yes **** 
Row A and E 172.6 141.5 to 203.7 Yes **** 
Row A and F 237.4 206.3 to 268.4 Yes **** 
Row A and G 161.9 130.8 to 192.9 Yes **** 
Row A and H 187.9 156.8 to 218.9 Yes **** 
Row B and C 461.7 430.7 to 492.8 Yes **** 
Row B and D 396.7 365.6 to 427.7 Yes **** 
Row B and E 413.8 382.8 to 444.9 Yes **** 
Row B and F 478.6 447.5 to 509.7 Yes **** 
Row B and G 403.1 372.0 to 434.1 Yes **** 
Row B and H 429.1 398.0 to 460.1 Yes **** 
Row C and D -65.07 -99.09 to -31.05 No *** 
Row C and E -47.90 -81.92 to -13.88 Yes ** 
Row C and F 16.87 -17.15 to 50.89 No NS 
Row C and G -58.64 -92.66 to -24.62 Yes ** 
Row C and H -32.65 -66.67 to 1.375 Yes NS 
Row D and E 17.17 -16.85 to 51.19 No NS 
Row D and F 81.94 47.92 to 116.0 No **** 
Row D and G 6.430 -27.59 to 40.45 No NS 
Row D and H 32.42 -1.605 to 66.44 No NS 
Row E and F 64.77 30.75 to 98.79 Yes *** 
Row E and G -10.74 -44.76 to 23.28 No NS 
Row E and H 15.25 -18.77 to 49.27 No NS 
Row F and G -75.51 -109.5 to -41.49 No *** 
Row F and H -49.52 -83.54 to -15.50 Yes ** 
Row G and H 25.99 -8.035 to 60.01 No  NS 
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Figure 24: Effects of combination of biochemical inhibitors on glycated albumin 
induced MCP-1 production 
 
 
Table 29: Statistical results relating to Figure 24 
MCP-1 
ELISA 
Experimental 
condition 
Mean 
Conc. 
SD N 
A GA + normoxia 305.45 5.87 3 
B All inhibitors  
GA + normoxia 
298.34 13.11 2 
C Ly294002 + 
SB202190 
GA + normoxia 
201.49 9.84 2 
D SB202190 + 
JSH-23 
GA + normoxia 
62.42 3.05 2 
E Ly294002 + 
JSH-23 
GA + normoxia 
288.27 49.97 2 
 
ANOVA summary 
F value: 47.63 
P value: 0.0001 
Are differences among means statistically significant? (p<0.05): Yes 
R square: 0.9695 
 
 
Experimental condition 
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Table 30: Tukey’s multiple comparison tests of data relating to Figure 24 
Test details Mean 
Difference 
95% CI of 
difference 
Significant? Summary 
Row A and B 7.110 -67.44 to 81.66      No NS 
Row A and C 104.0 29.41 to 178.5      Yes * 
Row A and D 243.0 168.5 to 317.6      Yes *** 
Row A and E 17.18 -57.37 to 91.73      No NS 
Row B and C 96.85 15.18 to 178.5      Yes * 
Row B and D 235.9 154.3 to 317.6      Yes *** 
Row B and E 10.07 -71.60 to 91.74      No NS 
Row C and D 139.1 57.40 to 220.7      Yes ** 
Row C and E -86.78 -168.4 to -5.111      Yes * 
Row D and E -225.9 -307.5 to -144.2      Yes *** 
 
 
Table 31: Effects of IL-1β induced MCP-1 production  
MCP-1 
ELISA 
Experimental 
condition 
Mean 
Conc. 
SD N 
A Normoxia 546.66 10.69 3 
B Hypoxia 498.58 24.06 3 
C IL-1β normoxia 722.56 221.16 3 
D IL-1β  normoxia 
+ mino 
537.66 152.13 3 
E IL-1β hypoxia 536.06 60.17 3 
F IL-1β hypoxia 
+ mino 
345.75 45.35 3 
 
ANOVA summary 
F value: 3.322 
P value: 0.0410 
P value: Are differences among means statistically significant? (p<0.05): Yes 
R square: 0.5806 
 
Table 32: Tukey’s multiple comparisons test of data relating to effects of IL-1β 
induced MCP-1 production 
 
Test details Mean 
difference 
95% CI of 
difference 
Significant? Summary 
Row A and B 48.08 -265.5 to 361.6 No NS 
Row A and C -175.9 -489.5 to 137.7 No NS 
Row A and D 9.000 -304.6 to 322.6 No NS 
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Row A and E 10.60 -303.0 to 324.2 No NS 
Row A and F 200.9 -112.6 to 514.5 No NS 
Row B and C -224.0 -537.5 to 89.57 No NS 
Row B and D -39.08 -352.6 to 274.5 No NS 
Row B and E -37.48 -351.0 to 276.1 No NS 
Row B and F 152.8 -160.7 to 466.4 No NS 
Row C and D 184.9 -128.7 to 498.5 No NS 
Row C and E 186.5 -127.1 to 500.1 No NS 
Row C and F 376.8 63.26 to 690.4 Yes * 
Row D and E 1.600 -312.0 to 315.2 No NS 
Row D and F 191.9 -121.6 to 505.5 No NS 
Row E and F 190.3 -123.2 to 503.9 No NS 
 
 
Table 33: Data relating to Figure 11 Concentration dependent effects of 
Minocycline on ARPE-19 cell viability 
 
Minocycline 
concentration (µM) 
Mean percentage of 
viable cells 
Standard deviation  N (number of 
independent 
experiments 
0 96 4 3 
5 94 5 3 
10 86 6 3 
15 80 8 3 
20 63 10 3 
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                                    Appendix D 
PATIENT INFORMATION SHEET 
Lead Researcher: Sobha Sivaprasad 
King’s protocol number: 06NB37 
 
1. Study title 
Combination therapy of Visudyne, Minocycline, Dexamethasone and 
Ranibizumab (VIMDER) for the treatment of subfoveal CNV 
2. Invitation paragraph 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it 
will involve. Please take time to read the following information carefully and 
discuss it with friends, relatives and your GP if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. Thank you fo reading this. 
3. What is the purpose of the study? 
To find out the effectiveness of combining for drugs to treat wet AMD. 
The medications that will be used are: 
1) Photodynamic therapy (PDT) is the standard treatment in the NHS for 
your condition 
2) Ranibizumab (Lucentis)- this drug blocks a molecule that is thought to be 
involved in the growth of new blood vessels as well as their leakage in 
the retina. This is not yet available on the NHS. It has been used in 
several research studies and found to be useful in stabilising vision. 
3) Dexamethasone- a steroid that helps to settle inflammation 
4) Minocycline- is commonly used as a treatment for acne. It helps to block 
the molecules that encourage blood vessels to grow. 
4. Why have I been chosen? 
You have been asked to take part in this study because you have wet AMD. 
This has caused the changes that you have noticed in your eyesight. Small 
abnormal blood vessels behind the retina leak fluid and blood into the 
central area of the retina causing it to malfunction, scar tissue also develops. 
If left untreated it may cause you to lose the central vision permanently. 
5. Do I have to take part? 
No- it is up to you to decide whether or not you take part. If you do decide to 
take part you will be given this information sheet to read and keep. You will 
be assessed to see if you are suitable and be asked to sign a consent form. 
Allergy to any of the treatments will obviously mean you cannot take part. If 
you decide to take part you are still free to withdraw at any time and without 
giving a reason. Your future treatment and care will not be affected. 
6. What will happen to me if I take part? 
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The study will last for 1 year. You will be asked to come to the clinic monthly 
for the first 12 months. At each visit you vision will be tested, your eye 
examined and a scan performed of the back of the eye. Fluorescein 
angiogram will be performed at the first visit only. 
Treatment 
First treatment visit 
Photodynamic therapy. An intravenous injection is given over 10 minutes 
and then a laser is applied with a contact lens over 2 minutes. 
Dexamethasone/ Ranibizumab injection. These two drugs are applied by 
one injection into the eye. This treatment takes around 10 minutes and for 
this you will lie on a bed. You will need to apply antibiotic drops for four days 
after this. 
You will be given Minocycline tablets to be taken every day for three months. 
 
Follow up treatment visits 
You may not require treatment after the first visit, this will depend on the 
results of the examination and scan. If further treatment is needed it will be 
an injection of ranibizumab only. 
 
7. What are the side effects of taking part? 
Study medication 
The injection of dexamethasone and Ranibizumab can cause transient 
discomfort during the procedure. There may be some redness, this usually 
settles in a few days. In a few cases there can be a mild inflammation of the 
eye. The injection has a low rate (less than 1%) of serious complication such 
as infection, haemorrhage or retinal detachment. A mild increase in the 
pressure inside the eye may occur. All these can be treated if develops. 
Photodynamic therapy 
A small number of patients (less than 5%) have dull back pain during the 
infusion, this passes off after a couple of minutes. A few patients (less than 
2%) have a temporary visual loss during the first week after PDT. Most 
patients recover within four weeks without treatment. 
Problems or side effects such as reactions to the medications may arise. 
Should any problems occur, you will be given appropriate care for your 
condition, and you may be withdrawn from the study. 
Other possible risks 
Fluorescein angiogram is a safe test routinely used in investigating the eye. 
Before the pictures of the eye are taken, you will receive an injection into an 
arm vein of fluorescein dye. There may be minor discomfort from the needle 
in your arm. Common side effects of the dye are nausea and vomiting. 
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There is a low risk of serious allergic reaction. The dye stains your skin and 
urine for approximately 36 hours. 
Ranibizumab is provided for 12 dosages only, and this might last between 1 
to 2 years. If after 12 dosages are finished, the study will not provide any 
further treatment. The management will revert back to standard NHS care. 
 
8. What are the possible benefits of taking part? 
We hope that the treatment will help you. However, this cannot be 
guaranteed. The information we get from this study is intended to help us 
design and perform further similar large studies in the future with the 
intention of treating wet AMD better in the long term. 
 
9. What if new information becomes available? 
      Sometimes during the course of a research project, new information    
      becomes available about the treatment/drug that is being studied. If this  
      happens, your research doctor will tell you about it and discuss with you  
      whether you want to continue in the study. If you decide to withdraw your    
      research the doctor will make arrangements for your care to continue. If you    
      decide to continue in the study you will be asked to sign an updated consent   
      form. Also, on receiving new information your research doctor might  
      consider it to be in your best interests to withdraw you from the study.  
      He/she will explain the reasons and arrange for your care to continue.  
 
10. What happens when the research study stops? 
 After the trial has ended, your follow up will continue in the normal clinical 
setting with regular follow up in your clinic. 
 
11. What if something goes wrong? 
Overall the treatment procedures have been shown to be extremely safe 
and we do not expect any health problems to arise as a result of taking part 
in this trial. However, if you have any complaints or concerns regarding the 
treatment you have received, this can be pursued through the normal NHS 
mechanisms. No compensation is available for non negligent harm. 
   
12. Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research 
will be kept strictly confidential. Any information about you, which leaves the 
hospital will have your name and address removed so that you cannot be 
recognised from it. With your consent, we would like to inform your GP of 
your participation in the trial. 
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13.  Who is organising and funding the research? 
The research is being supported partly by Novartis (the drug company which 
made the drug used in PDT and Lucentis). The money is used to fund tests 
needed for the research. 
 
14. Who has reviewed the study? 
The study has been approved by the King’s College Hospital Research 
Ethics Committee. 
 
15. Contact for Further Information 
Please ask any questions you have about the study before deciding to take 
part. If you wish to contact someone once you have left the hospital about 
the study please contact the doctor below who will be able to answer any 
questions you may have. 
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                                 Consent Form 
Combination therapy of Visudyne, Minocycline, Dexamethasone and 
Ranibizumab (VIMDER) in for the treatment of subfoveal CNV. 
Lead Researcher: Sobha Sivaprasad 
King’s protocol number: 06NB37 
Patient Trial Number: 
 
1. I confirm that I have read and understand the 
information sheet dated 10th July 2008 (Version 4.1)  
for the above study and have had the opportunity to  
ask questions. I agree to take part in this study. 
 
2. I understand that my participation is voluntary and  
that I am free to withdraw at any time, without giving  
any reason, without my medical care or legal rights  
being affected. 
 
3.I understand that sections of any of my medical  
notes may be looked at by responsible individuals  
authorised by the lead researcher or from regulatory  
authorities where it is releveant to my taking part in research.  
I give permission for these individuals to have access  
to my records. 
 
 
Print Name....................................    Signature............................................. 
Date....../......./........./ 
 
Explanation given by: 
 
...................................................... 
NB: Three copies should be made for (1) patient, (2) researcher, (3) hospital notes. 
Consent form: Date: 10th July 2008 
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